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ABSTRACT
The Rel/NF-B family of inducible transcription factors are evolutionarily conserved
structurally and functionally, from insects to humans. They are ubiquitously expressed
in a number of mature cell types, playing a pivotal role regulating cell growth,
differentiation and apoptosis. Under normal circumstances, the proliferation of new cells
is tightly regulated, as is the programmed lifespan of most cells, occasionally however
cells loose their responsiveness to growth control mechanisms, resulting in a tumor or
neoplasm.

Sustained or chronic inflammation has been linked to a number of

pathological conditions that destroy tissue and facilitate neoplastic growth. NF-B in
part mediates the opposing signals of cell survival and cell death, associated with this
response. We hypothesized that inhibition of NF-κB would inhibit tumor cell growth.
A number of anti-neoplastic drugs like some pro-inflammatory cytokines can activate
both the cellular apoptotic and pro-survival (via NF-κB) pathways. We demonstrate, in
vitro, that the use of Nitric Oxide mitigates NF-κB activation and induces program cell
death, when administered as an adjuvant with this subset of pro-inflammatory cytokines.
Secondly, several front-line anti-cancer drugs activate NF-κB as a result of their mode of
action, resulting in the survival of a resistant population of tumor cells. In order to
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abrogate this beneficial activity for the tumor cell we explore, both in vitro and in vivo,
the use of Nitric Oxide to inhibit NF-κB, augmenting the efficacy of the antineoplastic drugs. Thirdly, we identify that the intracellular signaling kinase, Inositol
Hexkisphosphate Kinase2 (IHPK2) , binds to a key component in the NF-κB signaling
pathway, inhibiting NF-κB activity promoting apoptosis in tumor cells. Lastly, an in
depth study investigating the major initiator of pro-inflammatory signaling during
bacterial infection of cells by Salmonela sp. was in fact due to recognition of the bacterial
protein flagellin by the cell surface receptor Toll-like receptor 5 (TLR5) leading to the
activation of NF-κB. Flagellin, the product of the bacterial fliC gene which encodes this
protein is the major protein constituent of the bacterial flagellar apparatus. Inflammation
is a double edged sword. Initially the inflammatory response acts to destroy invading
organisms and limit infection while alternatively, inflammation provides the cellular
signaling events and growth factors that promote tumor cell survival and growth. There
exists a fine balance between the cellular survival and death signal transduction
pathways. This dichotomy pinpoints the NF-κB signaling pathway at this fulcrum as a
potential target in drug development for the treatment of inflammation and inflammatorymediated disease.
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CHAPTER I
INTRODUCTION

1.1 NF-B
NF-B occupies a significant role in the transcriptional regulation of a number of
genes involved in the immune and inflammatory responses(Hayden and Ghosh, 2004).
There are five members in the mammalian NF-κB family of transcription factors. RelA
(p65), RelB, c-Rel, p50/105 (NF-κB1), and p52/p100 (NF-κB2)(Rothwarf and Karin,
1999). All NF-kB family members share a common protein domain, the REL homology
domain, which is functionally a DNA-binding / dimerization domain that contains a
nuclear localization sequence(Pahl, 1999).
NF-κB subunits p52 and p50 are formed from the proteolytic processing of precursor
proteins p100 and p105, respectively and lack a transactivation domain. These precursor
proteins p105 and p100 contain multiple copies of ankyrin repeats, which mediate
protein-protein interactions in the carboxy-terminal one-third of the protein(Hayden and
Ghosh, 2004). The second type of NF-κB subunits c-Rel, RelB-B and RelA/p65 contain
transactivation domains and form heterodimers with p50 and p52(Hayden and Ghosh,
2004). All family members are capable of forming both hetero- and homodimers, with
1

the exception of RelB which can only form heterodimers. REL-A and p50 form the most
common heterodimers, and it is the primary NF-κB transcription factor of interest in this
study (Hayden and Ghosh, 2004).
NF-κB transcription factors are held inactive in the cytoplasm, bound to a member of
a family of ankyrin repeat containing inhibitory proteins called the Inhibitor of kappaB
(IB). There are three members in this inhibitory family IB-, IB-, IB-(Hayden
and Ghosh, 2004). When bound to its inhibitor, NF-B is restricted to the cytoplasm by
virtue of shielding the access of the NF-B nuclear localization sequence, blocking
recognition and nuclear import(Rothwarf and Karin, 1999). Activation of NF-B is
initiated in the cytoplasm, by phorsphorylation-induced degradation of the IB. The
immediate upstream kinase phosphorylating IB is Inhibitor of kappaB kinase
(IKK)(Karin, 1999). IKK exists in the cytoplasm as multi-component signalasome,
containing three core subunits IKK-α, IKK-β and IKK-γ(Hacker and Karin, 2006).
IKK phosphorylates two conserved N-terminal serine residues, S32 and S36 of IB-,
triggering its polyubiquitination and degradation via the 26S proteasome(Hacker and
Karin, 2006). Once free of its inhibitor, NF-κB undergoes further modifications to make
it a more effective transcriptional activator and is then translocated to the nucleus(Li and
Stark, 2002).
NF-B promotes the transcription of a number of target genes involved in the
inflammatory and immune responses, thereby serving as a link between the innate and
adaptive immune systems(Karin and Ben-Neriah, 2000). The NF- B signal
transduction pathway is activated by a number of disparate ligands acting upon similar
2

cell surface and intracellular receptors including , the cytokines (TNF-, Il-1/ and
TRAIL)(Silverman and Maniatis, 2001); bacterial products (LPS, flagellin, and nonmethylated dsDNA)(Byrd-Leifer et al., 2001); viral components (dsDNA, dsRNA and
ssRNA)(Takeda et al., 2003); and DNA damaging agents (ionizing radiation or
oxidative stress and chemotherapeutic drugs)(Bender et al., 1998; Huang et al., 2003). A
majority of NF-B activators are functionally related by either pathogenic cellular
invasion or cellular insult that initiates an immune response.
Overall NF-κB is activated in parallel with other mitogenic pathways. The activation
of NF-κB regulates cell survival and cell death, mostly through inhibition of apoptosis or
programmed cell death(Karin and Lin, 2002). In most cases, the pro-survival signals
dominate, however if IKK or NF-B are inhibited, the apoptotic mechanisms will
predominate the cellular response.

1.2 IKK
Stimulation of numerous cellular transduction pathways may lead to the activation
of NF-B(Hayden and Ghosh, 2004). The key convergent point of these pathways is the
activation of its upstream regulatory activating kinase, the IB kinase (IKK)(Hacker and
Karin, 2006). The IKK complex consists of the two highly conserved kinase subunits,
IKK- and IKK- along with a structural, non-catalytic regulatory subunit IKK-
(NEMO)(Rothwarf and Karin, 1999). IKK- (85kD) and IKK-(87kD) are the catalytic
subunits in the IKK signaling complex, they are highly homologous proteins with 50%
protein sequence similarity(Kwak et al., 2000). They each contain the following protein
domains in the following order from amino to carboxyl end, the kinase domain, a leucine
3

zipper domain, and helix loop helix(Rothwarf and Karin, 1999).

IKK and  form

homo and heterodimers through their leucine zipper domain. IKK- has proven to be the
primary catalytic kinase in NF-B activation(Hayden and Ghosh, 2004). All three
subunits IKK exist as a large 600-900 kDa complex based upon gel permeation(Hayden
and Ghosh, 2004).
IKK- (NEMO) is an essential regulatory subunit of the IKK signaling complex.
It is a predominately helical 48kd scaffolding protein and has no catalytic function of its
own. The carboxy- terminal domain (C-ter) contains two coiled-coiled motifs’ a leucine
zipper, a proline rich region and a terminal zinc finger motif. The C-terminal region is
required for full IKK activation(Agou et al., 2004), with the two coiled-coiled domains
and leucine zipper essential for activation of NF-B by LPS and TNF-(Makris et al.,
2002), and the zinc finger domain necessary for activation of NF-B by DNA
damaging agents(Huang et al., 2002). It is this carboxy-terminal domain that links
upstream signaling events into the IKK complex.
Mutations in the zinc finger domain of IKK- result in the primary immune
deficiency that is characterized by hyper-IgM syndrome(Jain et al., 2001). This mutation
does not effect NF-B activation by TNF- or LPS. DNA damaging agents require the
zinc finger of IKK- for NF-B activation(Huang et al., 2002); conversely LPS and TNF are still able to activate NF-B in the absence of the IKK- zinc finger, efficiently(Jain
et al., 2001). Zinc and RING finger domains are common DNA binding and
protein/protein interaction motifs. Zinc coordinated complexes are redox sensitive, and it

4

has been demonstrated that Nitrosative stress may disrupt the zinc finger domain,
resulting in disruption of protein-protein interaction(Kroncke, 2003; Kroncke, 2001).

1.3 NF-B ACTIVATORS
1.3.1 Tumor Necrosis Factor (TNF)
The super family, Tumor-necrosis Factor (TNF) includes 19 distinct ligands
mediating their cellular response through 29 receptors. TNF ligands can either be soluble
or membrane bound(Aggarwal, 2003). The membrane bound ligands are classified as
Type II transmembrane proteins(Aggarwal, 2003).
The TNF receptors (TNFR) are classified into to two broad groups those containing a
death domain (DD) and those without(Aggarwal, 2003). The receptors containing the
DD are known as Death Receptors and when stimulated, may result in
apoptosis(Aggarwal, 2003). The extracellular domain of the TNFR contains a cysteine
rich region which facilitates receptor trimer formation,

within the cellular

membrane(Aggarwal, 2003). The trimer formation acts to mediate and expedite cellular
signal transduction.
TNF ligands are highly potent activators of NF-B, and are expressed primarily by
cells of the immune system(Aggarwal, 2003), and are Type II transmembrane
proteins(Contassot et al., 2007). The TNFR, on the other hand, is expressed in a wide
variety of cell types and are classified as Type I membrane receptors(Aggarwal, 2003).
Apoptotic and anti-apoptotic signaling can be simultaneously activated depending on the
TNF ligand(Aggarwal, 2003; Karin and Ben-Neriah, 2000).
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The apoptotic signaling is regulated through the death receptors. Upon ligand
binding the death receptors form an inter-cellular complex of accessory proteins,
identified as the Death Inducing Signaling Complex (DISC)(Contassot et al., 2007).
Anti-apoptotic signals are generally mediated via NF-B, the simultaneous activation of
these opposing pathways poses a balance between life and death of the cell(Karin and
Lin, 2002). The dominant pathway is dependent on the cell type and the ligand/receptor
combination occurring during the activation.
NF-κB is the transcription factor for a number of TNF-family ligands and once
activated causes an increase in transcription of both ligand and receptor genes(Brasier,
2006). The export of soluble ligand may affect the cell and surrounding cells in an
autocrin or a paracrine fashion, magnifying death or survival signaling depending on the
intensity and length of NF-κB activation(Brasier, 2006). TNF family members are also
involved in development of secondary lymphoid organs; and stimulating cytotoxic
immune effector cells, to recognize and destroy virally infected cells, as well aberrant
tumor cells(Aggarwal, 2003).
Typically, once the trimerized TNF ligand binds to its receptor, adapter proteins are
sequentially recruited to the TNFR and form a signaling complex.

Members of the

singling complex include TNF receptor-associated death domain protein (TRADD), TNF
receptor-associated factor protein (TRAF2), receptor-interacting protein (RIP), TGF-
activated protein kinase 1-binding protein 1 &2 (TAB1 and TAB2), TGF- activated
kinase (TAK1), and IKK (Brasier, 2006; Jackson-Bernitsas et al., 2007) (Fig 1.1).
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The adapter proteins are essential for the recruitment of caspases, ubiquitin ligases and
kinases, necessary for downstream NF-B activity as well as apoptotic
signaling(Jackson-Bernitsas et al., 2007). For example: Upon TNF family ligand
binding RIP is recruited to the complex and interacts via its DD. IKK-γ translocates to
the complex recruiting IKK-α and β. TAK1 phosphorylates critical serine residues on
IKK-β, causing autophosphorylation as well as cross phosphorylation between IKK-α and
IKK-β(Hayden and Ghosh, 2004), further activating the complex resulting in NF-κB
activation, as described previously.
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FIGURE 1.1

Figure 1.1: TNF-α mediated NF-κB activation involves recruitment of
intermediate adapter proteins, as well as degradive and non-degradive
Ubiquitination.
TNF-α ligand binding induces trimerization of its cognate receptor. This results in the
recruitment of TRADD, the E3 ligase, TRAF2 and/or TRAF5 and the kinase RIP1.
TRAF2 and/or TRAF5 Lys63 linked polyubiquitination of RIP1 results in the
recruitment of TAK1-TAB1-(TAB2 or TAB3) to the complex. This results in the
activation of the TAK1 kinase. The IKKα/β/γ is also recruited to the complex via an
ubiquitin binding domain on NEMO, which has been Lys63 linked polyubiqitinated,
facilitating recruitment to the complex. TAK1 then phosphorylates the IKKβ kinase
subunit in its activation loop. IKKβ then phosphorylates IκB- α, NF-κB’s inhibitory
subunit, causing its to be Lys 48 linked polyubiquitinated and subsequently degraded
by the proteasome. NF-κB is then translocated to the nucleus, activating its target
genes. CYCLD and A20, two NF-κB target genes, encode specific Lys63 deubiquitinase, whose activity facilitates the complex disassembly. Illustrated by:
(Israel, 2006)
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1.3.2 Tumor necrosis factor related apoptosis inducing ligand (TRAIL/ Apo2L)
TRAIL, as a member of the TNF super family, is capable of inducing both
survival and apoptotic pathways. It is expressed primarily by cells of the immune system
(Falschlehner et al., 2007). The TRAIL ligand is normally membrane bound, but may be
cleaved and become soluble (LeBlanc and Ashkenazi, 2003). It is associated with the
killing of virally infected as well as neoplastic transformed cells. It is currently in clinical
trials as a potential chemotherapeutic drug (Falschlehner et al., 2007).
Induction of the apoptotic pathway is mediated through the cytoplasmic formation of
a DISC death signaling complex, resulting in direct activation of the extrinsic apoptotic
pathway and indirect activation of the intrinsic pathway(Falschlehner et al., 2007).
Activation of the survival pathway, although weak, is accomplished through induction of
NF-κB (Fig. 1.2).
There are currently five known TRAIL receptors, TRAIL- R1 (DR4) and TRAIL-R2
(DR-5) both of which posses an intracellular Death Domain (DD) and are capable of
apoptotic signaling (LeBlanc and Ashkenazi, 2003). TRAIL-R3 (DcR1) and TRAIL-R4
(DcR2) are decoy receptors with no death signaling capabilities (LeBlanc and Ashkenazi,
2003). The fifth receptor is a soluble receptor osteoprotegerin (OPG). It has been
suggested that increased expression of the decoy receptors, may act as a regulatory
mechanism by sequestering the ligand from the complete signaling receptor.
The binding of Apo2L/TRAIL, to its cognate receptors, causes receptor trimerization
and formation of the death-inducing signaling complex (DISC)(Contassot et al., 2007).
Fas Associated Death Domain (FADD) is an essential adapter protein recruited to the
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cytosolic tail of the TRAIL receptors. Upon arrival, it is able to interact via its DD to the
DD on the cytoplasmic tails of the TRAIL receptors, priming formation of the
DISC(Contassot et al., 2007). FADD then recruits pro-caspase 8 and pro-caspase 10 to
the nascent DISC. The caspases are auto catalytically activated, inaugurating the
protease cascade crucial for transmission of the apoptotic signal(Contassot et al., 2007).
The activation of caspase 8, by TRAIL, links the intrinsic and extrinsic apoptotic
pathways. The activated initiator caspase, Caspase-8 has two preferred substrates, procaspase-3 and Bcl2 interacting protein (Bid)(Xiao-Ming Yin and Zheng Dong, 2003).
Caspase-8 cleaves the Caspase-3 zymogen into a smaller catalytically active form. ProCaspase-3 is one of a number of effector caspases. The effector caspases, once
catalytically activated, are directly or indirectly involved in the cleavage and degradation
of several crucial cellular proteins(Xiao-Ming Yin and Zheng Dong, 2003).
Caspase-8 cleaves Bid into a truncated version, tBid. The protein tBid translocates to
the mitochondria, activating other mitochondrial membrane proteins, resulting in the
formation of channels in the outer mitochondrial membrane. The channels permeabilize
the outer mitochondrial membrane, instigating the release of cytocrome c as well as other
pro-apoptotic proteins(Falschlehner et al., 2007). One group of proteins, such as
cytocrome c, initiates the activity of cellular pro-apoptotic caspases. The second group,
are endonucleases that translocate to the nucleus and induce DNA degradation(XiaoMing Yin and Zheng Dong, 2003).
The key nexus to NF-κB activation by TRAIL relies on the recruitment of Receptorinteracting protein (RIP), to the signaling complex. RIP along with FADD, TRAF2 and
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TRADD form a signaling complex that mitigates the activation of the IKK/NF-κB
signaling cascade(Falschlehner et al., 2007). Not all of the TNF family members activate
NF-B with the same intensity (Fig. 1.3). Apo1/TRAIL induces apoptosis but is a weak
activator of NF-B. However this activation is sufficient to somewhat contradict the
apoptotic effects of TRAIL. This weak inducer phenomenon may be exploited to combat
neoplastic growth. If NF-κB can be simultaneously inhibited, as TRAIL induces
apoptosis, the aberrant growth could be eliminated(Bauer et al., 2007).
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FIGURE 1.2

Figure 1.2: The TRAIL death pathway mediates cross talk between the “extrinsic
and intrinsic” apoptotic pathways.
TRAIL/ApoL ligand binding, through formation of the death-inducing signaling
complex (DISC), activates both the extrinsic and intrinsic apoptotic pathway, while
additionally activating the pro-survival NF-κB transduction pathway abrogating
and/or delaying the death signal. The adapter protein FADD plays a key dual role in
the pathway. It recruits both receptors interacting protein (RIP) to the DISC resulting
in eventual NF-κB activation and survival, as well as initiator pro-caspases 8/10
priming the death cascade. Illustrated by: (Falschlehner et al., 2007)
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FIGURE 1.3

Fig 1.3: TNF family members exhibit differential NF-B DNA binding activity.
TRAIL treated cells exhibit 75% less activation than TNF-α treated samples, as
demonstrated by Electrophoretic mobility shift assay (EMSA). EMSA was performed
using 25ug of A375 Whole cell Extract, as described in (Bauer et al., 2007)). The
Cells were treated for 1 hour with TRAIL/ApoL1 (100ng/ml) or 15min with TNF-
(20ng/mL) The concentration of ligand(s) used were several fold in excess necessary
to saturate available cellular receptors, in order to insure maximum NF-κB binding
activity.
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1.3.3 Pathogen Associated Molecular Patterns (PAMPS) and Toll-Like receptors
(TLR)
The innate immune system recognizes broad molecular patterns, of conserved
microbial components, that are characteristic of infection, or of microbial presence.
These pattern specific ligands include bacterial cellular wall components, organelles,
bacterial or viral DNA and viral RNAs(Dunne and O'Neill, 2005). These components are
specific to specific classes of organisms and signal the immune system the type, and
location of infection.

These components are known as Pathogen Associated Molecular

Patterns (PAMPS). PAMPS serve as ligands for Toll-Like receptors (TLR). TLR
activation primes the adaptive immune system for induction, involving multiple cell
types and tissues(Takeda et al., 2003).
TLRs are a Type I trans-membrane receptor, containing a cytoplasmic domain
homologous to the IL-I receptor(Krishnan et al., 2007). Toll receptors are evolutionarily
conserved from flies to man and are similar to receptors found throughout the animal and
plant kingdoms(Takeda et al., 2003). The receptor was initially discovered and named
Toll, in the fruit fly, Drosophila melanogaster. In Drosophila it is responsible for dorsoventral pattern development in the embryo, and serves a role in protection against fungal
invasion of the adult fly(Takeda et al., 2003). Thirteen TLR’s have been identified in
mammals, eleven in humans(Dunne and O'Neill, 2005). The mammalian Toll receptors
have no apparent developmental pattern involvement, but function in the innate immune
response only(Dunne and O'Neill, 2005).
Upon TLR ligand binding, the formation of a cytoplasmic signaling complex begins
with the recruitment of MyD88, a scaffolding protein containing a Death
14

Domain(Beutler, 2004). MyD88 recruits IRAK-4 which then phosphorylates IRAK-1
and IRAK-2, which in turn recruits TRAF-6. TRAF-6 interacts with and
ubiquitinase/activates TAK-1, an upstream activating kinase of IKK(Beutler, 2004).
Subsequently, NF-B, and MAPK-p38, via a parallel induction pathway, is activated
leading to production of pro-inflammatory cytokines and further immune response (Fig.
1.4) (Beutler, 2004).
TLR 5, a typical MyD88-dependent TLR, is expressed in Monocytes/macrophages,
Dendritic cells and mucosal epithelial cells of the respiratory and digestive tract. It is
also expressed in microvascular endothelial cells. The gut epithelial cells express TLR-5
on their basolateral surface only(Takeda et al., 2003). Activation of TLR-5 by its ligand
on this surface, signals a bacterial invasion of the gut epithelium from the lumen and
breakthrough to the basal layer threatening a systemic infection.
Most enteric pathogens are flagellated.

The flagella structure is relatively

conserved throughout a number of diverse bacterial species. Human pathogens
associated with the invasion of the alimentary canal or the respiratory tract, such as
Salmonella, Escherichia Coli, Pseudomonas and Legonella utilize flagellum, for
motility. Flagellin is the bacterial protein ligand responsible for activation of Toll like
receptor 5 (Tallant et al., 2004).

Throughout the course of microbial invasion the

bacteria are constantly shedding flagellin protein, exposing the organism to flagellin
monomers.
TLR’s occupy the first line of cellular receptors in defense against microbial
invasion. However the intensity of this response associated with chronic inflammation
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has been implicated in immune and inflammatory diseases as well as cancer
development(Coussens and Werb, 2002). Inappropriate activation and/or constitutive
activation of NF-B are commonly observed in many chronic inflammatory diseases
including inflammatory bowel disease, arthritis and atherosclerosis, hepatitis, and
H.pylori infection(Coussens and Werb, 2002; Killeen et al., 2006). A current belief is
that in addition to the TLRs’ ability to recognize exogenous pathogens and their products,
they may also recognize modified endogenous proteins/products that initiate or are
markers for a pathogenic condition(Cordon-Cardo and Prives, 1999).
Bacterial Lipopolysacharide (LPS) a bacterial cell wall component and TLR-4 ligand
has been implicated in tumor metastasis of a murine breast carcinoma model(Killeen et
al., 2006). Increased angiogenesis, vascular permeability and tumor cell invasion were
all noted. TLR activation via LPS may favor tumor growth and metastasis directly
through NF-κB activation(Coussens and Werb, 2002; Killeen et al., 2006). Activation of
NF-B is required for cells to undergo transformation and bypass the cellular death
program. NF-B activity also plays an important role in normal breast development and
its activity is tightly controlled. In a majority of breast cancer tumors and cell lines
derived from those tumors, NF-B is chronically active(Aggarwal et al., 2006).
Lastly, we have discovered that an as yet undescribed NF-B activation pathway
exists in some breast cancer cells. This pathway involves the production of a factor(s) by
some breast cancer cells that is recognized by a receptor protein that is a member of the
Toll-like receptors. It is likely that in breast cancer cells, that produce these factors, the
factor feeds back in an autocrine fashion and activates NF-B in those cells via
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recognition by the TLRs and provide for a growth, survival or metastatic advantage. Two
of six BC cell lines, MDA-MB-468 and MDA-MB-231, actively produce a factor(s) that
potently activate NF-B specifically through a subset of TLRs. (See Chapter VI).
We have examined the expression of many of the TLR family members in a
number of established breast cancer cell lines and in a limited number of breast cancer
tissues and normal breast tissue and discovered that various subsets of the TLRs were up
regulated in expression in a majority of breast cancer tumors but not in normal breast
tissue. (See Chapter VI).
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FIGURE 1.4

Figure 1.4: Toll Like Receptor (TLR) family members differentially utilizes
adapter proteins and are broadly grouped into two signaling categories, MyD88
dependent and MyD88 independent pathways.
All TLRs utilize MyD88 with the exception of TLR3. MyD88 binds with the TIR
domain of the receptor where it recruits and subsequently phosphorylates IRAK4.
IRAK4 cross phosphorylates IRAK1. IRAK1 phosphorylates TRAF6 leading to the
ubiquitination of TAK. TAK then activates the IKK signaling complex and NF-κB
leading to an inflammatory response. Illustrated by: (Krishnan et al., 2007) with
annotative modifications.
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1.3.5 Activation of NF-κB due to Genotoxic Stress
Cells are continuously being bombarded with environmental stimuli, as well as
bi- products of cellular respiration or activity, that may potentially damage its genetic
material. In order to insure genetic stability, cells have developed a surveillance strategy
to proofread the integrity of the genomic architecture(Ahn et al., 2004). These
surveillance pathways or checkpoints, act as sentinels to alert the cell of defective or
abnormal DNA. There are specific sensor proteins that are able to recognize the most
lethal of DNA abnormalities Double Stranded Breaks (DSB)(Abraham, 2001).
In mammalian cells ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad
3-related) are two such checkpoint sensor proteins(Abraham, 2001). They are members
of the phosphatidylinositol 3-kinase (PIKK) family and are multifunctional
serine/threonine protein kinases(Kastan and Lim, 2000). The ATM gene was named after
a genetic disorder called ataxia-telangiectasia (Kastan and Lim, 2000). Patients who
exhibit a deletion of this gene are susceptible to inducers of double stranded breaks
(DSB). ATM and ATR play prominent roles in sensing and signaling genomic
instability.
ATM is activated by signaling that a DSB has occurred. It is considered a primary
responder and mediates the activation of NF-B, due to DSB(Habraken and Piette, 2006).
The primary role of NF-κB is to protect the cell against the numerous apoptotic stimuli
activated by the event(Habraken and Piette, 2006). Current research has strongly
identified ATM as the primary mediating agent in NF-B activation due to DSB, caused
by genotoxic stress(Abraham, 2001). DNA damage caused by UV or ionizing radiation,
and chemotherapeutic drugs such as cisplatin, doxorubicin, and etoposide are the most
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characterized activators of NF-κB by ATM(Habraken and Piette, 2006).
Cells exhibiting a mutation in the ATM gene exhibit little or no NF-B activation in
response to DSB caused by genotoxic agents (Abraham, 2001).
Inactive nuclear ATM exists as a homodimer (Bakkenist and Kastan, 2003).

Upon

DNA damage recognition, ATM/ATR is recruited to the damaged site, and become
activated. (Bakkenist and Kastan, 2003). ATM activation takes place quickly, and in the
presence of a very small number of DSB or a disruption of the chromatin structure. A
number of protein targets for activated ATM/ATR have been identified, including p53,
Checkpoint kinase 2 (CHK2), and IKK- (NEMO) (Kastan and Lim, 2000)(Fig. 1.5).
NF-κB activation by ATM involves signaling from the nucleus to the cytoplasm
through NEMO. This is accomplished via a series of phosphorylations, sumoylations and
ubiquitinations (Mabb and Miyamoto, 2007; Ulrich, 2005; Wu et al., 2006).
Ubiquitin modification is primarily known for targeting a protein to the 26S
proteasome. This involves the multi-branching of ubiquitin chains covalently linked
on the target protein through a lysine 48 (K48) linkage of one ubiquitin unit, with the c
terminal glycine (G76) of a second ubiquitin unit (Sun, 2006).
Each ubiquitin unit has multiple lysines, and each of the lysine attachment sites is unique
and functionally diverse. For example, multi-branching of ubiquitin chains covalently
linked through Lysine 63 of one unit, with the c terminal glycine G76 of a second
ubiquitin unit (G76-K63) acts as signal transduction modification. Mono-ubiquitination
may signal for membrane transport or transcriptional regulation (Fig: 1.6) (Sun, 2006).
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FIGURE 1.5

Figure 1.5: Post translational Ubiquitin linked modification of proteins plays a
key role in the regulation of protein degradation, function and signal
Transduction.
The addition of ubiquitin to a target protein takes place in a sequential three step
process, involving three separate enzymes. Step1: Activation of ubiquitin by an
activating enzyme (E1) that forms a thiol ester with the G76 carboxyl group of
ubiquitin. Step 2: Conjugation, of the activated ubiquitin, to an intermediate protein
(E2) that transiently carries the charged ubiquitin as a thiol ester. Step 3: The transfer
of the activated ubiquitin from the E2 carrier protein, to a lysine on the final target
by a ligase (E3). The E3 substrate can either be a free protein, or another ubiquitin
molecule already bound to a target substrate. Illustrated by:(Sun, 2006)
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FIGURE 1.6

Figure 1.6: Sequential actions of SUMO and ubiquitin on NEMO.
The IKK regulatory subunit, NEMO, associates reversibly with the catalytic subunits
IKKα and IKKβ. Sumoylation of NEMO causes its retention in the nucleus, where
ATM-dependent signaling by DNA damage induces phosphorylation and subsequent
ubiquitination of NEMO. The ubiquitinylated form can leave the nucleus and
associate with ELKS and IKKα/β to yield an active kinase. Illustrated by (Ulrich,
2005), with modifications
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A second post translational modification protein involved in NF- κB signaling is
SUMO (small ubiquitin-like modifier) (Mabb and Miyamoto, 2007). SUMO utilizes a
similar activating, conjugation, and ligation scheme as ubiquitin, with the exception that
SUMO is generally thought to function as a monomer (Seeler and Dejean, 2001).
SUMO substrates are mostly known to be nuclear proteins, indicating that sumoylation is
part of a nuclear transport process (Seeler and Dejean, 2001). The first identified SUMOmodified protein, RanGAP, a small GTPase activating protein plays a role in nuclear
import.
Crosstalk between SUMO and Ubiquitin may exist either in an antagonistic or cooperative manner(Ulrich, 2005). The apparent cooperative cross talk between the two
conjugation systems of sumoylation and ubiquitination is demonstrated on their effects
involved with the modification of NEMO(Ulrich, 2005).
The C-terminal zinc-finger domain of NEMO is essential for activation of IKK due
to genotoxic stress caused by Ionizing Radiation, UV radiation or chemical DNA
damaging agents such as Doxorubicin, Daunorubicin, and VP-16(Huang et al., 2002).
Two zinc finger lysines, K277 and K309 of IKK are sumoylated upon cellular exposure
to DNA damaging agents causing NEMO to accumulate in the nucleus(Ulrich, 2005).
In order to maintain homeostasis, sumoylation and ubiquitination of NEMO takes
place constitutively(Mabb and Miyamoto, 2007). However, in response to DNA damage
additional NEMO is sumoylated and sequestered in the nucleus(Ulrich, 2005). NEMO is
then phosphorylated on Serine 85, by activated ATM. This is required for NEMO to
become mono-ubiquitinated directing export of NEMO from the nucleus back to the
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cytoplasm. Ubiquitinated NEMO is able to recruit additional protein components
necessary for IKK activation(Ulrich, 2005).
The requirement for NEMO ubiquitination to activate IKK has been demonstrated in
response to cytokine stimulation(Israel, 2006). This ubiquitin modification is cytoplasmic
directed. Multi-branched (G76-K63) ubiquitination of NEMO, on lysine 399 of its zinc
finger (Sebban et al., 2006), is necessary but not essential for the assembly and
subsequent activation of the IKK complex(Huang et al., 2002; Makris et al., 2002).
Mutations in the zinc finger diminishes but does not abrogate activation of NF-B by
stimulation with TNF- or IL-1. In addition TNF- is more sensitive to the mutations
than IL-1 (Makris et al., 2002).
The signal event resulting in activating NF-B, due to genotoxic stress,
originates in the nucleus of the cell and is caused by check point surveillance mechanisms
that sense the stalling of replication or transcription machinery due to double stranded
DNA breaks(Ulrich, 2005). This inside out signal to activate IKK contains a temporal
component that results in a slower kinetic activation of the transcription factor than
would normally be observed during cytokine activation (Huang et al., 2002).
The slower kinetic activators use distinct portions of IKK-, concentrating on or in
close proximity to the zinc finger(Huang et al., 2002). Disruption of the zinc finger
abrogates IKK activation(Huang et al., 2002). The inside out signal has two activating
components. The first component activates the apoptotic machinery of the cell, i.e.
activation of p53 by ATM (Ulrich, 2005; Wu et al., 2006).
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The second component activates the pro-survival cascade, spearheaded by NF-B,
retarding full activation of the apoptotic machinery, allowing the cell time to affect
repair.
The use of ionizing radiation and drugs such as cisplatin, doxorubicin, and
etoposide are commonly used in anti cancer therapy. However the activation of NF-κB
counteracts the apoptotic effects of these treatments. The temporal lag time in NF-κB
activation and necessity of the zinc finger for IKK activation, due to these chemotherapy
treatments, makes IKK-γ an interesting target for drug intervention. Specifically, zinc
fingers are redox sensitive (Kroncke and Carlberg, 2000), targeting the zinc finger for
nitrosative modification by a Nitric Oxide donating compound, may abrogate IKK
signaling due to functional loss of IKK’s zinc finger.
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1.4 NF-κB AND APOPTOSIS
Programmed cell death is a complicated cascade of cellular events, of which two
major pathways predominate, Apoptosis and Necrosis (Ghobrial et al., 2005). Typical
apoptotic characteristics include membrane blebbing, cellular collapse, nuclear and
organelle condensation and compartmentalization, and lastly DNA degradation (Jin and
El-Deiry, 2005).
In mammalian cells there are two major cellular apoptotic pathways extrinsic and
intrinsic (Fig. 1.7). The extrinsic pathway is ligand-specific and Death Receptormediated. The intrinsic pathway involves the mitochondria and a family of proteins
known as Bcl-2 family members (Xiao-Ming Yin and Zheng Dong, 2003). The two
apoptotic pathways generally depend on several members of a cysteine protease family
known as caspases (Jin and El-Deiry, 2005).
The caspases are aspartate-specific, and act in an initiator - effector manner. They
exist in the cytoplasm as an inactive pro-caspase. Early activated caspases are known as
initiator caspases. Initiator caspases activate a second tier of proteases known as effector
caspases (Ghobrial et al., 2005). The post-translational regulation of these proteins
insures a rapid and irreversible activation cascade. The activation of these effector
caspases is a clear indication that the cellular apoptotic pathway has been activated (Jin
and El-Deiry, 2005).
Cells undergoing necrosis swell, resulting in loss of membrane integrity and
eventually lyse (Jin and El-Deiry, 2005). This release of cellular contents results in a
massive inflammatory response that could possibly result in shock, organ failure, limb
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perfusion and death. The preferential strategy and cellular response to traditional cancer
therapy is controlled cellular apoptosis rather than necrosis.
A poor inducer of apoptosis is not necessarily a result of its ability to adequately
activate the cellular apoptotic machinery. It is just as likely to be a poor or weak inducer
of apoptosis due to its inability to fully activate NF-κB, whose target genes; the cellular
inhibitors of apoptosis (CIAPs) prevent programmed cell death (Ghobrial et al., 2005).
The activation of IKK and the subsequent activation of NF-B leads to the induction
of genes whose protein products, in most cases, results in the prevention of apoptosis and
necrosis. Many of the NF-κB activating ligands, receptors, adapter proteins, and
inhibitors of Apoptosis are target genes of NF-κB. TNF, TNF receptor, TRAF and Xlinked inhibitor of Apoptosis are just a few (Ghobrial et al., 2005). Once activated NFκB plays a major role in further providing key factors necessary for its further activation
in an autocrine fashion.
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FIGURE 1.7

Figure 1.7: Apoptosis occurs through two main pathways.
The extrinsic pathway is triggered through death receptor activation and formation of
DISC, leading to initiator pro-caspase congregation. Stimulation of the second
pathway, the intrinsic pathway, results in the release of cytochrome-c from the
mitochondria and activation of the death signal. The intrinsic and extrinsic pathways
converge to form a final common pathway resulting in the activation of caspases that
cleave regulatory and structural molecules effecting in the death of the cell. Illustrated
by (Ghobrial et al., 2005), with modifications.
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1.4.1 X-Linked Inhibitor of Apoptosis Protein (XIAP)
Inhibitors of apoptosis proteins are a family of proteins whose actions are known
to inhibit apoptosis. It is thought that they accomplish this action, utilizing one of two
mechanisms. Ubiquitinating apoptotic proteins thereby targeting them for degradation, or
by sterically hindering the protein from engaging its cognate substrate (Eckelman et al.,
2006). The most well known are cellular IAP-1, IAP-2 (cIAP-1 and cIAP-2 respectively)
and XIAP. These inhibitors act upon the caspase proteins, specifically caspases 3-7-9.
Inhibition of these caspases will subsequently block down stream activation of apoptosis
(Fig. 1.8).
The characterizing feature of the IAP family of proteins is a series of 70-80 amino
acid Baculovirus IAP Repeat (BIR) domains (Xiao-Ming Yin and Zheng Dong, 2003).
The domain is histidine and cysteine rich, and exists in a folded globular formation. Each
of the BIR domains are functionally independent and chelate a zinc ion(Xiao-Ming Yin
and Zheng Dong, 2003). The BIR domain is essential in allowing XIAP to associate with
both initiator and effector caspases (Salvesen and Duckett, 2002). This association
blocks activation of caspases, as previously described, thereby inhibiting apoptosis.
In addition, XIAP as well as other IAP’s, contain an E3 Ubiquitin ligase domain at
its C- terminus, containing a RING finger, a subset of the classical zinc finger domain
(Mani and Gelmann, 2005). The E3 ligase recruits target proteins, including other IAP’s
for ubiquitination and subsequent degradation regulating the cellular apoptotic signaling.
The ubiquitination and degradation of IAP’s correspond to an advancement of the
apoptotic signal (Salvesen and Duckett, 2002). It follows that inhibition of XIAP, either
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transcriptionally through inhibition of NF-B or by targeting its activitiy with a chemical
inhibitor, will enhance the apoptotic effect on the cell (Schimmer et al., 2006).
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FIGURE 1.8

Figure 1.8: XIAP inhibits caspases in both the intrinsic and extrinsic apoptotic
pathways.
XIAP directly inhibits key activated caspases, in both pathways. XIAP binds to the
effector caspase-3 and caspase-9, via its BIR domain, hindering substrate engagement
by the proteases. Illustrated by (Salvesen and Duckett, 2002), with modifications.
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1.4.2 Akt
Akt is a family of serine threonine protein-kinases. It has been demonstrated that
it may regulate cancer metastasis and chemotherapeutic resistance and has been found to
be constitutively active in a number of cancers (Vivanco and Sawyers, 2002). The
biological consequences of Akt activation effect cell survival, proliferation, and growth
(Datta et al., 1999).
Akt contains an N-terminal, pleckstrin homology domain (PH), a central kinase
domain, and a c-terminal regulatory domain (Vivanco and Sawyers, 2002). The PH
domain mediates recruitment to the cellular membrane as well as protein-protein and/or
protein-lipid interactions. Four activating phosphorylation sites have been identified on
Akt; however the primary activation targets are threonine 308 and serine 473 (Datta et al.,
1999). Several regulatory kinase complexes have been indentified that are capable of
phosphorylating Akt but both primary activation sites are phosphorylated by the kinase
complex, 3-phosphoinositide-dependant protein kinase (PDK1/PKR-2)(Datta et al.,
1999).
Upon cellular growth factor or cytokine stimulation phosphatidylinositol 3-kinase
(PI3K) activates the classical second messenger, phosphatidylinositol 3, 4, 5, triphosphate
(PIP3) (Datta et al., 1999). PIP3 recruits Akt, via its PH domain, to the inner leaflet of
cellular membrane. Upon membrane association it is targeted for phosphorylation and
subsequent activation, upon activation Akt is released into the cytosol (Datta et al., 1999).
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Activated Akt is involved in both pro-survival and apoptotic pathways. Akt has been
shown to phosphorylate IKK- triggering NF-B activation and subsequent pro-survival
signaling (Fig. 1.9) (Datta et al., 1999).
Two apoptotic proteins, examined in this study and affected by Akt are the Bcell lymphoma (Bcl) family of proteins and capasese-9. During apoptosis, following a
series of cascading events, the mitochondrial membrane becomes increasingly more
permeable (Ghobrial et al., 2005). This is accomplished through the formation of pores in
the mitochondrial membrane, mediating the release of cytochrome-C into the cytoplasm,
a hallmark signal of apoptosis (Xiao-Ming Yin and Zheng Dong, 2003). A member of
the Bcl family of proteins, Bcl-XL, mediates the inhibition of the formation of these
pores.
A second member of this family BAD, is an in inhibitor of Bcl-XL. Under homeostatic
conditions, BAD is phosphorylated by Akt, and forms a dimer with a protein named 143-3 (so called due to characteristic migration patterns in electrophoretic gels), keeping it
inactive (Kim and Chung, 2002). The non-phosphorylated species of BAD forms a dimer
with Bcl-XL, inhibiting its anti-apoptotic effects (Xiao-Ming Yin and Zheng Dong,
2003).
Caspase-9, an initiator caspase, exists in cytoplasm as a zymogen. Upon release of
cytocrome-C pro-caspase-9 is incorporated into an apoptotic structure, named the
apoptosome which facilities caspase-9 auto activation (Xiao-Ming Yin and Zheng Dong,
2003). Once activated caspase-9 is able to activate the executioner caspase, caspase-3
facilitating the apoptotic advance (Datta et al., 1999).
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It has been demonstrated that Akt is able to phosphorylate caspase-9 causing its
inactivation. This event takes places post -cytocrome C release from the mitochondria,
demonstrating Akt has both pre and post Apoptotic regulatory roles (Datta et al., 1999).
A number of studies have shown that the cell death inducing effect of chemotherapy
depends on induction of apoptosis and that disruption of the apoptosis signaling cascade
may thus be an important cause for chemotherapy resistance (Debatin, 2004; Ziegler and
Kung, 2008). Given the key role that Akt occupies in cell survival, it follows that
inhibition of constitutively active Akt and/or Akt activated by cytokines or
chemotherapeutic drugs, may increase the efficacy of the drug to destroy cancerous
lesions.
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FIGURE 1.9

Figure 1.9: Activated Akt Signal Transduction effects the inhibition of Apoptosis
through two distinct pathways.
The serine/threonine protein kinase Akt inhibits apoptosis by phosphorylating the Bad
component of the Bad/Bcl-XL complex. Bcl-XL is an anti-apoptotic protein and it is
inhibited by Bad. Phosphorylated Bad, binds to the 14-3-3 protein thereby blocking
it from complexing with Bcl-XL. BcL-XL unencumbered by Bad is then able to
promote cell survival. Secondly, Akt activates IKK-α which ultimately leads to NFκB activation and cell survival. (Illustrated by SIGMA)
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1.5 NITRIC OXIDE AND NF-κB
Nitric Oxide is a free radical that may affect a number of intracellular biological
functions (Beckman and Koppenol, 1996). First identified and named Endothelium
Derived Relaxation Factor (EDRF) (Mocellin et al., 2007),

NO is rapidly diffusible in

an aqueous medium and can freely cross cell membranes (Beckman and Koppenol,
1996). Within the aqueous milieu of the cell, Nitric Oxide can under go rapid autooxidation, resulting in the formation of a reactive nitrogen species that may engage a
broad range of molecular targets (Beckman and Koppenol, 1996).
Endogenous NO is predominately produced by L-arginine catabolism to L-citrulline
by a family of nitric oxide synthases (Korhonen et al., 2005). Cellular production, of
nitric oxide, occurs in response to tissues damage and bacterial or viral infection
(Mocellin et al., 2007). In addition, it has been identified as an inter- and intra-cellular
messenger. Lastly, mounting evidence suggests that chronic nitric oxide production is
responsible for inflammatory bowel disease, neurodegenerative disorders and cancer
(Wink and Mitchell, 1998).
The wide range of targets presented to NO is due to its ability to participate in Redox
Chemistry. The moieties of interest in protein chemistry that can be modified by nitric
oxide are tyrosine residues to form 3-nitrotyrosine and cysteine residues to form Snitrosothiols (Mikkelsen and Wardman, 2003; Squadrito and Pryor, 1998).
The formation of the S-nitrosothiols or 3-nitrotyrosine can disrupt the functionality of
the protein if either of these residues are located in: the active site of an enzyme or areas
involved in protein to protein or protein to DNA interaction (Marshall et al., 2000;
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Squadrito and Pryor, 1998). For example, this inhibition can be in the form of blocking
the active site of a kinase or changing the conformation of the protein and sterically
hindering its ability to phosphorylate or to complex with another protein(Mikkelsen and
Wardman, 2003).
The effects of NO are mediated mainly via three routes. NO can react specifically
with transition metals (iron, copper, and zinc) (Hess et al., 2005). These metals are
abundantly present in prosthetic groups of proteins. NO is a Lewis base forming a
nitrosyl complex with the transition metal (Hess et al., 2005). This may trigger a
conformational change in the protein affecting its activity. For example, soluble
guanylate cyclase contains a heme group required for activation. Nitric Oxide is able to
bind with the heme group modifying the porphyrin ring, activating the enzyme (Davis
et al., 2001).
Secondly, NO reacting with the cysteine residues of proteins may form Nitrosothiols.
This is commonly referred to as S-nitrosylation. As with phosphorylation, S-nitrosylation
may effect the activity of the protein, and is reversible (Hess et al., 2005; Kroncke, 2003).
Thirdly, through the formation of peroxynitrite (ONOO-), a powerful nitrating agent
that is able to modify proteins (Mocellin et al., 2007). It is formed in a reaction between
NO and superoxide ion. Peroxynitrite formation in excess, results in nitrated proteins, in
particular tyrosine moieties (Radi, 2004). Tyrosine nitration is a protein modification that
can be used as a marker for excess peroxynitrite formation. In addition Tyrosine nitration
can significantly modify the function a protein (Radi, 2004).
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Transcription factors commonly exhibit at least two functional domains, A DNA
binding domain and an activation domain. The transcription factor binds to a specific
sequence in the promoter or enhancer of a gene, thereby stimulating or blocking
transcription of that gene. The activation domain mediates protein to protein interactions
with other activators, co-activators and general transcription factors of the transcription
mechanisms to facilitate transcription (Alberts et al., 1994). It has been demonstrated that
treatment with exogenous NO donors can cause zinc finger domains to denature and thus
become non-functional(Kroncke and Carlberg, 2000). The NO will complex with a
critical cysteine in the zinc finger domain, the subsequent S-nitrosylation induces
dissociation of the cysteine-Zn2+ linkage, causing the zinc finger to disassociate
(Kroncke, 2001; Marshall et al., 2000).
It has been proposed that NO can regulate the activation of NF-B through several
modifications to the secondary structure. It has been demonstrated that S-nitrosylation of
a cysteine in the activation loop of the IKK- kinase, will limit its ability to
autophosphorylate as well as phosphorylate IB- (Reynaert et al., 2004).
S-nitrosylation of the p50 subunit of NF-B will result in blocking NF-B binding to its
consensus sequence (Matthews et al., 1996) (Marshall and Stamler, 2001). Similarly, two
tyrosine residues on the p65 subunit of NF-B, (Tyr-66 and Tyr-152) may be nitrated
hindering and or blocking the transactivation potential of the transcription factor (Park et
al., 2005). Lastly, nitration of a tyrosine residues on IB- (Tyr-181), an inhibitor of
NF-B, by constitutive NO synthase activation, leads to diasociation of intact IB- from
the p65-p50 dimer. This results in activating NF-B in an IKK- independent manner
(Yakovlev et al., 2007).
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1.6 NO DONORS
1.6.1 Nitrosylcobalamine (NO-Cbl)
NO-Cbl is a vitamin B12 analog, nitrosylated utilizing Nitric oxide gas. Once
nitrosylated NO-Cbl may be used as a nitric oxide donor in a biological system. Under
neutral or basic conditions NO-Cbl maintains a stable configuration. However, under
acidic conditions the nitric oxide moiety is released.
Nitric Oxide, from NO-Cbl enters the cell in two ways. Release of nitric oxide
from the B12 complex and diffusion through the cell membrane, as with other NO
donors, this is considered a minor or secondary release mechanism. The second or
primary mechanism is receptor mediated. The nitrosylated B12 molecule is a ligand for
the B12 receptor and are absorbed into the cell via endocytosis. Once inside the
endosome a reduction in the pH of the vesicle causes a release of the nitric oxide moieties
and they diffuse throughout the cell.
1.6.2 DETA NONOate (NOC-18)
A nitric oxide donor also known as NOC-18. Half-life at pH 7.4 220 C of 56hrs.
NOC-18 releases nitric oxide, in solution in a controlled manner allowing entry into the
cell by natural diffusion.
1.6.3 Sodium Nitropruside (SNP)
Also know as Sodium Nitroferricyanide (III) Dihydrate (SNP) Half life at pH 7.4
220C is a few minutes. NO begins being released up dissolution in water.
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1.7 TOPOISOMERASE POISINSAND NF-B
The winding nature and close packing of double helix DNA within the nucleus leads
to inter-tangling of individual chromosomes. This creates topological obstacles that must
be overcome in order to allow for replication, transcription, recombination, condensation,
and independent segregation. This obstacle is over come utilizing enzymes named
Topoisomerses (Alberts et al., 1994).
Mammalian cells contain two broad classes of Topoisomerase, Topoisomerase type I
and Topoisomerase type II, both types exist as several isoforms (Wang, 2002).
Topoisomerase covalently links itself to a DNA phosphate creating a strand break (either
a single for Topo I or a double break for Topo II in the DNA backbone (Alberts et al.,
1994). The enzyme then passes the other strand through the breaks and then reseals the
break and leaves the DNA. This breakage and reunion of the DNA strands facilitates the
release of the torsional tension in the wound DNA double helix due to transcription or
replication of the cellular DNA (Wang, 2002).
Topoisomerase type I enzymes introduce a single stranded break in the DNA double
helix. Replication,or translation is able to proceed by simply unraveling a short length of
DNA that is immediately ahead of the replication/translation fork (Wang, 2002).
Topoisomerase II is able to form covalent linkage with both strands of the DNA helix
simultaneously. In this manner it is able to make transient double strand break or a gate
within the backbone of the double helix. It then shepherds entangled DNA through the
gate. Reseals the break and dissociates from the DNA (Wang, 2002).
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In addition, during metaphase, an essential part of mitosis, chromosomes must be
able to independently segregate, then migrate to opposite poles. By untangling
intertwining DNA, Topoisomerase II facilitates this mechanism allowing cells to proceed
through to cytokinesis (Alberts et al., 1994). Chromosomes of cells treated with
Topoisomerase II poisons are extremely fragmented and stalled in G2 phase (McClendon
and Osheroff, 2007).
Standard anti- tumor therapy involves the use of Topoisomerase I and II poisons as
anti-neoplastic agents, for many forms of cancer. The primary function of the drugs
interferes with the ability of the enzyme to repair the single, or double stranded breaks in
the DNA double helix (Li and Liu, 2001). This disabled repair mechanism result in
permanent double stranded breaks, causing the cell to stall in either S1 or G2 triggering
activation of the Apoptotic cell death pathway (Kaufmann, 1998).
The Topoisomerase enzymes occupy an important role in cellular growth and
survival. They are especially critical in neoplastic malignancies due to their proliferative
potential. The introduction of unrepairable DSB exploits the ability of the DSB sentinel
mechanisms to stall cell propagation, guarding against further genomic instability.
Genomic instability in the form of double stranded breaks results in a concomitant
activation of NF-κB and the cell survival pathway, a conundrum in application of these
drugs as anti-neoplastic agents.

Development of an adjuvant therapy that would

eliminate or reduce the NF-κB activation could likely increase the efficacy of these
poisons. We have demonstrated, in vitro and in vivo, that the use of nitric oxide donating
compounds as an adjuvant with chemotherapeutic drugs, is able to inhibit NF-κB activity
while simultaneously increasing apoptotic cytotoxicity.
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CHAPTER II
SUPPRESSION OF NF- B SURVIAL SIGNALING BY
NITROSYLCOMBALAMINE SENSITIZES NEOPLASMS TO THE ANTITUMOR EFFECTS OF Apo2L/TRAIL

2.1 ABSTRACT
The anti-tumor activity of nitrosylcobalamin (NO-Cbl), an analog of vitamin B12 that
delivers nitric oxide (NO) and increases the expression of tumor necrosis factor-related
apoptosis-inducing ligand (Apo2L/TRAIL) and its receptors in human tumors, has been
previously demonstrated. The specific aim of this study was to examine whether NO-Cbl
could sensitize drug-resistant melanomas to Apo2L/TRAIL. Antiproliferative effects of
NO-Cbl and Apo2L/TRAIL were assessed in malignant melanomas and non-tumorigenic
melanocyte and fibroblast cell lines. Athymic nude mice bearing human melanoma A375
xenografts were treated with NO-Cbl and Apo2L/TRAIL. Apoptosis was measured by
TUNEL and confirmed by examining levels and activity of key mediators of apoptosis.
The activation status of NF- B was established by assaying DNA binding, luciferase
reporter activity, the phosphorylation status of I B , and in vitro IKK activity. NO-Cbl
sensitized Apo2L/TRAIL-resistant melanoma cell lines to growth inhibition by
Apo2L/TRAIL but had minimal effect on normal cell lines. NO-Cbl and Apo2L/TRAIL
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exerted synergistic anti-tumor activity against A375 xenografts. Treatment with NO-Cbl
followed by Apo2L/TRAIL induced apoptosis in Apo2L/TRAIL-resistant tumor cells,
characterized by cleavage of caspase-3, caspase-8, and PARP. NO-Cbl inhibited IKK
activation, characterized by decreased phosphorylation of I B and inhibition of NF- B
DNA binding activity. NO-Cbl suppressed Apo2L/TRAIL- and TNF- -mediated
activation of a transfected NF- B-driven luciferase reporter. XIAP, an inhibitor of
apoptosis, was inactivated by NO-Cbl. NO-Cbl treatment rendered Apo2L/TRAILresistant malignancies sensitive to the anti-tumor effects of Apo2L/TRAIL in vitro and in
vivo. The use of NO-Cbl and Apo2L/TRAIL capitalizes on the tumor-specific properties
of both agents and represents a promising anti-cancer combination.

2.2 INTODUCTION
Apoptosis is the rigorously controlled process of programmed cell death. Current
trends in cancer drug design focus on selective targeting to activate the apoptotic
signaling pathways within tumors while sparing normal cells (Reed, 2003). The tumor
specific properties of tumor necrosis factor-related apoptosis-inducing ligand
(Apo2L/TRAIL) have been widely reported (Ashkenazi, 2002; Pitti et al., 1996; Walczak
et al., 1999; Wiley et al., 1995). Apo2L/TRAIL has been used as an anti-cancer agent
alone and in combination with other agents (Ashkenazi et al., 1999; Frese et al., 2002;
Gliniak and Le, 1999; Mizutani et al., 2002; Yamanaka et al., 2000) including ionizing
radiation (Chinnaiyan et al., 2000; Di Pietro et al., 2001; Kim et al., 2001).
Apo2L/TRAIL can initiate apoptosis in cells that overexpress the survival factors Bcl-2
and Bcl-XL, and may represent a treatment strategy for tumors that have acquired
resistance to chemotherapeutic drugs (Walczak et al., 2000).
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Apo2L/TRAIL binds its cognate receptors and activates the caspase cascade
utilizing adapter molecules such as FADD(Ashkenazi, 2002; Pan et al., 1997). TRAIL
receptors, type II membrane-bound proteins, are members of the tumor necrosis factor
(TNF) superfamily of receptors (Wiley et al., 1995). To date, five Apo2L/TRAIL
receptors have been identified (Ashkenazi, 2002). Two receptors TRAIL-R1 (DR4) and
TRAIL-R2 (DR5) mediate apoptotic signaling, and three non-functional receptors, DcR1,
DcR2, and osteoprotegerin (OPG) may act as decoy receptors (Ashkenazi, 2002). Agents
that increase expression of DR4 and DR5 may exhibit synergistic anti-tumor activity
when combined with Apo2L/TRAIL (Gibson et al., 2000).
The anti-tumor effects of nitrosylcobalamin (NO-Cbl), an analogue of vitamin B12
(cobalamin, Cbl) coordinated with nitric oxide (NO) as a ligand, has been demonstrated
(Bauer et al., 2002). Anti-tumor activity correlated with the expression of the
transcobalamin II receptor (TCII-R) on the plasma membrane of tumor cells. NO-Cbl is
an ideal candidate to be used in combination with Apo2L/TRAIL because NO-Cbl
induced the mRNAs of DR4, DR5, and Apo2L/TRAIL in ovarian carcinoma cells (Bauer
et al., 2002). Treatment of leukemia cells with Apo2L/TRAIL resulted in increased
Apo2L/TRAIL mRNA and protein, suggesting autocrine regulation that can function in a
positive feedback loop (Herr et al., 2000). Transfecting ovarian carcinoma cells with a
non-functional, dominant negative DR5 receptor (DR5 ) (Gong and Almasan, 2000)
abrogated increases in DR4, DR5, and Apo2L/TRAIL when treated with NO-Cbl.2 This
suggested that a functional Apo2L/TRAIL receptor was necessary for the autoinduction
of Apo2L/TRAIL, and that DR5

interfered with positive feedback signaling.
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Cytokines of the TNF superfamily, upon receptor ligation, simultaneously induce an
apoptotic signal (mediated via caspase-8) in addition to a survival signal (mediated by
activation of NF- B) (Bharti and Aggarwal, 2002). NF- B is a transcription factor that
generally functions to suppress apoptosis (Bharti and Aggarwal, 2002; Bours et al.,
2000). Binding of TNF- (DiDonato et al., 1997a) or Apo2L/TRAIL (Baetu et al., 2001)
to their cognate receptors results in the phosphorylation and activation of the inhibitor of
B-kinase (IKK). In its quiescent state, NF- B is complexed to the inhibitor of B (I B)
in the cytoplasm (DiDonato et al., 1995b). Activated IKK phosphorylates serine 32 and serine 36
of I B (DiDonato et al., 1996). Once phosphorylated, I B is ubiquitinated and targeted
for proteolysis as it remains complexed to NF- B (DiDonato et al., 1995a). Within the
proteosome I B is degraded, while NF- B is not, allowing NF- B to translocate to the
nucleus where it binds to NF- B response elements, which activate transcription of target
genes (DiDonato et al., 1997a; DiDonato et al., 1995b). NF- B stimulates transcription
of genes such as Bcl-XL and cIAP that function as survival factors (Chen et al., 2000;
LaCasse et al., 1998). Therefore, agents that inhibit NF- B may have anti-tumor activity.
NO is a ubiquitous, multifaceted signaling molecule (Anggard, 1994; Gross and
Wolin, 1995) that inhibits NF- B DNA binding activity (DelaTorre et al., 1997) and
suppresses the cell survival function of NF- B (D'Acquisto et al., 2001; Kang et al.,
2002). Sulfasalazine, an anti-inflammatory agent, inhibits NF- B activity, enhancing
Apo2L/TRAIL-induced apoptosis in human leukemia cells (Goke et al., 2000).
Furthermore, Apo2L/TRAIL-induced apoptosis was increased in prostate carcinoma cells
that were infected with a mutant I B, supporting the role of NF- B as a TRAIL-induced
survival factor (Eid et al., 2002). The use of NO-Cbl to deliver nitric oxide and suppress the
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survival arm of NF- B is a promising strategy to enhance the anti-tumor effects of
Apo2L/TRAIL in resistant tumors.
In this study we pretreated cells with NO-Cbl to inhibit NF- B activity and enhance the
apoptotic signal of Apo2L/TRAIL. Our specific aims were to: 1) measure the anti-tumor
effects of NO-Cbl and Apo2L/TRAIL in Apo2L/TRAIL-resistant cell lines, and to 2)
determine the mechanism by which NO-Cbl inhibits NF- B activation.
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2.3 MATERIAL AND METHODS
2.3.1 Synthesis of Nitrosylcobalamin
Nitrosylcobalamin was synthesized as previously described (Bauer, 1998; Bauer et al.,
2002). Hydroxocobalamin (vitamin B12a) acetate (George Uhe Company, Paramus, NJ)
was dissolved in dichloromethane (Burdick and Jackson, Muskegon, MI) and exposed to
CP grade NO gas (Praxair, Wickliff, OH) at 150 psi. The reaction proceeds in a closed
system within a high-pressure gas cylinder (Praxair, Cleveland, OH). The system was
nitrogen-purged daily and evacuated prior to NO exposure. The NO gas was scrubbed
prior to entering the system using a stainless steel cylinder (Swagelok, Abbott valve and
fitting, Solon, OH) containing NaOH pellets. The solid NO-Cbl product was collected
following rotary evaporation of the solvent and stored at –80 °C prior to use.
2.3.2 Cell Culture and Cytokine Treatments
Human melanoma tumor cell lines, WM9 and WM3211 (Wistar Institute,
Philadelphia, PA), and A375(ATCC, Manassas, VA) were grown in Dulbecco's modified
Eagle medium (DMEM; Invitrogen) supplemented with heat-inactivated 10% fetal bovine
serum (FBS; HyClone, Logan, UT) and 1% Antibiotic-Antimycotic (Invitrogen). Cells
were maintained in 5% CO2 at 37 °C in a humidified tissue culture incubator. Primary nontumorigenic melanoma cell lines (DMN-1 and CMN-1, A. Gudkov, CCF, Cleveland, OH), and

human foreskin fibroblasts (HFF; CCF, Cleveland, OH) were cultured in DMEM-F12
medium supplemented with 10% fetal bovine serum. Cells were confirmed as
mycoplasma free.
All experiments were performed using trimeric recombinant human Apo2L/TRAIL
(Lawrence et al., 2001) (Genentech Inc., San Francisco, CA) and were independently
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confirmed using recombinant Apo2L/TRAIL from another source (Peprotech Inc, NJ).
Apo2L/TRAIL (Genentech Inc.), consisted of >99% trimeric protein with Zn+2, which is
necessary for optimal biologic activity of Apo2L/TRAIL (Lawrence et al., 2001).
2.3.2 Sulforhodamine B cell Growth Assay
Cells were harvested with 0.5% trypsin/0.53 mM EDTA, washed with phosphatebuffered saline and resuspended in media containing 10% fetal bovine serum. Cells were
plated in 96-well plates in 0.2-ml aliquots containing 10,000 cells. Cells were allowed to
adhere to the plate for 4 h and then NO-Cbl was added in different dilutions (25, 50 and
100 µM) to the assay plate. Replicates of four were performed for each treatment. After
16 h, recombinant human Apo2L/TRAIL was added at different concentrations (25–100
ng/ml). Growth was monitored by the sulforhodamine B (SRB; Sigma Chemical)
colorimetric assay (Skehan et al., 1990). After 40 h growth, the medium was removed,
and the cells were fixed with 10% trichloroacetic acid and stained with SRB. Bound dye
was eluted from the cells with 10 mM Tris-HCl (pH 10.5) and absorbance was measured
at 570 nm using Lab systems Multiskan RC 96-well plate reader (Lab Systems Multiscan
RC, Thermo Lab Systems, Franklin, MA). To quantify the growth of the cells, the
experimental absorbance values (Aexp) were compared with initial absorbance readings
representing the starting cell numbers (Aini). To determine the starting cell number, an
additional 96-well plate was seeded with cells and fixed at the beginning of the
experiment. The absorbances derived from the initial plate and from the untreated cells at
the end of the growth period (Afin) were defined as 0 and 100% growth, respectively. The
percentage control growth (100% x [Aexp – Aini]/[Afin – Aini]) is expressed as a percentage
of untreated controls.
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2.3.3 In Vivo Experiments
The Institutional Animal Care and Use Committee at the Cleveland Clinic Foundation
approved all procedures for animal experimentation. 5-week-old NCR male athymic nude
homozygous (nu/nu) mice (Taconic, Germantown, NY) were inoculated with A375
tumors. There were four experimental groups (untreated, single agents, and the
combination) n = 8. Cultured tumor cells (4 x 106) were inoculated into flanks in the midaxillary line. NO-Cbl was given twice daily (50 mg/kg s.c.) and recombinant trimeric
Apo2L/TRAIL (50 mg/kg s.c.) (Skehan et al., 1990) was administered every other day,
starting on day 2. Tumor volume was measured three times a week using the formula for
a prolate spheroid: (4/3) ab2 where 2a = major axis, 2b = minor axis. Formalin-fixed
sections were processed by the Cleveland Clinic Histology Core. Sections were stained
with hematoxylin and eosin and evaluated for pathologic changes in a blinded fashion.
2.3.4 TUNEL Assay
A375 cells were cultured for 36 h and exposed to various treatments (control, NOCbl, Apo2L/TRAIL, and NO-Cbl + Apo2L/TRAIL). Apoptotic cells were detected by
TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end-labeling)
staining using a commercially available kit (APO-BRDU kit, BD PharMingen, San
Diego, CA). Cells were processed according to the manufacturer's recommended
protocol. The percentage of fluorescein isothiocyanate-positive cells was analyzed by
fluorescent-activated cell scanning (FACS, Becton Dickinson, Facsvantage, and San
Diego, CA).
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2.3.5 Gel Electrophoresis and Immunoblot Analyses
Whole cell lysates were prepared in 1x lysis buffer (50 mM Tris-Cl, pH 8.0, 1%
Triton X-100, 10% glycerol, 1 mM EDTA, 250 mM NaCl, 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 10 µg/ml
pepstatin) for subsequent immunoblotting studies. SDS-PAGE was conducted by using
the Laemmli buffer system and 12% polyacrylamide gels. Proteins were transferred onto
polyvinylidene difluoride membranes by the semidry method (Trans Blot S.D., BioRad,
Hercules, and CA). Binding of the primary and secondary antibodies was performed
according to standard protocols (Chawla-Sarkar et al., 2002). Membranes were
immunoblotted with pAb to caspase-3, caspase-8, XIAP (BD PharMingen), PARP
(BioMOL), FLIP (Calbiochem), pI B , I B (Cell Signaling), cIAP-1, anti-IKK /
(Santa Cruz Biotechnology) followed by incubation with horseradish peroxidaseconjugated secondary antibodies (Pierce). Immunoreactive bands were visualized by
using enhanced chemiluminescence (PerkinElmer). Equal protein loading was confirmed
by reprobing with monoclonal anti-actin antibody (Sigma Chemical Co.). All
immunoblots in this study were repeated 3 times with reproducible results.
2.3.6 Electrophoretic Mobility Shift Assay (EMSA)
A375 cells were treated with NO donors (NO-Cbl, NOC-18, SNAP, 100 µM, 16 h),
or with Apo2L/TRAIL (100 ng/ml) or TNF- (20 ng/ml) for 15 min and 1 h, or with NO
donors (16 h) followed by Apo2L/TRAIL or TNF- (15 min and 1 h). Plates were
washed twice with ice-cold phosphate-buffered saline. Cells were resuspended in cold 1x
lysis buffer (20 mM HEPES, 20 mM NaF, 1 mM Na3VO4, 1 mM EDTA, 1 mM
dithiothreitol, 100 mM NaCl, 10% glycerol, and protease inhibitors) as previously
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described (Li et al., 2000) and incubated on ice for 30 min followed by centrifugation at 4
°C at 10,000 rpm for 10 min. Supernatants were transferred to fresh tubes and protein
concentrations were assessed using the Bradford method (BioRAD protein assay,
BioRad). The NF- B consensus binding sequence
(5'-AGTTGAGGGGACTTTCCCAGGC-3') from the IFN- gene promoter was endlabeled with [ -32P]dATP (3000 Ci/mol) using T4 polynucleotide kinase. DNA binding
reactions were performed in 20 µl reaction volumes for 20 min at 25 °C containing 10 µg
of protein, 20 mM HEPES, 10 mM KCl, 0.1% Nonidet P-40, 0.5 mM dithiothreitol, and
10% glycerol. Complexes were separated from the free probe on 6% nondenaturing
polyacrylamide gels in 0.5x TBE buffer at 200 V for 2 h. Gels were dried and exposed to
film. To verify the identity of the band observed lysates from A375 cells stimulated for
15 min with TNF- (20 ng/ml) were incubated with anti-NF- B p50 or p65 antibodies
(Santa Cruz Biotechnology).
2.3.7 Dual Luciferase NF- B Reporter Assay
The NF- B-luciferase (NF- B-luc) reporter plasmid, containing a 2xNF- B
response element fused to luciferase, has been previously characterized (Elewaut et al.,
1999). Renilla luciferase (pRL-TK, Promega, Madison, WI) was co-transfected to
normalize for transfection efficiency. A375 cells were co-transfected with 20 µg of NFB-luc and 10 µg of pRL-TK using Lipofectamine plus (Invitrogen). After transfection
cells were allowed to recover overnight and were plated in 6-well plates. Cells were
pretreated with NO-Cbl (100 µM) for 16 h followed by TNF- (10 ng/ml) or
Apo2L/TRAIL (100 ng/ml) for 4 h. Cells were then harvested in 1x passive lysis buffer
and luciferase activity was measured according to the manufacturer's protocol (Promega,
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Madison, WI) using a Wallac 1420 multilabel counter (PerkinElmer). Fold induction of
NF- B-luciferase for each treatment was based on untreated values normalized to the
fold induction of pRL-TK reporter values. The assays were performed in triplicate.
2.3.8 I B kinase (IKK) assay
Whole cell extracts (300 µg) were supplemented with 150 µl of Buffer A (20 mM
HEPES, pH 7.9, 20 mM -glycerophosphate, 10 mM NaF, 0.1 mM orthovanadate, 5 mM
p-nitrophenyl phosphate (pNPP), 10 mM 2-mercaptoethanol, 0.5 mM
phenylmethylsulfonyl fluoride, and protease mixture), 2 µl of normal rabbit serum, and
mixed by rotation at 4 °Cfor1has previously described (DiDonato, 2000). A 50% slurry of
protein G-Sepharose (80 µl) (Amersham Biosciences) prepared in Buffer A (without
mercaptoethanol or phenylmethylsulfonyl fluoride) was added and mixed by rotation at 4
°C for 1 h. Protein G-Sepharose was removed by centrifugation at 800 x g for 1 min and
discarded. Anti-IKK monoclonal antibody (0.5 µg, BD PharMingen), or anti- -actin
epitope antibody was added to the supernatant and mixed by rotation at 4 °C for 2 h. A
50% slurry of protein G-Sepharose (60 µl) prepared in Buffer C (Buffer A plus 50 mM
NaCl and 10 mM MgCl2, without mercaptoethanol and phenylmethylsulfonyl fluoride)
was added and mixed by rotation in the cold for 30 min. Protein G immunopellets were
collected by centrifugation at 800 x g for 30 s, washed three times with Buffer B (Buffer
A plus 250 mM NaCl), and once with Buffer C (Buffer A plus 50 mM NaCl and 10 mM
MgCl2). Immunopellets were resuspended in 30 µl of kinase buffer with 0.1 mM
orthovanadate, 50 µM unlabeled ATP, 5 µCi of [ -32P]ATP, 2 mM dithiothreitol, and 2
µg of recombinant GST-I B 1–54 (DiDonato et al., 1997a) and incubated at 30 °C for
30 min. Reactions were stopped by the addition of 15 µl of 4x SDS-PAGE loading buffer
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(200 mM Tris-HCl, pH 6.8, 8% SDS, 40% glycerol, 0.2% 2-mercaptoethanol), heated at
95 °C for 10 min, and resolved by SDS-PAGE on a 12% acrylamide gel by standard
procedures. Gels were rinsed, stained with Bio-Safe Coomassie (BioRad) to visualize
protein bands, rinsed, photographed, then dried and exposed to Kodak X-OMAT AR film
(Eastman Kodak Co., Rochester, New York) to detect substrate phosphorylation. IKK
activation was quantified by PhosphorImage analysis on a Storm-840 imager using Image
Quant v 4.2 software (Molecular Dynamics, Amersham Biosciences).
2.3.9 Statistical Analysis
Median effect analysis was used to characterize the interaction between NO-Cbl and
Apo2L/TRAIL (Chou and Talalay, 1984). A combination index (CI) >1 indicates antagonism, CI
= 1 indicates additivity, and CI <1 indicates synergy. Differences in mean tumor volume
between groups were compared using the unpaired two-tailed Student's t test, using a
pooled estimator of variance to determine statistical significance.

2.4 RESULTS
2.4.1 Anti-tumor Effects of NO-Cbl, Apo2L/TRAIL Vitro and in Vivo
To test our hypothesis that NO-Cbl would enhance the anti-cellular effects of
Apo2L/TRAIL against malignant Apo2L/TRAIL-resistant cell lines, we measured the
antiproliferative effects of three melanoma lines A375, WM9, and WM3211 (previously
shown to be resistant to Apo2L/TRAIL) (Chawla-Sarkar et al., 2002). Three nonmalignant human cell lines CMN1 and DMN1 (normal melanocytes) and primary human
foreskin fibroblasts (HFF) were examined to demonstrate the tumor-specific effects of
NO-Cbl and Apo2L/TRAIL. We used the SRB antiproliferative assay, used by the
National Cancer Institute (NCI) to evaluate new chemotherapeutic agents (Skehan et al.,
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1990). Median effect analysis was used to characterize the interaction between NO-Cbl
and Apo2L/TRAIL (Chou and Talalay, 1984). Cells were pretreated with NO-Cbl for 16
h followed by Apo2L/TRAIL for 24 h. Sequential drug treatment resulted in synergistic
antiproliferative activity in all three malignant cell lines (Fig. 2.1a). Non-malignant cells
were resistant to the antiproliferative effects of NO-Cbl, Apo2L/TRAIL and the combination
(Fig. 2.1b). This is consistent with the tumor-specific properties of both NO-Cbl and
Apo2L/TRAIL (Bauer et al., 2002; Lawrence et al., 2001).
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FIGURE 2.1
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Figure 2.1: Effects of nitrosylcobalamin (NO-Cbl), Apo2L/TRAIL, and the
combination on the proliferation of melanoma cell lines A375, WM9, and
WM3211 and normal cell lines CMN1, DMN1, and primary HFF fibroblasts.
Left panels, cells were treated with NO-Cbl (open bars), Apo2L/TRAIL (hatched
bars), or pretreated with NO-Cbl followed by Apo2L/TRAIL (solid bars) for 3 days,
and growth was measured by the colorimetric sulforhodamine B assay (Skehan et al.,
1990). Data points represent the mean of four replicates ± S.E. Right panels, synergy
between NO-Cbl and Apo2L/TRAIL was determined by median effect analysis (Chou
and Talalay, 1984; Rubinstein et al., 1990), (combination index >1 indicates
antagonism, = 1 indicates additivity, and <1 indicates synergy). a, the sequential
treatment of NO-Cbl and Apo2L/TRAIL induced synergistic antiproliferative activity
in A375, WM9, and WM3211 cells at each combined dose. b, normal melanocyte
CMN1 and DMN1 cell lines, and normal HFF fibroblasts were completely resistant to
simultaneous exposure to NO-Cbl, Apo2L/TRAIL, or the pretreatment with NO-Cbl
followed by Apo2L/TRAIL.
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To test drug activity in vivo, subcutaneous A375 xenografts were established in nude
mice. Daily drug treatments began on day 2 following implantation, at which time tumors
were both visible and palpable (Fig. 2.2). After 21 days, the tumors in mice treated with
single agent NO-Cbl or Apo2L/TRAIL were not significantly smaller than controls.
However, the tumors in mice treated with the combination of NO-Cbl and Apo2L/TRAIL
were 82.42% smaller than control tumors (p 0.00016). The mice maintained their
weight and activity and exhibited no adverse side effects due to single agents or the
combination. Compared with the in vitro activity of Apo2L/TRAIL, the enhanced antitumor activity observed in vivo likely results from multiple biological effects. It has been
confirmed that Apo2L/TRAIL up-regulates NK activity in vivo resulting in synergistic
anti-tumor effects (Sato et al., 2001). Though athymic nude mice lack T-cells, they
possess robust NK cell activity.
2.4.2 Mechanism of NO-Cbl/Apo2L/TRAIL-initiated Apoptosis
The A375 cell line has a defect in Apo2L/TRAIL gene induction (Chawla-Sarkar et
al., 2001). Therefore, additive cellular responses from endogenous Apo2L/TRAIL were
avoided. We performed TUNEL assays of A375 cells treated in vitro with NO-Cbl,
Apo2L/TRAIL, or the combination. Treatment with NO-Cbl (100 µM) or Apo2L/TRAIL
(100 ng/ml) for 36 h induced 6.2% and 5.4% TUNEL-positive cells, respectively
(Fig. 2.3). The simultaneous co-treatment of A375 cells with NO-Cbl (100 µM) and
Apo2L/TRAIL (100 ng/ml) for 36 h resulted in 28.2% TUNEL-positive cells. However,
sequential pre-treatment of A375 cells with NO-Cbl (100 µM) for 12 h, followed by
Apo2L/TRAIL (100 ng/ml) for an additional 24 h induced 98.4% TUNEL-positive cells,
suggesting that
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NO-Cbl primes cells to Apo2L/TRAIL-induced apoptosis. In contrast, pre-treatment with
Apo2L/TRAIL followed by NO-Cbl did not enhance TUNEL staining.
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FIGURE 2.2

Figure 2.2: Effect of NO-Cbl, Apo2L/TRAIL and the combination on the growth
of A375 melanoma Xenografts.
NCR male athymic nude (nu/nu) mice were injected subcutaneously with 4 x 106
A375 cells (n = 8 per group). Crug treatments began on day 2 after injection of tumor
cells. NO-Cbl was administered twice daily for the duration of the study.
Apo2L/TRAIL was administered every other day. Control mice received phosphate
buffered saline. Tumor volume was measured three times per week. Data points
represent volume (in cubic mm) +/- S.E.
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FIGURE 2.3

Figure 2.3: TUNEL apoptosis assay
A375 cells were treated with NO-Cbl and Apo2L/TRAIL alone, and in combination
with NO-Cbl. NO-Cbl and Apo2L/TRAIL were minimally effective as agents but
demonstrated greater apoptosis when administered concomitantly. The highest levels
of apoptosis were observed when cells were pretreated with NO-Cbl for 12 h followed
by Apo2L/TRAIL treatment for 24h. Conversely, the effect of Apo2L/TRAIL
followed by NO-Cbl was no different than Apo2L/TRAIL alone.
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To further examine apoptosis pathways, we performed immunoblot analysis using
antibodies to various components of the apoptosis signaling cascade. A375 cells were
treated with NO-Cbl (50–100 µM) for 16 h followed by Apo2L/TRAIL (100 ng/ml)
treatment for 6–12 h. Whole cell lysates were probed for caspase-8, caspase-3, and PARP
cleavage. Cells pre-treated with NO-Cbl followed by Apo2L/TRAIL demonstrated
enhanced cleavage of caspase-8, caspase-3, and PARP, indicating activation of initiators
and effectors of apoptosis (Fig. 2.4a). In addition, cleavage of the X-linked inhibitor of
apoptosis (XIAP) was enhanced by NO-Cbl pre-treatment followed by Apo2L/TRAIL
(Fig. 2.4b), indicating that NO-Cbl promoted degradation of an apoptosis inhibitor. Some
melanomas have increased XIAP activity which may contribute to their resistance
(Lillehoj et al., 2002). This effect was specific to XIAP, as there was no change in the
levels of cIAP-1 or FLIP (Fig. 2.4b).
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FIGURE 2.4
A

B

Figure 2.4: Western blot analysis of mediators of Apoptosis
a, A375 cells were pre-treated with NO-Cbl for 16h, followed by Apo2L/TRAIL
for 6 or 12h, which resulted in cleavage of caspase-3, caspase-8 and PARP. b,
sequential NO-Cbl and Apo2L/TRAIL treatment caused cleavage of XIAP but
not cIAP or FLIP
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2.4.3 Inhibition of NF- B Survival Signaling by NO-Cbl
We next used EMSA to examine the effects of NO-Cbl on NF- B activation. The NFB binding element from the IFN- gene promoter was used as a probe to assess DNA
binding activity. A375 cells were treated with TNF- (20 ng/ml), Apo2L/TRAIL (100
ng/ml) or NO-Cbl (100 µM). Pretreatment with NO-Cbl (16 h) completely inhibited NFB DNA binding activity induced by 1 h stimulation with Apo2L/TRAIL (Fig. 2.5a, lanes
4 and 6). NO-Cbl only partially inhibited NF- B DNA binding activity induced by TNFat 15 min and 1 h (Fig. 5a, compare lanes 7–10). Antibodies to NF- B-p50 or p65
induced a supershift and confirmed the presence of the p50 and p65 components of the
NF- B complex. Compared with TNF- , which strongly activates NF- B after 15 min,
Apo2L/TRAIL is a weaker activator of NF- B; band shifts are not detectable 15-min
poststimulation with Apo2L/TRAIL, but do appear by 1 h. This effect has previously
been observed in renal cell carcinomas (Oya et al., 2001). Pretreatment with other NO
donors including NOC-18 (100 µM) and SNAP (100 µM) also inhibited NF- B DNA
binding activity induced by Apo2L/TRAIL (Fig. 2.5b).
Transient transfection assays were performed to assess NF- B transcriptional activity.
A375 cells were co-transfected with a NF- B-luciferase reporter (NF- B-luc) and
Renilla luciferase (to assess transfection efficiency). Cells were pretreated with NO-Cbl
(100 µM) for 16 h followed by treatment with Apo2L/TRAIL (100 ng/ml) or TNF- (10
ng/ml) for 4 h. NO-Cbl pretreatment caused a 34 and 51% inhibition of NF- B activity in
response to Apo2L/TRAIL and TNF- , respectively (Fig. 2.5c).
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FIGURE 2.5

Figure 2.5: EMSA: NF-B DNA Binding activity.
a, pretreatment of A375 cells with NO-Cbl (16h) inhibited the NF-B DNA binding
activity induced by Apo2L/TRAIL, or TNF-. Incubation of lysates with anti-NF-B
p50 or anti-NF-B p65 antibodies resulted in supershift (SS) of the NF-B complex.
b, pretreatment with NO donors, NOC-18 and SNAP for 16h also reduced
Apo2L/TRAIL-induced NF-B DNA binding. c, NF-B-luc-transfected A375 cells
were pretreated with NO-Cbl for 1h followed by Apo2L/TRAIL or TNF- for 4h.
Renilla luciferase was co-transfected to normalize samples for transfection efficiency.
Cell lysates were analyzed for NF-B-luc reporter activity. NO-Cbl pretreatment
inhibited Apo2L/TRAIL and TNF- induced activation of NF-B luc reporter.
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We next determined whether NO-Cbl treatment could affect the degradation of I B ,
the prototypic inhibitor of NF- B (DiDonato et al., 1995b). After a 15-min stimulation
with TNF- (20 ng/ml) or Apo2L/TRAIL (100 ng/ml, 30 min), I B was almost
completely degraded (Fig. 2.6a). However, NO-Cbl pretreatment for 16 h (100 µM)
completely blocked I B degradation following stimulation with Apo2L/TRAIL. NOCbl was much less efficient at blocking I B degradation following TNF- stimulation.
Pretreatment with NO-Cbl for 16 h (100 µM) completely blocked I B phosphorylation
induced by 1 h stimulation using Apo2L/TRAIL (100 ng/ml) and decreased that induced
by TNF- (20 ng/ml) (Fig. 2.6b). At 1 h following TNF- stimulation, IKK remains
activated, albeit at reduced levels compared to15 min (DiDonato et al., 1997b).
Phosphorylation of I B (all of which has been newly synthesized by 1 h) is evident.
After 1 h, total I B levels were comparable between treatment groups. Accordingly,
phospho-I B migrates slower than I B (Fig. 2.6b, compare lanes 3 and 4 to other
lanes). NOC-18 (100 µM) and SNAP (100 µM) also inhibited Apo2L/TRAIL induced
phosphorylation of I B (Fig. 2.6c).
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FIGURE 2.6
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Figure 2.6: Western blot analysis of I B and phospho-I B .
A375 cells were pre-treated for 16 h with NO-Cbl followed by Apo2L/TRAIL or
TNF- stimulation. I B and phospho-I B protein levels were determined in A375
whole cell lysates. a, after stimulation with Apo2L/TRAIL (30 min) or TNF- (15
min), I B was almost totally degraded. NO-Cbl efficiently blocked I B
degradation following Apo2L/TRAIL, but only partially blocked I B degradation
following TNF- . b, after 1 h, cellular levels of I B are restored as a result of
resynthesis. NO-Cbl blocks the phosphorylation of newly translated I B . Band
retardation of I B is evident following Apo2L/TRAIL or TNF- stimulation.
Phospho-I B migrates slower than I B (compare middle two lanes to other four
lanes). c, NO-Cbl, NOC-18, and SNAP pretreatment all inhibited Apo2L/TRAILinduced I B phosphorylation.
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2.4.4 Inactivation of I B Kinase Activity by NO-Cbl
I B kinase (IKK) is responsible for phosphorylation and activation of I B , therefore
we examined the effect of NO-Cbl upon IKK activity. A375 cells were pretreated with
NO-Cbl (100 µM) for 16 h followed by stimulation with Apo2L/TRAIL (100 ng/ml) or
TNF- (20 ng/ml) and whole cell extracts were prepared at 30 and 15 min after treatment,
respectively. IKK was immunoprecipitated from A375 whole cell extracts and IKK
activity was assessed using recombinant GST-I B as a substrate (DiDonato et al.,
1997a). NO-Cbl effectively inhibited IKK activity induced by TNF- and Apo2L/TRAIL
by 22 and 92%, respectively (Fig. 2.7a). Anti- -actin antibody was used as an irrelevant
antibody control for immunoprecipitation and yielded no signal. The kinase assay gel was
stained with Coomassie Blue to visualize total protein and demonstrated equal loading of
the substrate, GST-I B (Fig. 2.7b). The same cell extracts were probed for total IKK by
immunoblot analysis and demonstrated equal loading of IKK (Fig. 2.7c).
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FIGURE 2.7

Figure 2.7: I B kinase (IKK) activity
IKK activity was assessed using recombinant GST-I B -(1–54) and [ -32P]ATP as
substrates. The phosphorylated GST fusion protein was detected by autoradiography.
a, IKK activity was determined in A375 cells pretreated with NO-Cbl followed by
Apo2L/TRAIL or TNF- stimulation for 30 min and 15 min, respectively. NO-Cbl
treatment inhibited IKK activity more effectively when Apo2L/TRAIL was the
stimulus, compared with stimulation by TNF- . Anti- -actin antibody served as the
irrelevant antibody with no phosphorylation of GST-I B -(1–54) observed. b,
Coomassie Blue-stained gel shows equal loading of GST-I B -(1–54) substrate. c,
immunoblot analysis shows the presence of equal amounts of total IKK in the lysates.
-actin was used as a loading control.
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2.5 DISCUSSION
Induction of apoptosis by exogenous Apo2L/TRAIL requires effective activation of
the Apo2L/TRAIL receptors and downstream signaling components. Apo2L/TRAIL as
well as the DR4 and DR5 receptors are ubiquitously expressed in malignant cells.
Moreover, sensitivity of melanoma cell lines to Apo2L/TRAIL correlated with levels of
death receptor expression (Zhang et al., 1999). Cellular resistance to Apo2L/TRAIL may
be due to defects in caspase signaling or caspase inhibition rather than over-expression of
decoy receptors (Zhang et al., 1999). Defects in Apo2L/TRAIL gene induction as well as
overexpression of inhibitors of apoptosis (such as XIAP) in melanoma cell lines which
express Apo2L/TRAIL receptors, may account for resistance to Apo2L/TRAIL (ChawlaSarkar et al., 2001; Chawla-Sarkar et al., 2002). Additionally, Apo2L/TRAIL resistance
has been reported in nasopharyngeal carcinomas due to a homozygous deletion of DR4
(Ozoren et al., 2000). Conversely, enhanced survival signaling may also confer a growth
advantage. Certain renal cell carcinomas may be resistant to Apo2L/TRAIL as a result of
constitutively activated NF- B (Oya et al., 2001). Also, constitutive activation of
Akt/protein kinase B in melanomas increased basal NF- B activity (Dhawan et al.,
2002).
It has been demonstrated that IFN- treatment increased expression of endogenous
Apo2L/TRAIL and thus sensitized melanoma lines to the anti-tumor effects of
exogenously administered recombinant Apo2L/TRAIL (Chawla-Sarkar et al., 2002). IFNdid not alter the DNA binding activity of NF- B in melanoma cells (Chawla-Sarkar et
al., 2002). Previously it has been demonstrated that the anti-tumor effects of IFN- and
NO-Cbl were synergistic in vitro and in vivo (Bauer et al., 2002). Treatment with NO-Cbl
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increased the expression of Apo2L/TRAIL, DR4, and DR5 mRNAs, and caspase-8
enzymatic activity, indicating activation of the extrinsic apoptotic pathway (Bauer et al.,
2002). Thus, IFN- mediates anti-growth effects in melanoma by enhancing
Apo2L/TRAIL expression, rather than by inhibiting NF- B activation.
In the current study we have shown that the anti-tumor activity of NO-Cbl was
mediated in part by inhibition of NF- B activation. NO-Cbl inhibited IKK enzymatic
activity, preventing phosphorylation of I B in response to Apo2L/TRAIL. Remarkably,
NO-Cbl was more effective at inhibition of Apo2L/TRAIL-induced IKK activity
compared with activation by TNF- . We hypothesize that NO-Cbl may nitrosylate and
deactivate a component of the Apo2L/TRAIL pathway that is absent from the TNFpathway. This functional divergence is under active investigation.
NO can inhibit NF- B by nitrosylating critical cysteine residues (DelaTorre et al.,
1997; Marshall and Stamler, 2001; Matthews et al., 1996). Interestingly, prostaglandins
(PGA1 and 15dPGJ2) can inhibit IKK by covalently modifying a critical cysteine residue
(C179) within the activation loop (Rossi et al., 2000). In a similar manner, NO-Cbl may
inhibit IKK, or an IKK-related kinase which is critical for Apo2L/TRAIL signaling, but is
less important for TNF- signaling.
Although SNAP and NOC-18 can inhibit NF- B signaling, these NO donors release
NO indiscriminately and completely lack any tumor specificity. High concentrations of
the NO donor sodium nitroprusside (SNP, 1 mM) in combination with Apo2L/TRAIL
was effective at killing human colorectal carcinoma cells (Lee et al., 2001). The
combination of SNP and Apo2L/TRAIL activated caspase-8, caspase-3, and cytochrome c
release, which were blocked by Bcl-2, suggesting that SNP-induced apoptosis was
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mediated by the mitochondrial pathway. The combination of SNP and Apo2L/TRAIL is
active against hematologic malignancies (Secchiero et al., 2001). Similarly, another NO
donor, glycerol trinitrate (GTN) induced Apo2L/TRAIL mRNA in human leukemia cells
and demonstrated antitumor activity (Chlichlia et al., 1998). However, most conventional
NO donors, especially those with short half-lives such as GTN, SNP, and SNAP, induce
significant toxicity to normal cells due to spontaneous NO release (Volk et al., 1995;
Wink et al., 1996), a drawback to their use.
A major advantage of the pro-drug NO-Cbl is its tumor-specific accumulation.
Cobalamin (Cbl) is avidly taken up by tumor cells relative to most normal tissues (Collins
et al., 2000; Cooperman, 1960; Flodh and Ullberg, 1968). Unlike other nitric oxide
donors, NO-Cbl releases NO inside the cell, and therefore minimizes systemic toxicity as
a result of high plasma NO concentration. By taking advantage of the "Trojan Horse"
properties of NO-Cbl, adverse side effects such as inappropriate vasodilation can be
minimized. NO-Cbl is relatively tumor-specific due to higher transcobalamin receptor
(TCII-R) expression in tumor cells compared with normal tissues. Fibroblasts and nontumorigenic cell lines were quite resistant to NO-Cbl (ID50 of 85–250 µM) compared with
tumor cell lines (ID50 as low as 2 µM) (Bauer et al., 2002). Drug schedule is a critical
determinant of the anti-tumor activity of NO-Cbl. NO-Cbl pretreatment followed by
Apo2L/TRAIL was most effective, whereas the converse treatment, or even simultaneous
co-treatment, was less effective. NO-Cbl inhibits the NF- B pro-survival arm of
Apo2L/TRAIL signaling, allowing the apoptotic arm to proceed unopposed. We believe
the combined tumor specific properties of NO-Cbl and Apo2L/TRAIL represent an
improved targeted approach to anti-tumor therapy.
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CHAPTER III

NITROSYLCOBALAMIN POTENTIATES THE ANTI-NEOPLASTIC EFFECTS
OF CHEMOTHERAPEUTIC AGENTS VIA SUPPRESSION OF SURVIAL
SIGNALING

3.0 ABSTRACT
Nitrosylcobalamin (NO-Cbl) is a chemotherapeutic pro-drug derived from vitamin
B12 that preferentially delivers nitric oxide (NO) to tumor cells, based upon increased
receptor expression. NO-Cbl induces Apo2L/TRAIL-mediated apoptosis and inhibits
survival signaling in a variety of malignant cell lines. Chemotherapeutic agents often
simultaneously induce an apoptotic signal and activation of NF-κB, which has the
undesired effect of promoting cell survival. The specific aims of this study were to 1)
measure the anti-tumor effects of NO-Cbl alone and in combination with conventional
chemotherapeutic agents, and to 2) examine the mechanism of action of NO-Cbl as a
single agent and in combination therapy. Using anti-proliferative assays, electrophoretic
mobility shift assay (EMSA), immunoblot analysis and kinase assays, we demonstrate an
increase in the effectiveness of chemotherapeutic agents in combination with NO-Cbl as
a result of suppressed NF-κB activation. Eighteen chemotherapeutic agents were tested in
combination with NO-Cbl, in thirteen malignant cell lines, resulting in a synergistic anti74

proliferative effect in 78% of the combinations tested. NO-Cbl pre-treatment resulted in
decreased NF-κB DNA binding activity, inhibition of IκB kinase (IKK) enzymatic
activity, decreased AKT activation, increased caspase-8 and PARP cleavage, and
decreased cellular XIAP protein levels. The use of NO-Cbl to inhibit survival signaling
may enhance drug efficacy by preventing concomitant activation of NF-κB or AKT.

3.1 INTRODUCTION
A major obstacle to conventional chemotherapy is the unwanted activation of survival
signaling which leads to acquired resistance and decreased therapeutic efficacy. Nuclear
factor kappa-B (NF-κB) (Baldwin, 2001) and Akt (Kim and Chung, 2002) are critical
mediators of cell survival that are activated following chemotherapy.
NF-κB is a family of heterodimers: NF-κB1 (p50/p105), NF-κB2 (p52/p100), REL,
RELA (p65/NF-κB3) in mammals, Dorsal, Dif, and Relish in Drosophilia (Karin et al.,
1999a). In its quiescent state, NF-κB is complexed to the inhibitor of κB (IκB) in the
cytoplasm. Once phosphorylated , IκB is ubiquitinated and targeted for proteolysis as it
remains complexed to NF-κB(DiDonato et al., 1995a). Within the proteosome IκB is
degraded, while NF-κB is not, allowing NF-κB to translocate to the nucleus where it
binds to NF-κB response elements which activate transcription of target genes (Karin et
al., 1999b). NF-κB activation is mediated by kinase cascades that activate IκB kinase
(IKK) which is comprised of the subunits IKKα, IKKβ, IKKγ and function to initiate the
signal for degradation of IκB[3], (Wang et al., 1999).
Constitutive activation of NF-κB has been implicated in the development of chemoresistance in several human carcinoma cell lines (Das and White, 1997; Wang et al.,
1999; Weldon et al., 2001). Low dose doxorubicin can induce drug resistance in cervical
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carcinoma cells(Yeh et al., 2003). Human breast cancer specimens contain high levels of
NF-κB/RelA indicating constitutive NF-κB activation (Sovak et al., 1997). High levels of
NF-κB and its downstream induced anti-apoptotic genes, bcl-2 and bax correlated with
poor response in numerous breast cancer patients (Buchholz et al., 2005). Constitutive
NF-κB activity is increased in colorectal cancer (Lind et al., 2001) and effective
treatment is achieved by inhibiting NF-κB (Hochwald et al., 2003). Inhibitor of Kappa B
Kinase (IKK), an activator of NF-κB, has been shown to be constitutively active in some
prostate carcinoma cell lines (Gasparian et al., 2002). Inhibition of NF-κB increased the
efficacy of a variety of chemotherapeutic agents including paclitaxel, etoposide,
doxorubicin, cisplatin, 5-FU, irinotecan, CPT-11, and camptothecin (Arlt et al., 2001;
Bava et al., 2005; Mabuchi et al., 2004a; Mabuchi et al., 2004b; Uetsuka et al., 2003)
thereby potentiating apoptosis. Similarly, inhibition of AKT can enhance anti-tumor
activity of paclitaxel against cervical carcinomas (Bava et al., 2005).
Akt, a serine/threonine kinase that mediates survival signaling, functions as an
oncogene and is implicated in resistance to chemotherapy (Khwaja, 1999). AKT1 kinase
was found to be elevated in the majority of primary prostate, breast and ovarian
carcinomas examined and correlated with high grade and stage of disease (Sun et al.,
2001). AKT2 was up-regulated in human ovarian (Cheng et al., 1992) and breast
carcinomas (Yuan et al., 2003) and was associated with paclitaxel (Kim et al., 2007) and
cisplatin resistance (Yuan et al., 2003). In addition, decreased activation of AKT via
inhibition of phosphoinositide-3-kinase (PI3K) resulted in increased apoptosis of ovarian
cancer cells (Yuan et al., 2000). AKT phosphorylates X-linked inhibitor of apoptosis
(XIAP) thereby promoting cell survival (Dan et al., 2004). Thus, NF-κB and AKT-
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mediated survival signaling limit the apoptotic-potential of chemotherapeutic agents
suggesting that inhibitors of these pathways can suppress drug resistance and improve
therapeutic efficacy.
We have previously demonstrated the anti-tumor activity of nitrosylcobalamin (NOCbl) as a single agent and in combination with biological therapies such as IFN-β (Bauer
et al., 2002) and Apo2L/TRAIL (Chawla-Sarkar et al., 2003). NO-Cbl is a vitamin B12
based, nitric oxide donor, that functions as a biological ―Trojan Horse‖ targeting cancer
cells via vitamin B12 receptor (Transcobalamin II receptor, TCIIR) (Seetharam et al.,
1999; Seetharam and Li, 2000) mediated uptake (Bauer et al., 2002) similar to clinical
studies that target TCIIR in the detection of cancer (Collins and Hogenkamp, 1997;
Collins et al., 2000).
We have previously shown that NO-Cbl suppressed Apo2L/TRAIL- and TNF-αmediated IKK activation with subsequent decreased phosphorylation of IκBα and
inhibition of NF-κB DNA binding activity(Chawla-Sarkar et al., 2003). NO-Cbl
sensitized Apo2L/TRAIL-resistant cells to Apo2L/TRAIL-mediated cell death(ChawlaSarkar et al., 2003). We have determined that NO-Cbl mediated apoptosis caused in part
via activation of the death receptor 4 (DR4) by S-nitrosylation (Tang et al., 2006). DR4
mediated apoptosis is tumor specific because Apo2L/TRAIL is overexpressed on the
surface of tumors but not on normal tissues such as liver or kidney (Ashkenazi et al.,
1999). Thus, NO-Cbl is a promising candidate to promote apoptosis and minimize
toxicity in combination chemotherapy. In the current study, we examined whether NOCbl pre-treatment could potentiate the anti-tumor effects of several chemotherapeutic
agents.
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3.2 MATERIALS AND METHODS
3.2.1 Synthesis of Nitrosylcobalamin

Nitrosylcobalamin was synthesized as previously described (Bauer, 1998).
Hydroxocobalamin (vitamin B12a) acetate (Hebei Huarong Pharmaceutical Co, Hebei
Province, China) was dissolved in dichloromethane (OmniSolv, EMD Chemicals,
Gibbstown, NJ) and exposed to CP grade NO gas (Praxair, Wickliff, OH) at 75 psi. The
reaction proceeds in a closed system within a high-pressure stainless steel reactor (Parr
Instrument Co, Moline, IL). The system was purged daily and evacuated prior to NO
exposure. The NO gas was scrubbed prior to entering the system using a stainless steel
cylinder (Midwest Process Controls, Bay Village, OH) containing NaOH pellets. The
solid NO-Cbl product was collected following rotary evaporation of the solvent and
stored under argon at −80°C prior to use.
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3.2.2 Cell Culture and Cytokine treatments

Human tumor cell lines (ATCC, Manassas, VA) were grown in RPMI 1640 and
Dulbecco's modified Eagle medium as appropriate (DMEM, Cellgro, Mediatech
Herndon, VA) supplemented with 10% fetal bovine serum (FBS, Mediatech) and 1%
Antibiotic-Antimycotic (GIBCO BRL, Invitrogen, Carlsbad, CA) according to ATCC
recommendations. Cells were maintained in 5% CO2 at 37°C in a humidified incubator.
Cells were confirmed as mycoplasma free using a commercially available kit
(MycoAlert, Cambrex Corporation, East Rutherford, NJ).

3.2.3 Sulforhodamine B Cell Growth Assay

Cells were harvested with 0.5% trypsin/0.53 mM EDTA, washed with PBS and
resuspended in media containing 10% FBS. Cells were plated in 96-well plates in 0.2 mL
aliquots containing 2,000 cells. Cells were allowed to adhere to the plate for 4 h and then
NO-Cbl was added in different dilutions to the assay plate. Replicates of eight were
performed for each treatment. After 16 h, chemotherapeutic agents were added at
different concentrations. Growth was monitored by the sulforhodamine B (SRB, Sigma
Chemical, St. Louis, MO) colorimetric assay (Rubinstein et al., 1990; Skehan et al.,
1990). After 80 h growth, the medium was removed, and cells were fixed with 10%
trichloroacetic acid and stained with SRB. Bound dye was eluted from cells with 10 mM
TRIS (pH 10.5) and absorbance was measured at 570 nm using a Lab Systems Multiskan
RC 96-well plate reader (Lab Systems Multiscan RC, Thermo Lab Systems, Franklin,
MA). To quantify growth of the cells, experimental absorbance values (Aexp) were
compared with initial absorbance readings representing the starting cell numbers (Aini).
79

To determine the starting cell number, an additional 96-well plate was seeded with cells
and fixed at the beginning of the experiment. The absorbances derived from the initial
plate and from the untreated cells at the end of the growth period (Afin) were defined as
0% and 100% growth, respectively. The percentage control growth (100%×[Aexp–
Aini]/[Afin–Aini]) was expressed as a percentage of untreated controls.

3.2.4 In vivo experiments

Five week-old NCR male athymic nude homozygous (nu/nu) mice (Taconic,
Germantown, NY) were inoculated with NIH-OVCAR-3 tumors. There were four
experimental groups (untreated, single agents, and the combination), n = 10. Tumor cells
(2×106) were inoculated into flanks in the mid-axillary line. NO-Cbl was given once daily
(150 mg/kg, s.c.) and etoposide (2 mg/kg, s.c.) was administered once weekly, starting on
day 2. Tumor volume was measured three times a week using the formula for a prolate
spheroid: (4/3) πab2 where 2a = major axis, 2b = minor axis. Formalin-fixed sections
were processed by the Cleveland Clinic Histology Core. Sections were stained with
hematoxylin and eosin and evaluated for pathologic changes in a blinded fashion. For
syngeneic studies, five week-old DBA/2 male mice (Taconic) were inoculated with P388
murine leukemia cells. There were four experimental groups (untreated, single agents,
and the combination), n = 10. Tumor cells (105) were inoculated i.p.. NO-Cbl was given
twice daily (165 mg/kg, i.p.) and doxorubicin (4 mg/kg, i.p.) was administered once
weekly, starting on day 2. Animals were monitored for ninety days. The Institutional
Animal Care and Use Committee at the Cleveland Clinic Foundation approved all
procedures for animal experimentation.
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3.2.5 Gel Electrophoresis and Immunoblot analyses

Cells were pre-treated with NO-Cbl (300 µM) for 16 h followed by doxorubicin (20
µM, 4 h), cisplatin (20 µM, 1 h), 5 flurouracil (5-FU, 100 µM, 5 h), etoposide (20 µM, 4
h), or paclitaxel (20 µM, 5 h). As a positive control for NF-κB induction, cells were
treated with TNF-α (20 ng/mL, 15 min). Whole cell lysates were prepared in 1× high salt
lysis buffer (20 mM HEPES, 400 mM NaCl, 25 mM β-glycerol phosphate, 25 mM NaF,
10 mM, para-nitrophenyl phosphate (PNPP), 10% glycerol, 0.5 mM NaOrthovanadate,
1mM PMSF, 0.5% NP40 and 1× protease inhibitor cocktail set I (Calbiochem) and 1×
phosphatase inhibitor cocktail set II (Calbiochem) for subsequent immunoblotting
studies. Total cell protein (80 µg per sample) was resolved by electrophoresis on a 10%
Bis-TRIS gel (Criterion, Bio-Rad, Hercules, CA) resolved at 160 V for 1 hour and
transferred to a PVDF membrane (Immobilon-P, Millipore, Bedford, MA) with the use of
a wet transfer apparatus (Bio-Rad) for 30 min at 100 V . The membranes were incubated
in blocking buffer (Starting Block T20, Pierce, Rockford, IL) for 1 h at room temperature
and then incubated overnight with primary antibody [anti-phospho-AKT (Ser473)
1:1000, Cell Signaling, Boston, MA; anti-AKT 1:1000, Cell Signaling; anti-XIAP, 1:2502000, BD Biosciences, San Jose CA; anti-Caspase-8 (1C12) 1:1000 Cell Signaling; antiPARP 1:1000, Cell Signaling] diluted in Starting Block. After washing in 1× TBST (USB
Corp, Cleveland, OH) membranes were incubated with horseradish peroxidaseconjugated goat secondary antibodies (Biorad) diluted in Starting Block for 1 h at room
temperature. The protein bands were visualized by enhanced chemiluminescence
(SuperSignal West Pico chemiluminescent substrate, Pierce). Antibodies against
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glyceraldehyde-3-phosphate dehydrogenase (Trevigen, Gaithersburg, MD) were used to
ensure equal loading.

3.2.6 Electrophoretic mobility shift assay (EMSA)

Cells were pre-treated with NO-Cbl (300 µM) for 16 h followed by doxorubicin (20
µM, 4 h) or cisplatin (20 µM, 1 h) or 5 flurouracil (5-FU, 100 µM, 5 h) or etoposide (20
µM, 4 h) or paclitaxel (20 µΜ, 5 h). As a positive control for NF-κB induction, cells were
treated with TNF-α (20 ng/mL, 15 min). Plates were washed three times with ice-cold 1×
DPBS (Cellgro, Mediatech). Cells were scraped from plates and resuspended in 1× high
salt lysis buffer as above. The lysates were transferred to pre-chilled microcentrifuge
tubes and incubated at 4°C using a vortex for 30 min followed by centrifugation at
20,000g for 15 min. Samples were snap frozen with liquid nitrogen and stored at −70°C
until needed. Supernatants were transferred to fresh tubes and protein concentrations
were assessed using the Bradford method (Bio-RAD protein assay, BioRad, Hercules,
and CA). We used a commercially available consensus binding site for NFκB/c-Rel
homodimeric and heterodimeric complexes as a probe to assess DNA binding activity.
The NF-κB consensus binding sequence (5′AGTTGAGGCGACTTTCCCAGGC 3′)
(sc-2505: Santa Cruz Biotechnology, Santa Cruz, CA) was end-labeled with γ32P-dATP
(3000 Ci/mol, Perkin Elmer, Boston MA), using T4 polynucleotide kinase (Roche,
Indianapolis, IN). DNA binding reactions were performed in 28 µL reaction volume for
30 min on ice containing 20 µg protein, 100 mM HEPES, 3.0 mM EDTA, 50% glycerol,
3 mM DTT, 25 mM MgCl2, 20 mM TRIS, pH 7.90, 5 ug Poly [d(I-C)] and labeled probe.
Complexes were separated from the free probe on 6% non-denaturing polyacrylamide
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gels in 0.5× TBE buffer at 195 V for 2 h. Gels were dried and exposed to film. To verify
that the band shifts were comprised of NF-κB, lysates from cells that were stimulated by
TNF-α (20 ng/mL, 15 min) were incubated with anti-NF-κB p65 antibody (100 ng/mL,
Zymed, S. San Francisco, CA).
3.2.7 IκB kinase (IKK) assay

Whole cell extracts (200 µg) treated as above were supplemented with 150 µL of
Buffer A (20 mM Hepes, pH 7.9, 20 mM beta-glycerophosphate, 10 mM NaF, 0.1 mM
orthovanadate, 5 mM para-nitrophenyl phosphate (PNPP), 10 mM 2-mercaptoethanol
(BME), 0.5 mM PMSF, and protease cocktail), 2 µL normal rabbit serum (NRS), and
mixed by rotation at 4°C for 1 h as previously described (DiDonato and John, 2000). A
50% slurry of Protein G Sepharose (80 µL) (Amersham-Pharmacia, Piscataway, NJ)
prepared in Buffer A (without BME or PMSF) was added and mixed by rotation at 4°C
for 1 h. Protein G Sepharose was removed by centrifugation at 800g for 1 min and
discarded. Anti-IKKα monoclonal antibody (0.5 µg, BD-Pharmingen, San Diego, CA), or
anti-HA epitope antibody (Covance, Berkeley, CA) was added to the supernatant and
mixed by rotation at 4°C for 2 h. A 50% slurry of Protein G Sepharose (60 µL) prepared
in Buffer C (Buffer A plus 50 mM NaCl and 10 mM MgCl2, without BME and PMSF)
was added and mixed by rotation in the cold for 30 min. Protein G immunopellets were
collected by centrifugation at 800 g for 30 sec, washed 3 times with Buffer B (Buffer A
plus 250 mM NaCl), and once with Buffer C (Buffer A plus 50 mM NaCl and 10 mM
MgCl2). Immunopellets were re-suspended in 30 µL kinase buffer with 0.1 mM
orthovanadate, 50 µM unlabeled ATP, 5 µCi γ32P-ATP, 2 mM DTT, and 2 µg of
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recombinant GST-IκBα1-54[39] and incubated at 30°C for 30 min. Reactions were
stopped by the addition of 15 µL 4× SDS-PAGE loading buffer (200 mM Tris-HCl, pH
6.8, 8% SDS, 40% glycerol, 0.2% 2-mercaptoethanol), heated at 95°C for 10 min, and
resolved by SDS-PAGE on a 12% acrylamide gel by standard procedures. Gels were
rinsed, stained with Bio-Safe Coomassie (BioRad, Hercules, CA) to visualize protein
bands, rinsed, photographed then dried and exposed to Kodak BioMax MR film (Eastman
Kodak Co., Rochester, NY) to detect substrate phosphorylation. IKK activation was
quantified by PhosphorImage analysis on a Storm-840 imager using Image Quant v 5.2
software (Molecular Dynamics, Amersham Biosciences, and Piscataway, NJ).
3.2.8 Statistical Analysis

Median effect analysis was used to characterize the interaction between NO-Cbl and
various chemotherapeutic agents (Chou and Talalay, 1984). A combination index >1
indicates antagonism, = 1 indicates additivity, and <1 indicates synergy. Unless otherwise
stated, results are expressed as means with 95% confidence intervals (95% CI).
Differences in mean tumor volume between groups were compared using the unpaired
two-tailed Student's t test, using a pooled estimator of variance, to determine statistical
significance using Sigma Plot 10.0 (SPSS, Chicago, IL). The logrank test was used to
calculate the significance of the Kaplan Meir survival curve. The experimental design
utilized the same set of cell lysates for Figures 2-5, and the data was expressed as means
(n = 3).
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3.3 RESULTS
3.3.1 Anti-proliferative effects of NO-Cbl and chemotherapeutic agents in vitro

To test the hypothesis that NO-Cbl might potentiate the anti-neoplastic effects of
various chemotherapeutic agents, we measured antiproliferative effects in thirteen cell
lines using 18 chemotherapeutic agents (Figure 3.1). We used the SRB antiproliferative
assay, which is utilized by the National Cancer Institute to evaluate new
chemotherapeutic agents (Skehan et al., 1990). Median effect analysis characterized the
interaction between NO-Cbl and the chemotherapeutic agents (Chou and Talalay, 1984).
Cells were pre-treated with NO-Cbl for 16 h followed by the chemotherapeutic drugs for
80 h. Sequential treatment of tumor cell lines resulted in synergistic antiproliferative
activity in 77.78% of the combinations tested, with a mean combination index of 0.44
(95% CI = 0.39 to 0.50). Antagonistic responses were observed in 22.22% of
combinations, with an average combination index of 1.73 (95% CI = 1.33 to 2.12).
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FIGURE 3.1

Figure 3.1. Effects of nitrosylcobalamin (NO-Cbl) and chemotherapeutic agents
on the proliferation of A375 (melanoma), A549 (lung), ACHN (renal), HeLa
(cervical) HEY (ovarian), HT29 (colon), MCF-7 (breast), OC-2 and OC-3
(platinum and paclitaxel refractory ovarian), OVCAR-3 (ovarian), WM9 and
WM3211 (melanoma), and P388 (murine leukemia).
Cells were pre-treated with NO-Cbl for 16 h followed by addition of
chemotherapeutic agents for five days, and growth was measured by the colorimetric
sulforhodamine B assay (Skehan et al., 1990). Data points represent the combination
index comparing low, medium, and high combinations of NO-Cbl and each
chemotherapeutic agent (mean of eight replicates) to assess synergy. Synergy between
NO-Cbl and various chemotherapeutic agents was determined by median effect
analysis (Chou and Talalay, 1984), (combination index >1 indicates antagonism, = 1
indicates additivity, and <1 indicates synergy). The sequential treatment of NO-Cbl
and chemotherapeutic drugs induced synergistic antiproliferative activity in 77.7% of
the combinations examined.
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3.3.2 NO-Cbl inhibits activation of NF-κB by chemotherapeutic agents
EMSA was utilized to examine the effects of NO-Cbl on NF-κB activation by
chemotherapeutic agents (Figure 3.2). We examined four histologically distinct human
tumor cell lines [A375 (melanoma), MCF-7 (breast carcinoma), SW480 (colon
carcinoma), and OVCAR-3 (ovarian carcinoma)], assaying the effects of multiple
chemotherapeutic drugs. TNF-α was used as a positive control for induction of NF-κB
DNA binding activity. Specific antibodies to NF-κB-p65 induced a supershift and
confirmed the presence of the p65/RelA component of NF-κB.
Doxorubicin treatment resulted in NF-κB activation in all four cell lines. NO-Cbl
inhibited NF-κB DNA binding activity in A375 cells by 40.71% (95% CI = 40.52% to
40.87%), MCF-7 cells by 46.99% (95% CI = 46.41% to 47.64%), SW480 cells by 7.52%
(95% CI = 5.71% to 9.14%), and OVCAR-3 cells by 40.13% (95% CI = 39.30% to
41.08%).
Cisplatin treatment resulted in low-level NF-κB activation in A375 cells. NO-Cbl
inhibited cisplatin-induced activation by 41.54% (95% CI = 40.77% to 42.41%) in A375
cells. Cisplatin did not activate NF-κB in OVCAR-3 cells.
5-FU activated NF-κB in each cell line treated. NO-Cbl inhibited NF-κB activation in
A375 cells by 6.89% (95% CI = 6.43% to 7.28%), SW480 cells by 38.14% (95% CI =
34.91% to 40.69%), and OVCAR-3 cells by 18.34% (95% CI = 17.90% to 18.72%).
Etoposide activated NF-κB in A375 and OVCAR-3 cells. Pre-treatment with NO-Cbl
inhibited NF-κB DNA binding activity by 29.70% (95% CI = 28.79% to 30.69%) in
A375 cells, and 30.37% (95% CI = 30.00% to 30.67%) in OVCAR-3 cells.
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Paclitaxel treatment of MCF-7 and OVCAR-3 cells induced NF-κB activation in both
cell lines. NO-Cbl inhibited paclitaxel-induced activation by 47.28% (95% CI = 46.23%
to 48.43%) and 43.40% (95% CI = 42.48% to 44.47%) respectively, in MCF-7 and
OVCAR-3 cells.
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FIGURE 3.2

Figure 3.2: Electrophoretic Mobility Shift Assay (EMSA): NF-κB DNA binding
activity.
Pretreatment of A375 (melanoma), MCF-7 (breast carcinoma), SW480 (colon
carcinoma) and OVCAR-3 (ovarian carcinoma) cells with NO-Cbl (300 µM, 16 h)
inhibited the NF-κB DNA binding activity induced by doxorubicin (20 µM, 4 h) or
cisplatin (20 µM, 1 h) or 5 flurouracil (5-FU, 100 µM, 5 h) or etoposide (20 µM, 4 h)
or paclitaxel (20 µΜ, 5 h). TNF-α (15 min) stimulation served as a positive control of
NF-κB activation (T). Incubation of TNF-α treated lysates with anti-NF-κB p65
antibody resulted in supershift (SS) of the NF-κB complex (Ta). An irrelevant
antibody was incubated with TNF-α treated lysates which did not result in a supershift
(Tx).
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3.3.3 NO-Cbl affects IκB kinase activity
IκB kinase (IKK) mediates phosphorylation of IκBα, marking it for eventual
polyubiquitination and proteolysis thereby resulting in NF-κB activation (DiDonato et al.,
1997a). Hence, we examined the effect of NO-Cbl upon IKK activity (Figure 3.3) using
the same lysates used to assess NF-κB DNA binding activity. NO-Cbl treatment reduced
basal IKK activity in all treatments, although IKK activity was not noticeably increased
in A375 cells following treatment with any of the chemotherapeutic agents.
Doxorubicin activated IKK in MCF-7, SW480 and OVCAR-3 cells. NO-Cbl
decreased IKK activity in MCF-7, SW480 and OVCAR-3 cells by 41.70% (95% CI =
39.65% to 44.47%), 45.22% (95% CI = 41.43% to 50.07%) and 50.69% (95% CI =
48.39% to 53.57%), respectively.
Cisplatin treatment resulted in minor activation of IKK only in OVCAR-3 cells. NOCbl was effective at inhibiting this activation by 17.06% (95% CI = 15.48% to 19.06%).
5-FU treatment resulted in IKK activation in SW480 and OVCAR-3 cells. NO-Cbl
inhibited 5-FU induced IKK activation in SW480 cells by 18.85% (95% CI = 17.20% to
21.05%), and OVCAR-3 cells by 34.12% (95% CI = 31.21% to 37.74%). Paclitaxel did
not activate IKK in MCF-7 or OVCAR-3 cells. Treatment of OVCAR-3 cells with
etoposide resulted in IKK activation which was inhibited by NO-Cbl by 71% (95% CI =
70.22% to 71.96%).
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FIGURE 3.3
Figure 3

Figure 3.3: IκB kinase (IKK) activity. IKK activity was assessed using
recombinant GST-IκBα(1-54) and γ32P-ATP as substrates.
The phosphorylated GST fusion protein was detected by autoradiography. IKK
activity was determined in cells that were pre-treated with NO-Cbl (300 µM, 16 h)
followed by doxorubicin (20 µM, 4 h) or cisplatin (20 µM, 1 h) or 5 flurouracil (5-FU,
100 µM, 5 h) or etoposide (20 µM, 4 h) or paclitaxel (20 µΜ, 5 h). Anti-β-actin
antibody was used as an irrelevant antibody control for immunoprecipitation and
yielded no signal. After exposure to film, the gel was stained with Coomassie blue to
visualize total protein and demonstrated equal loading of the GST-IκBα(1-54)
substrate. The same cell extracts were probed for total IKK by immunoblot analysis
and demonstrated equal loading of IKK.
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3.3.4 Inhibition of AKT activation by NO-Cbl

Next we examined the role of the pro-survival protein AKT and the effects of NO-Cbl
on its activation (Figure 3.4), using the same lysates utilized in the previous two
experiments. In A375 cells, phosphorylation of AKT was enhanced following treatment
by cisplatin, 5-FU and etoposide. NO-Cbl inhibited AKT activation following cisplatin
treatment by 51.24% (95% CI = 50.73% to 51.73%), 5-FU by 42.82% (95% CI = 39.84%
to 47.26%), and with etoposide by 46.85% (95% CI = 44.00% to 49.32%).
Doxorubicin increased the phosphorylation of AKT in MCF-7 and SW480 cells which
was inhibited by NO-Cbl by 83.77% (95% CI = 81.43% to 86.21%) and 52.60% (95% CI
= 49.62% to 55.04%), respectively. Treatment of MCF-7 cells with paclitaxel resulted in
increased phosphorylation of AKT which was inhibited by 43.74% (95% CI = 42.01% to
45.00%) following NO-Cbl. Treatment of SW480 cells with 5-FU increased AKT
activation which was inhibited by NO-Cbl by 32.50% (95% CI = 31.28% to 33.61%).
Although increased phosphorylation of AKT did not occur with any of the
chemotherapeutic agents in OVCAR-3 cells, which exhibited a high basal level of
phosphorylated AKT, NO-Cbl reduced the high basal AKT phosphorylation levels.
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FIGURE 3.4

Figure 3.4: Western blot analysis of phospho-AKT.
Cells were pre-treated with NO-Cbl (300 µM, 16 h) followed by doxorubicin (20 µM,
4 h) or cisplatin (20 µM, 1 h) or 5 flurouracil (5-FU, 100 µM, 5 h) or etoposide (20
µM, 4 h) or paclitaxel (20 µΜ, 5 h). Whole cell lysates were probed with antiphospho-AKT and then re-probed with anti-AKT (unphosphorylated) which served as
a loading control.
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3.3.5 XIAP expression is decreased with NO-Cbl treatment

X-linked mammalian inhibitor of apoptosis (XIAP), one of the most potent inhibitors
of apoptosis, is a NF-κB-induced gene (Salvesen and Duckett, 2002).
Hence we examined effects of NO-Cbl upon downstream gene products induced by NFκB (Figure 3.5).
Consistent with AKT phosphorylation in A375 cells, XIAP protein expression was
enhanced following doxorubicin, cisplatin, 5-FU, and etoposide treatment. NO-Cbl
blunted XIAP expression by 20.12% (95% CI = 14.64% to 23.79%) with doxorubicin,
19.40% (95% CI = 17.06% to 22.00%) with cisplatin, 21.12% (95% CI = 20.89% to
21.31%) with 5-FU, and 18.62% (95% CI = 17.57% to 20.09%) with etoposide.
In addition, doxorubicin increased XIAP expression in MCF-7, SW480, and OVCAR3 cells; expression was inhibited with NO-Cbl treatment by 44.96% (95% CI = 39.66% to
47.85%), 12.16% (95% CI = 10.57% to 13.79%), and 64.90% (95% CI = 60.46% to
66.85%), respectively. 5-FU treatment increased XIAP expression in SW480 cells which
was inhibited with NO-Cbl by 13.66% (95% CI = 11.87% to 15.75%). NO-Cbl treatment
inhibited basal XIAP expression when combined with every chemotherapeutic agent in
all cell lines examined.
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FIGURE 3.5

Figure 3.5: Western blot analysis of XIAP.
Cells were pre-treated with NO-Cbl (300 µM, 16 h) followed by doxorubicin (20 µM,
4 h) or cisplatin (20 µM, 1 h) or 5 flurouracil (5-FU, 100 µM, 5 h) or etoposide (20
µM, 4 h) or paclitaxel (20 µΜ, 5 h). XIAP protein levels were determined in whole
cell lysates. GAPDH was used as a loading control.
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3.3.6 Effect of NO-Cbl on mediators of apoptosis

A375 cells were stimulated with doxorubicin, followed by assessment of AKT
phosphorylation, XIAP expression, and caspase-8 and PARP cleavage. (Figure 3.6a).
NO-Cbl inhibited doxorubicin-mediated AKT activation at all time points, resulting in
reduction of 85.73% (95% CI = 85.26% to 86.24%) at 8 h, 94.05% (95% CI = 92.44% to
96.02%) at 12 h, 60.94% (95% CI = 58.93% to 63.73%) at 16 h, and completely
abrogated the signal at 24 h. In addition, degradation of XIAP was enhanced when NOCbl was combined with doxorubicin; this inhibition was 82.94% (95% CI = 81.27% to
84.14%) at 8 h, 49.36% (95% CI = 41.51% to 58.74%) at 12 h, 64.67% (95% CI =
60.68% to 67.69%) at 16 h, and 35.81% (95% CI = 33.93% to 36.54%) at 24 h.
Concordantly, caspase-8 activity was enhanced when NO-Cbl was combined with
doxorubicin at 8, 12, 16 and 24 h by 41.39% (95% CI = 27.98% to 47.95%), 36.82%
(95% CI = 32.79% to 39.87%), 17.54% (95% CI = 12.22% to 23.98%), and 25.28%
(95% CI = 7.88% to 34.92%), respectively. PARP cleavage was increased at all time
points following treatment with NO-Cbl and doxorubicin. NO-Cbl enhanced the cleavage
of PARP by 82.94% (95% CI = 81.27% to 84.14%) at 8 h, 49.36% (95% CI = 41.51% to
58.74%) at 12 h, 64.67% (95% CI = 60.68% to 67.69%) at 16 h, and by 35.81% (95% CI
= 33.93% to 36.54%) at 24 h.
Next, we examined the expression of XIAP in OVCAR-3 cells treated with etoposide
and NO-Cbl (Figure 3.6b). Expression of XIAP protein, normally induced by etoposide,
was reduced by NO-Cbl at 8, 12, and 16 h by 92.82% (95% CI = 89.60% to 97.78%),
8.57% (95% CI = 70.12% to 89.26%), and 98.59% (95% CI = 96.71% to 100%),
respectively. After 24 h of NO-Cbl treatment, XIAP protein was undetectable.
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FIGURE 3.6

Figure 3.6: Western blot analysis of mediators of apoptosis.
a, Time course analysis of A375 cells pre-treated with NO-Cbl (300 µM, 16 h)
followed by doxorubicin (20 µM, 4 h). Phospho-AKT, XIAP, caspase-8 and PARP
immunoblots were performed on whole cell lysates. Note that caspase-8 and PARP
cleavage were maximal with combination treatment at all time points. Degradation of
XIAP was increased following combination treatment at all time points. b, OVCAR-3
cells were pre-treated with NO-Cbl (300 µM, 16 h) followed by etoposide (20 µM, 4
h). XIAP protein levels were determined. GAPDH was used as a loading control.
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3.3.7 Anti-tumor effects of NO-Cbl and chemotherapeutic agents in vivo

In vitro combination therapy with NO-Cbl on tumor cells in culture exhibited positive
effects in inhibiting cell proliferation and decreasing cell survival signaling (Figs. 3.1–
3.6). To test drug combinations in vivo, subcutaneous NIH-OVCAR-3 xenografts were
established in athymic nude mice. Daily drug treatments began on day 2 after cell
inoculation, at which time tumors were both visible and palpable (Figure 3.7a). After 25
days, the tumors from mice treated with NO-Cbl were reduced in volume by 66.94%
(95% CI = 60.90% to 69.81%; P = 0.00068) compared to controls. Tumors from mice
treated with etoposide were smaller by 27.30% (95% CI = 19.70% to 30.90%; P =
0.14099) compared to control tumors. Mice receiving the combination of NO-Cbl and
etoposide displayed tumors that were inhibited by 99.01% (95% CI = 98.48% to
100.12%; P = .000012) compared to controls. In two mice, tumors disappeared
completely and did not recur 60 days after treatment cessation.
In a syngeneic P388 murine leukemia model, cells were inoculated into the
peritoneal cavities of DBA/2 mice. Daily drug treatments began on day 2 following
inoculation (Figure 3.7b). Untreated animals died by day 14. NO-Cbl treated animals
survived until day 21. Doxorubicin treated animals survived until day 33. Combination
drug treatment was discontinued on day 40 and resulted in 60% survival, monitored
through day 90. Logrank analysis determined P<0.001 comparing Kaplan Meier survival
curves.
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FIGURE 3.7

Figure 3.7: Effects of NO-Cbl and chemotherapeutic agents in vivo.
a, NCR male athymic nude (nu/nu) mice (n = 10 per group) were injected
subcutaneously (s.c.) with 2×106 NIH-OVCAR-3 cells. Daily drug treatments of
control (PBS), NO-Cbl (150 mg/kg, s.c.), etoposide (2 mg/kg, s.c.), and the
combination began on day 2 following inoculation. Tumor volume was measured
every other day. Points represent the mean tumor volume±95% CI. b, Kaplan-Meir
survival curve. DBA/2 male mice (n = 5) were inoculated intraperitoneally (i.p.) with
105 P388 murine leukemia cells. NO-Cbl was given twice daily (165 mg/kg, i.p.) and
doxorubicin (4 mg/kg, i.p.) was administered once weekly, starting on day 2.
Treatment in the combination group ceased on day 40 and the animals continued to be
monitored for ninety days. Significance comparing the survival of groups was
calculated using the logrank test.
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3.4 DISCUSSION
Nitric oxide (NO) is a ubiquitous multi-faceted signaling molecule critical to many
physiological and pathological processes (Ray et al., 2007). A comprehensive review by
Mocellin et al. details the use of NO donors to induce apoptosis (Mocellin et al., 2007).
The connection between NO donors and apoptosis often seems paradoxic and depends
upon cell type, site of delivery, and NO concentration. However, it is widely accepted
that high levels of NO (>1 µM) can activate the extrinsic pathway of programmed cell
death via protein nitrosylation (Mannick and Schonhoff, 2004; Tang et al., 2006) and can
also activate the intrinsic pathway via oxidative stress and cytochrome c release (Murphy,
1999). Most conventional NO donors, especially those with short half-lives such as GTN,
SNP and SNAP, induce significant toxicity to normal cells due to rapid NO release in
biological fluids (Volk et al., 1995; Wink et al., 1996) a drawback to their use.
A major advantage of the pro-drug NO-Cbl is its tumor-specific accumulation due to
higher transcobalamin receptor (TCII-R) expression in tumor cells compared to normal
tissues (Bauer et al., 2002). Cobalamin (Cbl) is avidly taken up by tumor cells relative to
most normal tissues (Collins et al., 2000; Cooperman, 1960; Flodh and Ullberg, 1968)
Unlike other donors, NO-Cbl preferentially releases NO inside the cell, and therefore
minimizes systemic toxicity due to high plasma NO concentration. By taking advantage
of the ―Trojan Horse‖ properties of NO-Cbl, side effects such as vasodilation can be
minimized. We have not observed hypotension, bone marrow suppression or abnormal
liver or kidney function in our rodent or canine studies following acute or chronic NOCbl administration (data not shown).
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NO inhibits survival signaling via inhibition of NF-κB (Marshall and Stamler, 2001;
Matthews et al., 1996) and AKT (Storling et al., 2005), both well characterized mediators
of cell survival. A recent review by Nakanishi and Toi implicates NF-κB activation as a
major contributor to lowering the apoptotic efficacy of chemotherapeutic agents and
increasing drug resistance (Nakanishi and Toi, 2005).
The activation of NF-κB is a highly complex process. There are cell type-specific
variations in NF-κB activation that differ between cell lines as well as activation
differences among known NF-κB-activators. Taxol treatment of pancreatic cancer cell
lines induces formation of several different NF-κB/IκB complexes, suggesting the
presence of multiple up-stream activators of NF-κB (Dong et al., 2002). UV-induced
DNA damage in HeLa cells is characterized by IKK-independent activation of NF-κB at
early time points (30 min) and IKK-dependent activation at later times (15–20 h) (Bender
et al., 1998). Doxorubicin initiates phosphoinositide-3-kinase (PI3K)-mediated
degradation of IκB that is independent of the IKK signalosome (Tergaonkar et al., 2003).
Conversely, both PI3K and AKT can mediate NF-κB activation via phosphorylation of
threonine 23 of IKKα, leading to NF-κB activation (Ozes et al., 1999). In comparison,
AKT required IKK in order to activate NF-κB (Madrid et al., 2000), specifically IKKβ
(Madrid et al., 2001). In addition, AKT potentiates the effects of gemcitabine and
paclitaxel in pancreatic cancer possibly via NF-κB activation (Fahy et al., 2004).
Similarly, AKT can transiently bind and activate IKK following stimulation with plateletderived growth factor (PDGF) (Romashkova and Makarov, 1999). In melanoma, AKT
may activate NF-κB in an IKK-independent fashion (Dhawan et al., 2002) possibly
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mediated by MAPK (Dhawan and Richmond, 2002). Undoubtedly, the complex nature of
NF-κB activation can be as paradoxic as the cellular actions of NO.
Our data demonstrates consistent inhibition of NF-κB by NO-Cbl, irrespective of the
survival pathways induced by a variety of chemotherapeutic agents. We demonstrate
increased NF-κB DNA binding induced by almost every chemotherapeutic agent across
all cell lines. Doxorubicin, etoposide, and paclitaxel induced NF-κB activation in all cell
lines examined (Figure 3.2). Interestingly, A375 cells had greater constitutive IKK
activation compared to MCF-7, SW480, and OVCAR-3 cells, and IKK activity in A375
cells was not noticeably enhanced by any chemotherapeutic agent (Figure 3.3). Yet,
treatment of A375 cells with NO-Cbl reduced basal IKK activity. The absence of
increased IKK activity in A375 cells following chemotherapeutic drug treatment may be
attributed to: 1) differences in the kinetics of activation of IKK vs. NF-κB, and 2)
preferential phosphorylation of the GST-IκBα(1-54) substrate by IKK-β rather than IKKα (Zandi et al., 1998). These factors may result in understated IKK-α contributions to
activation using the current kinase assay. Admittedly, IKK-α may play a more dominant
role in NF-κB activation as compared to IKK-β mediated NF-κB activation in A375 cells,
but this topic is ancillary to the conclusion of this study. The key observation is that
where NF-κB is activated, NO-Cbl inhibits the activation and furthermore, in activation
pathways that clearly utilize IKK to trigger NF-κB activation, NO-Cbl treatment inhibits
IKK activity.
Conversely, AKT was activated by cisplatin, 5-FU, and etoposide in A375 cells. NOCbl markedly reduced AKT phosphorylation following all treatments (Figure 3.4). Thus,
AKT may be involved in NF-κB activation, independent of IKK, as previously reported
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(Dhawan et al., 2002). This may also explain activation of NF-κB in MCF-7 cells
following treatment by paclitaxel, accompanied by AKT activation in the absence of IKK
activation (Figure 3.4). Alternatively, AKT and IKK may act in concert to activate NFκB (Romashkova and Makarov, 1999). In OVCAR-3 cells, AKT was not activated by
any chemotherapeutic agent whereas IKK activation was induced by doxorubicin,
etoposide, cisplatin, and 5-FU, suggesting IKK-dependent activation in these cells
(Figure 3.4). Our results with paclitaxel are in agreement with results obtained by others
in ovarian cancer cells using paclitaxel (Huang and Fan, 2002). Clearly, NF-κB signaling
is a complex process involving several pathways that provide diverse control points
resulting in a balance between apoptosis and survival.
NO-Cbl inhibited expression of a NF-κB-induced survival factor, namely X-linked
inhibitor of apoptosis (XIAP) (Figure 3.5), consistent with other studies in which Snitrosoglutathione (GSNO) inhibited XIAP expression (Manderscheid et al., 2001). Our
data suggest that the inhibitory effects of NO-Cbl on XIAP are post-translational as well
as transcriptional (Figure 3.5). The increase in caspase-8 activation, PARP cleavage and
XIAP degradation are consistent with the synergistic anti-proliferative effects of NO-Cbl
(Figure 3.6) and provide further evidence as to the chemopotentiating effects of NO-Cbl.
Elimination of OVCAR-3 and P388 tumors in vivo (Figure 3.7) is consistent with the
antiproliferative synergy observed in vitro.
We are continuing to study the mechanism by which NO-Cbl inhibits NF-κB
activation. This likely involves S-nitrosylation (Stamler et al., 2001). Prostaglandins
(PGA1 and 15dPGJ2) inhibit IKK by covalently modifying a critical cysteine residue
(C179) within the activation loop (Rossi et al., 2000). S-nitrosylation of IKK-β leads to
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its inactivation (Reynaert et al., 2004). In addition, the NO donor SNAP has been shown
to inhibit IKK-β (Waldow et al., 2006) as well as suppress AKT activation (Storling et
al., 2005). Also, inactivation of AKT can result from S-nitrosylation and may be involved
in insulin resistance (Yasukawa et al., 2005). Alternatively or in addition, both IKK-γ and
XIAP contain zinc fingers which are known targets for nitrosylation (Kroncke and
Carlberg, 2000). Others have shown that NO can inhibit NF-κB by direct S-nitrosylation
of the DNA binding subunits (DelaTorre et al., 1997; Marshall and Stamler, 2001;
Matthews et al., 1996) or tyrosine nitration (Park et al., 2005).
Therefore, NO-Cbl likely nitrosylates redox-sensitive residues in its target proteins,
causing inhibition of NF-κB-mediated survival signaling and this appears to also be the
case with AKT-mediated survival signaling. We have shown that NO-Cbl maximizes the
anti-tumor effectiveness of primary chemotherapeutic agents. The use of NO-Cbl to
inhibit survival signaling may prevent drug resistance, a common occurrence in multiple
cycle chemotherapy, and may improve response rates and enhance drug efficacy.
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CHAPTER IV
EFFECTS OF INOSITOL HEXAKISPHOSPHATE KINASE 2 ON
TRANSFORMINGGROWTH FACTOR -ACTIVATED KINASE 1 AND NF- B
ACTIVATION
4.1 ABSTRACT
It has been previously shown that inositol hexakisphosphate kinase 2 (IHPK2)
functions as a growth-suppressive and apoptosis-enhancing kinase during cell stress.
Overexpression of IHPK2 sensitized ovarian carcinoma cell lines to the growthsuppressive and apoptotic effects of interferon (IFN- ), IFN- 2, and -irradiation.
Expression of a kinase-dead mutant abrogated 50% of the apoptosis induced by IFN- .
Because the kinase-dead mutant retained significant response to cell stressors, we
hypothesized that a portion of the death-promoting function of IHPK2 was independent
of its kinase activity. We now demonstrate that IHPK2 binds to tumor necrosis factor
(TNF) receptor-associated factor (TRAF) 2 and interferes with phosphorylation of
transforming growth factor -activated kinase 1 (TAK1), thereby inhibiting NF- B
signaling. IHPK2 contains two sites required for TRAF2 binding, Ser-347 and Ser-359.
Compared with wild type IHPK2-transfected cells, cells expressing S347A and S359A
mutations displayed 3.5-fold greater TAK1 activation following TNF- . This mutant
demonstrated a 6–10-fold increase in NF- B DNA binding following TNF- compared
with wild type IHPK2-expressing cells in which NF- B DNA binding was inhibited.
105

Cells transfected with wild type IHPK2 or IHPK2 mutants that lacked S347A and S359A
mutations displayed enhanced terminal deoxynucleotidyltransferase-mediated dUTP nick
end-labeling staining following TNF- . We believe that IHPK2-TRAF2 binding leads to
attenuation of TAK1- and NF- B-mediated signaling and is partially responsible for the
apoptotic activity of IHPK2.

4.2 INTRODUCTION
Inositol polyphosphates play diverse biologic roles, including regulation of endocytic
trafficking (Saiardi et al., 2002), protein phosphorylation (Saiardi et al., 2004),
chemotaxis (Luo et al., 2003), regulation of non-homologous end joining (Abraham,
2001; Hanakahi et al., 2000; Ma and Lieber, 2002), and apoptosis (Morrison et al., 2001;
Nagata et al., 2005). Inositol hexakisphosphate kinase 2 (IHPK2) is a kinase that
catalyzes the synthesis of diphosphoinositol pentakisphosphate and bis-diphosphoinositol
tetrakisphosphate. Overexpression of IHPK2 sensitizes ovarian carcinoma cell lines to the
growth-suppressive and apoptotic effects of IFN- , IFN- 2 treatment, and ionizing
radiation(Morrison et al., 2002). Snyder and co-workers (Nagata et al., 2005) recently
demonstrated that IHPK2 enhanced the cytotoxic actions of several different cell
stressors.
By co-immunoprecipitation, we found that IHPK2 associated with TRAF2. The tumor
necrosis factor (TNF) receptor-associated factor (TRAF) family of proteins serve as
adapter proteins for the TNF-R and interleukin-1 receptor superfamilies (Arch et al.,
1998; Kopp and Medzhitov, 1999). The role of TRAF2 in mediating the TNF- response
is controversial. Early studies with TRAF2 and TRAF5 knock-out mice or dominant
negative (DN) TRAF2 mice suggested that these proteins were not essential or played
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redundant roles in TNF-induced NF- B activation (Lee et al., 1997; Nakano et al., 1999;
Yeh et al., 1997). TRAF2–/– fibroblasts are severely impaired in their ability to activate cJun N-terminal kinase in response to TNF- (Nakano et al., 1999). Subsequent studies
suggested that TRAF2–/– fibroblasts (Devin et al., 2000) or TRAF2/TRAF5 double knockout murine fibroblasts (Tada et al., 2001) were impaired in their ability to activate NF- B
in response to TNF- . Most recently, Aggarwal and co-workers (Jackson-Bernitsas et al.,
2007) have shown that NF- B activation in carcinomas could be disrupted by expression
of DN-TRAF2 but not by DN-TRAF5, suggesting that TRAF2 plays a critical role in
TNF- -induced NF- B activation.
Within the trimeric signaling complex TRAF2 serves to recruit I B kinase (IKK) and
RIP1 to the TNF-R1 (Devin et al., 2001; Song et al., 1997). Transforming growth factor
-activated kinase (TAK1) is a critical component of this cascade, functioning downstream
of RIP1 and TRAF2 to activate IKK (Shim et al., 2005). We hypothesized that the
binding of IHPK2 to TRAF2 might disrupt TNF- signaling. The aims of this study were
to identify motifs in IHPK2 required for TRAF2 binding and to determine whether
disruption of IHPK2-TRAF2 binding would affect TNF- signaling.
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4.3 EXPERIMENTAL PROCEDURES
Materials—Human IFN- (Serono, Rockland, MA)-specific activity, 2.7 x 108 units/mg,
was used in these studies.
4.3.1 Construction of IHPK2 SXXE Mutants
IHPK2 was cloned into the pCXN2myc mammalian expression vector (Kinoshita et
al., 1998). Using PCR, point mutations were made in IHPK2. The serine residues in
SXXE were changed to AXXE. Thus, the wild type sequences (in bold) SXXE1,
VDIVDNSDCEPKS; SXXE2, LLENLTSRYEVPC; SXXE3, PEVVLDSDAEDLE; and
SXXE4, EDLSEESADESAG were changed to SXXE1, VDIVDNADCEPKS; SXXE2,
LLENLTARYEVPC; SXXE3, PEVVLDADAEDLE; and SXXE4, EDLSEEAADESAG.
This was done using primers 5'pGTGGACATTGTAGATAATGCAGACTGTGAACCAAAAAGT-3' and 5'pACTTTTTGGTTCACAGTCTGCATTATCTACAATGTCCAC-3' for SXXE1, 5'pTTACTGGAAAACCTGACTGCCCGCTATGAGGTGCCTTGT-3' and 5'pACAAGGCACCTCATAGCGGGCAGTCAGGTTTTCCAGTAA-3' for SXXE2, 5'pCCCGAAGTGGTCCTGGACGCAGATGCTGAGGATTTGGAG-3' and 5'pCTCCAAATCCTCAGCATCTGCGTCCAGGACCACTTCGGG-3' for SXXE3, and 5'pGAGGACCTGTCAGAGGAAGCAGCTGATGAGTCTGCTGGT-3' and 5'pACCAGCAGACTCATCAGCTGCTTCCTCTGACAGGTCCTC-3' for SXXE4 (p
indicates phosphorylated 5'-nucleotide). The PCR product was digested with EcoRI and
XhoI and cloned into pCXN2myc. Mutations were confirmed by sequencing. TRAF2
cDNA was cloned into pCXN2myc in a similar manner. Constructs were transfected into
NIH-OVCAR-3 cells by nucleofection with Cell Line Nucleofector kit T (Amaxa, Koeln,
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Germany). For transient transfection studies, cells were utilized after 48 h. In other coimmunoprecipitation studies, transfectants were selected with G418 for 4 weeks of
selection, and clones were pooled. Expression of mutants was monitored by
immunoblotting.
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4.3.2 siRNA Target Sequence
The IHPK2 target sequence consisted of a 29-mer oligonucleotide representing the
21-nucleotide sequence starting at nucleotide 181 (AAAUUCACUCCCCAGUACAAA)
and contained an 8-nucleotide sequence at the 3'-end complementary to the T7 promoter
primer provided in the Silencer siRNA construction kit (Ambion, Austin, TX).
Complementary oligonucleotides were annealed, and double-stranded RNA was prepared
by in vitro transcription. The resulting double-stranded RNA was then treated with RNase
A and DNase I to generate the final siRNA product. An oligonucleotide sequence that
does not silence any mammalian gene (siRNA-scrambled, siSCR) was utilized as a
negative control. Nucleofection was used to transiently transfect siRNAs into cells at a
concentration of 40 nM.
4.3.3 Immunopercipitation
Mouse monoclonal antibody (15 µg) made in our laboratory was incubated with
Protein A-Sepharose beads (Amersham Biosciences) in cell lysis buffer (0.1% Nonidet P40, 50 mM Tris, pH 8.0, 0.1 mM EDTA, 0.5 mM dithiothreitol, 75 mM NaCl, 10%
glycerol, and protease inhibitors). For in vitro interaction studies, recombinant purified
IHPK2 and TRAF2 (50 µg), encoded in pET32a and expressed in BL21-DE3 bacteria,
were incubated in 20 mM Hepes, pH 7.9, 150 mM NaCl, 10 mM EDTA, 0.1% Nonidet P40 (v/v), 10% glycerol, 1 mM dithiothreitol, 1 mM phenylmethanesulfonyl fluoride, 20
µg/ml leupeptin. For in vivo interaction studies, total cell protein (100 µg) was
immunoprecipitated with IHPK2 monoclonal antibody. Precipitate was subjected to
electrophoresis, transferred to polyvinylidene difluoride membrane, and immunoblotted
with rabbit anti-mouse TRAF2 polyclonal antibody (Leinco Technologies, St. Louis,
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MO). Membranes were incubated with anti-mouse IgG antibody conjugated to
horseradish peroxidase and developed using ECL reagents (Pierce). Converse
experiments were performed by immunoprecipitating with anti-TRAF2 and probing with
anti-IHPK2. Lysates were also immunoprecipitated with anti-NF- B p50 antibody
(Zymed Laboratories Inc., San Francisco, CA), anti-TAK1 (Cell Signaling Technology,
Danvers, MA), or anti-DR4 (Genetex, San Antonio, TX) and probed for IHPK2.
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4.3.4 Immunoblot Analysis
Total cell protein (50 µg) was separated on 10% SDS-polyacrylamide gels and
transferred to polyvinylidene difluoride membrane. Membranes were incubated with
antibody raised against TAK1, or phospho-TAK1, or phospho-AKT or AKT (Cell
Signaling Technology), or human XIAP (BD Transduction Laboratories, San Jose, CA),
or GAPDH (Trevigen, Inc., Gaithersburg, MD). After washing, membranes were
incubated with appropriate secondary antibody conjugated to horseradish peroxidase and
developed using ECL reagents (Pierce). Band intensity was quantitated using
densitometry (FluorChem SP imaging station; Alpha Innotech, San Leandro, CA). -Fold
induction was expressed as the ratio of normalized band intensities: (TNF-treated)/(PBStreated).
4.3.5 Electrophoretic Mobility Shift Assay (EMSA)
As a positive control for NF- B induction, cells were treated with TNF- (20 ng/ml)
for 15 min. Plates were washed with cold Dulbecco's phosphate-buffered saline (Sigma).
Cells were scraped from plates and resuspended in cold CellLytic M lysis reagent
(Sigma) with phosphatase and protease inhibitors (Calbiochem). Lysates were incubated
(4 °C, 30 min) followed by centrifugation (20,000 x g for 15 min). Supernatant protein
concentrations were assessed using the Bradford method (Bio-Rad protein assay). The
NF- B consensus binding sequence oligonucleotide (5'AGTTGAGGCGACTTTCCCAGGC-3') (Santa Cruz Biotechnology, Santa Cruz, CA)
was end-labeled with [

32

-P]dATP (PerkinElmer Life Sciences), using T4 polynucleotide

kinase (Roche Applied Science). DNA binding reactions were performed (30 min, 4 °C,
20 µg of protein) in 100 mM HEPES, 3.0 mM EDTA, 50% glycerol, 5 mM dithiothreitol,
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25 mM MgCl2, 20 mM Tris, pH 7.90, 5 µg of poly d(I-C), and labeled probe. Complexes
were resolved on 6% non-denaturing polyacrylamide gels. Gels were dried and exposed
to film. To verify that band shifts were comprised of NF- B, lysates were stimulated for
15 min with TNF- (20 ng/ml) and incubated with 1 µg of anti-NF- B p50 antibody
(Zymed Laboratories Inc., San Francisco, CA). Band intensity was quantitated by
phosphor image analysis on a Storm-840 imager using Image Quant v 5.1 software
(Amersham Biosciences). -Fold induction was expressed as the ratio of normalized band
intensities: (TNF-treated)/(PBS-treated).
4.3.6 IKK Assay
Whole cell extracts (300 µg of protein) were supplemented with 150 µl of Buffer A
(20 mM Hepes, pH 7.9, 20 mM -glycerophosphate, 10 mM NaF, 0.1 mM
orthovanadate, 5 mM para-nitrophenyl phosphate, 10 mM 2-mercaptoethanol, 0.5 mM
phenylmethylsulfonyl fluoride, and protease mixture) and 2 µl of normal rabbit serum
and mixed by rotation (4 °C, 1 h) (DiDonato, 2000). A 50% slurry of Protein GSepharose (80 µl) (Amersham Biosciences) in Buffer A (without -mercaptoethanol or
phenylmethylsulfonyl fluoride) was added and mixed by rotation at 4 °C, 1 h. Protein GSepharose was removed by centrifugation (800 x g, 1 min) and discarded. Anti-IKK
monoclonal antibody (0.5 µg; BD Biosciences) or anti- -actin antibody was added to the
supernatant and mixed by rotation (4 °C, 2 h). A 50% slurry of Protein G-Sepharose (60
µl) prepared in Buffer C (Buffer A plus 50 mM NaCl and 10 mM MgCl2, without mercaptoethanol and phenylmethylsulfonyl fluoride) was added and mixed by rotation (4
°C, 30 min). Protein G immunopellets were collected by centrifugation (800 x g, 30 s)
and washed three times with Buffer B (Buffer A plus 250 mM NaCl) and once with
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Buffer C (Buffer A plus 50 mM NaCl and 10 mM MgCl2). Immunopellets were
resuspended in 30 µl of kinase buffer with 0.1 mM orthovanadate, 50 µM unlabeled ATP,
5 µCi of [ -32P]ATP, 2 mM dithiothreitol, and 2 µg of recombinant GST-I B -(1–54)
and incubated (30 °C, 30 min). Reactions were stopped with 15 µl of 4x SDS-PAGE
loading buffer (200 mM Tris-HCl, pH 6.8, 8% SDS, 40% glycerol, 0.2% 2mercaptoethanol), heated (95 °C, 10 min), and resolved by SDS-PAGE on 12%
acrylamide gels. Gels were rinsed, stained with Bio-Safe Coomassie (Bio-Rad) to
visualize protein bands, rinsed, photographed, dried, and exposed to Kodak X-OMAT AR
film (Eastman Kodak Co., Rochester, NY) to detect substrate phosphorylation. IKK
activation was quantified by phosphor image analysis (GE Healthcare).
4.3.7 Antiproliferative Assays
Cells were treated with IFN- during growth in RPMI 1640 (Mediatech Inc.,
Herndon, VA) and 5% fetal bovine serum (HyClone, Logan, UT). Cells were confirmed
mycoplasma-free by PCR. Growth was monitored using a colorimetric assay (Skehan et
al., 1990). Each treatment group contained 8 replicates. Cells were fixed and stained with
sulforhodamine B after 4 days. Bound dye was eluted from cells, and absorbance (Aexp)
was measured at 570 nm. One plate was fixed 8 h after plating to determine the
absorbance representing starting cell number (Aini). Absorbance with this plate and that
obtained with untreated cells at the end of the growth period (Afin) were taken as 0 and
100% growth, respectively. Thus, Percent Control Growth = 00%*(Aexp – Aini)/Afin – Aini).
Expressed as a percent of untreated controls, a decrease in cell number (relative to
starting cell number) is a negative number on the y-axis.
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4.3.8 TUNEL Assay
NIH-OVCAR-3 cells were exposed to TNF- (10 ng/ml) for 16 h. Apoptotic cells
were detected by TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP-biotin
nick end-labeling) staining using a kit (APO-BRDU kit; BD Biosciences). Cells were
processed according to the manufacturer's protocol. The percentage of fluorescein
isothiocyanate-positive cells was analyzed by fluorescent-activated cell scanning
(Facsvantage; BD Biosciences).

4.4 RESULTS
4.4.1 IHPK2 Binds TRAF2
Bacterially translated proteins were co-immunoprecipitated with antibody specific for
IHPK2 (Fig. 4.1a, top lane), whereas antibody to the DR4 death receptor did not
precipitate TRAF2 (Fig. 4.1a, bottom lane). Untransfected NIH-OVCAR-3 cells were
treated with PBS or IFN- (100 units/ml, 24 h); lysates were immunoprecipitated (IP)
with anti-IHPK2 followed by immunoblot (IB) with anti-TRAF2 antibody (Fig. 4.1b, top
lane). IFN- increased the interaction of IHPK2 with TRAF2. The converse experiment
(IP with anti-TRAF2 and IB with IHPK2) gave similar results (Fig. 4.1b, second lane).
Immunoprecipitation with irrelevant antibodies (p50 and TAK1) yielded no signal.
4.4.2 IHPK2 Knock Down Induces IFN- Resistance
It has been previously shown that IFN- induced IHPK2 in a post-transcriptional
manner (Morrison et al., 2001). This induction could be detected after IFN- (100
units/ml, 24 h, Fig. 4.1c, top lane). Transient transfection with siRNA against IHPK2
(siIHPK2) efficiently suppressed IHPK2 expression, whereas scrambled siRNA (siSCR)
did not. Because siRNA can potentially induce an IFN response, we examined effects of
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siRNA transfection on activation and phosphorylation of the transcription factor STAT1.
Treatment of untransfected cells with IFN- induced phosphorylation of STAT1 after 30
min, which was no longer detectable after 24 h. Similar activation of STAT1 was
detected in siIHPK2- and siSCR-expressing cells, suggesting that down-regulation of
IHPK2 did not affect IFN signaling. The expression of STAT1, an IFN-stimulated gene,
was increased in untransfected, siIHPK2-transfected, and siSCR-transfected cells (Fig.
4.1c, third lane).
Transiently transfected NIH-OVCAR-3 cells were subjected to TUNEL analysis (Fig.
4.1d). Following IFN- , cells expressing scrambled siRNA (siSCR) displayed 2-fold
greater TUNEL staining (55%) compared with cells expressing siIHPK2 (23%).
Similarly, siIHPK2 reduced the level of apoptosis following TNF- from 67 to 32%.
Hence, knock down of IHPK2 mRNA conferred resistance to apoptosis induced by IFNand by TNF- . Inhibition of apoptosis correlated with enhanced proliferation. Antiproliferative assays (Fig. 4.11e) revealed a 2-fold increase in ID50 for IFN- in siIHPK2
cells compared with siSCR cells: 16 and 8 units/ml, respectively.
4.4.3 IHPK2 Mutation Inhibits IHPK2-TRAF2 Binding
Ligation of death receptors such as Fas, TNFR1, DR4, and DR5 activates the external
apoptotic pathway. TNF- binds TNFR1, inducing clustering of TRADD and receptorinteracting protein (RIP1), which leads to caspase activation. However, ligation of
TNFR1 generates not only a death signal but an additional survival signal mediated by
NF- B. Apo2L/TRAIL triggers apoptosis via binding to death receptors DR4 and DR5.
Immunoprecipitation of NIH-OVCAR-3 cell lysates with IHPK2 monoclonal antibody
showed that there was no association between IHPK2 and DR4 or DR5 (not shown).
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Treatment with IFN- enhanced binding of IHPK2 to TRAF2 (Fig. 4.1b). The interaction
was even stronger when TRAF2 and IHPK2 were co-transfected (Fig. 4.2a). When cells
are transfected with only one construct (either IHPK2 or TRAF2, Fig. 4.2, a and b, lanes
1–2) less TRAF2 is immunoprecipitated when compared with co-transfection. IHPK2
contains four SXXE motifs, putative binding sites for TRAF2 (Park et al., 1999). For
brevity, we named these sites S1 (S102), S2 (S211), S3 (S347), and S4 (S359). The four
SXXE sites were point mutated (serine to alanine) singly and in combination. NIHOVCAR-3 cells were stably co-transfected with IHPK2 mutants and TRAF2. Cell lysates
were immunoprecipitated with IHPK2 monoclonal antibody. Immunoblot analysis
demonstrated that two of the SXXE mutations (S3 and S4) in combination (but not singly)
reduced TRAF2 binding activity (Fig. 4.2a). Protein levels of IHPK2 and TRAF2 were
comparable in transfected cells (Fig. 4.2b).
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FIGURE 4.1
1
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Figure 4.1: IHPK2-TRAF2 interaction.
a, interaction of recombinant proteins in vitro. Presence and absence of proteins
indicated by + and–, respectively. The reaction was subject to immunoprecipitation
(IP) followed by immunoblot (IB) with the indicated antibodies. b, wild type NIHOVCAR-3 cells were treated with IFN- (100 units/ml x 24 h). Lysates were subject
to immunoprecipitation followed by immunoblot with the indicated antibodies. Antip50 NF- B and anti-TAK1 were included as negative controls. As additional controls,
lysis buffer (LB) alone, without cell lysate, was immunoprecipitated. c, untransfected
(WT) cells were treated with PBS (0h) or IFN- as above and harvested at 0.5 and 24
h. Immunoblots indicate induction of IHPK2 and STAT1 (at 24 h) and induction of
pSTAT1 (at 30 min). Cells were transiently transfected with siRNA directed against
IHPK2 (siIHPK2) or scrambled siRNA (siSCR) by nucleofection. Two days later cells
were treated with PBS or IFN- (0.5 and 24 h) and subjected to immunoblot analysis.
d, transiently transfected cells were treated with PBS, IFN- (100 units/ml), or TNF(10 ng/ml) for 24 h and subjected to TUNEL staining. e, transiently transfected cells
were grown in the presence of IFN- (0–100 units/ml). After 4 days of growth, cells
were fixed and stained, and cell number (proportional to intensity of retained SRB
dye) was expressed as a percentage of PBS-treated control cells (n = 8 replicates/data
point).
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FIGURE 4.2

Figure 4.2: Effect of IHPK2 mutation on binding of IHPK2 to TRAF2.
a, NIH-OVCAR-3 cells were co-transfected with IHPK2 and TRAF2 by
nucleofection. Pluses and minuses indicate the presence or absence of indicated
construct, respectively. Total cell protein (100 µg) from each transfected cell line was
immunoprecipitated with IHPK2 mouse monoclonal antibody. Precipitate was
subjected to immunoblot analysis with TRAF2 polyclonal antibody (bottom row).
Immunoblot analysis demonstrated that the IHPK2 S3&4 mutations in combination
(but not single mutations) caused reduced TRAF2 binding when compared with the
interaction of wild type IHPK2 and all other IHPK2 mutations. b, immunoblot to
demonstrate protein levels of IHPK2, TRAF2, and GAPDH in lysates of transfected
cells. The experiment was performed three times with similar results.
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4.4.4 Effect of IHPK2 Mutation on TAK1 Phosphorylation
Because TAK1 plays an important role in the TNFR-mediated cascade and functions
immediately downstream of TRAF2 (Shim et al., 2005), we determined whether IHPK2
mutation had any effect on phosphorylation of TAK1. Wild type untransfected and
vector-transfected cells displayed a 2.5- to 3-fold induction of phospho-TAK1 (pTAK1)
in response to TNF- (Fig. 4.3a). TNF- failed to activate TAK1 above base line in cells
expressing IHPK2 or the S3 or S4 single mutants (<1.5-fold induction of pAKT).
However, phosphorylation of TAK1 following TNF- was restored in cells containing
S3&S4 double mutants (3- to 3.5-fold induction). Hence, the S3&S4 double mutant had
diminished TRAF2 binding and no longer inhibited TAK1 phosphorylation.
4.4.5 Effect of IHPK2 Mutation on AKT Phosphorylation
Because AKT may also contribute to NF- B activation, mainly through
phosphorylation of IKK (Ozes et al., 1999), we determined whether IHPK2 mutation
had any effect on activation of AKT. Wild type untransfected and vector-transfected cells
displayed a 6-fold induction of phospho-AKT (pAKT) in response to TNF- (Fig. 4.3b).
The TNF- response of cells expressing IHPK2 or the S3 or S4 single mutants was
suppressed (1- to 1.5-fold induction of pAKT). However, the TNF- response was
restored in cells containing S3&S4 double mutants; they displayed 5- to 17-fold induction
of pAKT (Fig. 4.3b, bars 6–9). Hence, the S3&S4 double mutant lost the ability to
inhibit pAKT activation.
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FIGURE 4.3

Figure 4.3: Effect of IHPK2 mutation on phosphorylation of TAK1 and AKT.
a, untransfected (WT), vector-transfected (pCXN2), and mutant-transfected cells were
treated with PBS (–) or TNF- , 15 ng/ml (+) for 1 h. Lysates were subjected to
immunoblot with anti-phospho-TAK1 followed by stripping and reprobing with antiTAK1. Expression of IHPK2 transgene is indicated, and GAPDH served as loading
control. Bands were quantitated by densitometry, and -fold induction was calculated
(n = 3). b, using the same lysates, similar studies were performed with anti-phosphoAKT and anti-AKT.
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4.4.6 Effect of IHPK2 Mutation on I B Kinase Activity
The IKK complex, consisting of , , and subunits, is responsible for
phosphorylation of I B, leading to I B degradation, and subsequent nuclear translocation
of NF- B. TAK1 phosphorylates IKK , the main catalytic subunit, whereas AKT
phosphorylates IKK . We examined IKK enzymatic activity in lysates of cells stably
transfected with IHPK2 mutants. IKK was immunoprecipitated from cell extracts using
anti-IKK antibody, and kinase activity was assessed using recombinant GST-I B -(1–
54) as a substrate. TNF- induced IKK activity in wild type untransfected cells, vectortransfected cells, and all transfectants (Fig. 4.4). Cells expressing IHPK2 S3&4 double
mutants displayed similar kinase activity as wild type cells or other transfectants.
Therefore, the S3&4 mutant did not appear to modulate IKK enzymatic activity in vitro.
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FIGURE 4.4

Figure 4.4: IKK activity.
IKK activity was assessed using recombinant GST-I B -(1–54) and [ -32P]ATP as
substrates. The phosphorylated GST fusion protein was detected by autoradiography.
a, IKK activity was determined in NIH-OVCAR-3 cells co-transfected with IHPK2
(wild type or mutants) and TRAF2, followed by TNF- stimulation for 15 min. Cells
expressing the double mutant did not show significant differences in IKK activity
compared with cells expressing wild type IHPK2. Untreated cells typically exhibit 5–
10% the activity of stimulated cells (DiDonato et al., 1997a). Expression of IHPK2
transgene is indicated, and GAPDH served as loading control. The experiment was
performed three times with similar results. b, Coomassie blue-stained gel
demonstrated equal loading of GST-I B -(1–54) substrate utilized in the kinase
assay.
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4.4.7 Effect of IHPK2 Mutation upon NF- B DNA Binding
We next determined whether IHPK2-TRAF2 binding and inhibition of TAK1
phosphorylation disrupted NF- B signaling. In untransfected wild type NIH-OVCAR-3
cells, treatment with TNF- resulted in robust NF- B activation as demonstrated by
EMSA (Fig. 4.5a). Supershift (ss) with anti-p50 confirmed the identity of NF- B.
Transfection with IHPK2 reduced the intensity of DNA binding activity in response to
TNF- (Fig. 4.5b, compare lanes 3–6). Quantitation of the band shift indicated a 3-fold
reduction (Fig. 4.5b, bars 2 and 3). Hence, overexpression of IHPK2 blunted NF- B
DNA binding activity in response to TNF- . Cells expressing two IHPK2 mutations
(S3&4) demonstrated 7- to 11-fold activation of NF- B compared with cells cotransfected with wild type IHPK2. The other IHPK2 mutants that lacked S3&4 mutations
had blunted NF- B activation (1-fold induction).
4.4.8 Effect of IHPK2 Mutation on XIAP
Activated NF- B translocates to the nucleus and induces transcription of target genes
such as inhibitor of apoptosis proteins (IAPs). The X-linked mammalian inhibitor of
apoptosis protein (XIAP) binds to caspase 3, caspase 9, DIABLO/Smac, HtrA2/Omi, and
TAB1 (Auphan et al., 1995). Cells expressing IHPK2 mutants S3&4 displayed up to a
2.4-fold increase in XIAP. The IHPK2 single mutants (S3 and S4) acted like wild type
IHPK2, resulting in suppressed XIAP expression (fold increase 0.1–0.9) (Fig. 4.6). Thus,
effects of IHPK2 mutation upon XIAP induction correlated with changes in NF- B DNA
binding activity.
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FIGURE 4.5
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Figure 4.5: Effect of IHPK2 mutation upon NF- B DNA binding activity.
a, wild type untransfected NIH-OVCAR-3 cells were treated with TNF- , and EMSA
was performed. Lysates were incubated with anti-GAPDH or anti-NF- B(p50) prior
to EMSA to demonstrate supershift (ss). b, cells transfected with IHPK2 S3&4
mutations (S347A and S359A) displayed enhanced NF- B DNA binding activity
induced by TNF- . Cells transfected with wild type IHPK2 or IHPK2 mutants that
lacked S3&4 mutations had suppressed NF- B DNA binding activity. Cells were
stimulated with TNF- (20 ng/ml) for 15 min. Expression of IHPK2 transgene is
indicated, and GAPDH served as loading control. EMSA band intensities were
quantified with a Phosphorimager, and -fold induction was calculated. Cells
expressing IHPK2 mutants S3&4, S1&3&4, S2&3&4, and S1&2&3&4 were 7- to 11fold more effective at activation of NF- B compared with cells transfected with wild
type IHPK2, whereas cells expressing IHPK2 and single mutants had <2-fold
induction. Data are expressed as mean ± S.E. of three separate experiments.
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FIGURE 4.6

Figure 4.6: Effect of IHPK2 mutation on XIAP levels.
Immunoblotting for XIAP was performed with lysates harvested 24 h after TNF(15 ng/ml). Expression of IHPK2 transgene is indicated, and GAPDH served as
loading control. Cells expressing IHPK2 mutations S3&4 had up to 2.4-fold increase
in XIAP. XIAP was not induced in cells expressing IHPK2, or IHPK2 single
mutations, demonstrating -fold increases of -0.1 to -0.9. -Fold increase <1.0
corresponds to decreased XIAP expression following TNF- (n = 3).
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4.4.9 IHPK2 Mutants Inhibit TNF- -induced Apoptosis
The effects of IHPK2 mutation on TNF- -induced apoptosis were analyzed by
TUNEL (Fig. 4.7). Untransfected wild type and vector-transfected cells displayed 40 and
26% TUNEL positivity following TNF- , respectively. Cells expressing IHPK2 or S3 or
S4 single point mutations had enhanced TUNEL staining, 64, 51, 52%, respectively. Cells
expressing the S3&S4 double mutation were 33% TUNEL-positive, a response that was
similar to untransfected or vector-transfected cells. Therefore, the double mutant was
defective in enhancing TNF- -induced apoptosis.
4.4.10 IHPK2 Mutants Affect Growth-suppressive Activities of IFNThe biological relevance of the IHPK2 mutations was determined in antiproliferative
assays using pools of stable transfectants. Overexpression of IHPK2 sensitized cells to
IFN- , as the IC50 value fell from 15 to 6 units/ml in vector-transfected and IHPK2transfected cells, respectively (Fig. 4.8). Constructs containing the S3&4 mutations
conferred resistance to IFN- , as the IC50 value increased from 15 units/ml in vectortransfected cells to 20–75 units/ml in double mutant-transfected cells, respectively. Cells
expressing irrelevant IHPK2 mutations (IRREL, constructs lacking S3&4 mutations)
displayed sensitivity to IFN- between that of vector- and IHPK2-transfected cells.
Therefore, overexpression of IHPK2 sensitized cells to IFN- , and the S3&4 double
mutation conferred resistance to IFN- .
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FIGURE 4.7

Figure 4.7: Effect of IHPK2 mutation on apoptosis induction by TNF- .
Untransfected (WT), vector-transfected (pCXN2), and mutant-transfected cells were
treated with PBS or TNF- , 15 ng/ml for 16 h. Induction of apoptosis was determined
by TUNEL staining.
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FIGURE 4.8

Figure 4.8: Effect of IHPK2 mutation on IFN-β antiproliferative activity.
NIH-OVCAR-3 cells were stably transfected with IHPK2 constructs and grown in the
presence of 5–500 units/ml IFN-β. After 4 days, cells were fixed and stained with
sulforhodamine B. Absorbance of bound dye was expressed as percent of untreated
controls (n = 8, each data point). Overexpression of IHPK2 sensitized cells to IFN-β.
Cells expressing IHPK2 mutations S3&4 in combination conferred relative resistance
to IFN-β. The dose response curve of cells expressing irrelevant IHPK2 mutations
(S1, S2, S3, S4, S1&2, S1&3, S1&4, S2&3, S2&4, S1&2&3, S1&2&4) lay in a
narrow band between pCXN2 (vector) and IHPK2 and is represented as a single curve
(IRREL).
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4.5 DISCUSSION
In previous studies, overexpression of the kinase-dead IHPK2 mutant suppressed IFNinduced cell death, but the magnitude of suppression was 50%, even though transfection
efficiency was 90%. Snyder and co-workers (Nagata et al., 2005) recently demonstrated
that transfection of IHPK2 augmented the apoptotic activities of several cell stressors.
Although transfection of all three subtypes of IHPK increased cell death, suppression of
IHPK2, but not IHPK1 or IHPK3, abrogated apoptosis.
Our study and those of Snyder and co-workers suggest that kinase activity is not the
sole determinant of the apoptotic activity of IHPK2. The present study provides evidence
that IHPK2 is a TRAF2-interacting protein that suppresses TAK1 phosphorylation and
inhibits NF- B activation. In the absence of cell stressors such as IFN- or TNF- ,
IHPK2-TRAF2 interaction is still detected at low levels (Fig. 4.1b). This may be
responsible for the 10% constitutive levels of apoptosis observed in NIH-OVCAR-3
cells. Immunoprecipitation analysis confirmed that the SXXE mutations (S347A and
S359A) in combination inhibited TRAF2 binding. Therefore, these residues are important
for IHPK2-TRAF2 association. Cells expressing these IHPK2 mutations were more
effective at phosphorylation of TAK1 and activation of NF- B compared with cells
expressing wild type IHPK2. Similarly, the double mutants were more effective at XIAP
induction and more resistant to the apoptotic effects of IFN- .
The NF- B pathway is activated following degradation of I B (Senftleben et al.,
2001). This pathway depends on the IKK complex, which contains three subunits, IKK ,
IKK , and IKK . TRAF2 functions to recruit IKK and IKK to the TNF-R1 receptor
(Devin et al., 2001). Although initial studies utilizing TRAF2 knock-out MEFs suggested
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that TRAF2 did not play a role in activation of NF- B by TNF- (Yeh et al., 1997), later
studies indicated that TRAF2 was indeed required for NF- B activation. Nakano and coworkers (Tada et al., 2001) showed that TRAF2/TRAF5 double knock-out MEFs were
severely impaired in NF- B activation following TNF- , suggesting that TRAF2 and
TRAF5 function may be redundant. In squamous carcinoma, expression of DN-TRAF2
strongly inhibited transcription of an NF- B reporter plasmid, whereas DN-TRAF5 had
no effect on NF- B activation (Jackson-Bernitsas et al., 2007). Hence, in some
carcinomas TRAF2 and TRAF5 function is not redundant.
A model for this signaling cascade is: TNFR1-(RIP1/TRAF2)-TAK1-IKK -NF- B.
Knock-out MEFs that lack TAK1 cannot activate NF- B in response to TNF- and are
highly sensitive to TNF- -induced apoptosis, indicating that the survival pathway is
severely inhibited in these cells (Shim et al., 2005). Phosphorylation of IKK , mediated
by NF- B-inducing kinase, appears to be intact in TAK1 knock-out MEFs (Shim et al.,
2005). Thus, TAK1 phosphorylates IKK but does not appear to phosphorylate IKK .
Immunoprecipitation experiments with recombinant proteins demonstrated that IKK is
the main catalytic subunit of the IKK complex (Zandi et al., 1998).
The GST-I B -(1–54) fusion protein, containing glutathione and the first 54 residues
of I B , is phosphorylated by IKK in the kinase assay. Antibodies directed against IKK
disrupt IKK activity; therefore, antibodies against IKK or IKK are generally utilized to
precipitate the complex. Other proteins such as Cdc37 and Hsp90 may be required for
optimal activity of the IKK complex (Chen et al., 2002). If such auxiliary proteins are not
pulled down efficiently, the assay may not reflect the full extent of I B phosphorylation
in vivo.
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Mutation of IHPK2 clearly affected TAK1 phosphorylation (Fig. 4.3a) but did not
affect IKK kinase activity in vitro (Fig. 4.4a). There is also cross-talk between TRAF2
and AKT in NIH-OVCAR-3 cells, as overexpression of IHPK2 inhibited AKT activation
(Fig. 4.3b). CD40, a TNF receptor superfamily member, requires TRAF2 to activate
AKT. In TRAF2 knock-out MEFs, and carcinoma cells that received siRNA-TRAF2,
AKT phosphorylation was severely impaired (Davies et al., 2005). Our studies suggest
that following binding to TRAF2, IHPK2 functions to inhibit TAK1 phosphorylation,
AKT phosphorylation, and subsequent NF- B activation.
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CHAPTER V

FLAGELLIN ACTING VIA TLR5 IS THE MAJOR ACTIVATOR OF KEY
SIGNALING PATHWAYS LEADING TO NF-B AND PROINFLAMMATORY
GENE PROGRAM ACTIVATION IN INTESTINAL EPITHELIAL CELLS

5.1 ABSTRACT
Infection of intestinal epithelial cells by pathogenic Salmonella leads to activation of
signaling cascades that ultimately initiate the proinflammatory gene program. The
transcription factor NF-κB is a key regulator/activator of this gene program and is
potently activated. We explored the mechanism by which Salmonella activates NF-κB
during infection of cultured intestinal epithelial cells and found that flagellin produced by
the bacteria and contained on them leads to NF-κB activation in all the cells; invasion of
cells by the bacteria is not required to activate NF-κB. Purified flagellin activated the
mitogen activated protein kinase (MAPK), stress-activated protein kinase (SAPK) and
Ikappa B kinase (IKK) signaling pathways that lead to expression of the proinflammatory
gene program in a temporal fashion nearly identical to that of infection of intestinal
epithelial cells by Salmonella. Flagellin expression was required for Salmonella invasion
of host cells and it activated NF-κB via toll-like receptor 5 (TLR5). Surprisingly, a
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number of cell lines found to be unresponsive to flagellin express TLR5 and expression
of exogenous TLR5 in these cells induces NF-κB activity in response to flagellin
challenge although not robustly. Conversely, overexpression of dominant-negative TLR5
alleles only partially blocks NF-κB activation by flagellin. These observations are
consistent with the possibility of either a very stable TLR5 signaling complex, the
existence of a low abundance flagellin co-receptor or required adapter, or both.
These collective results provide the evidence that flagellin acts as the main determinant
of Salmonella mediated NF-κB and proinflammatory signaling and gene activation by
this flagellated pathogen. In addition, expression of the fli C gene appears to play an
important role in the proper functioning of the TTSS since mutants that fail to express fli
C are defective in expressing a subset of Sip proteins and fail to invade host cells.
Flagellin added in trans cannot restore the ability of the fli C mutant bacteria to invade
intestinal epithelial cells. Lastly, TLR5 expression in weak and non-responding cells
indicates that additional factors may be required for efficient signal propagation in
response to flagellin recognition.

5.2 INTRODUCTION
Intestinal epithelial cells serve as a barrier between the luminal microflora and the
body and as such are perfectly positioned to monitor the approach/invasion of pathogens.
These intestinal epithelial cells (IECs) serve as innate immune sentinels and monitor their
environment and constantly give out innate host defense instruction to local immune
effector cells (Eckmann et al., 1995; Kagnoff and Eckmann, 1997). Pathogens such as
Salmonella and other enteroinvasive pathogenic bacteria such as enteroinvasive E. Coli,
Shigella and Yersinia upon infection of IECs leads to the up-regulation of the expression
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of host genes, the products of which activate mucosal inflammatory and immune
responses and alter epithelial cell functions (Eckmann et al., 1997; Elewaut et al., 1999;
Jung et al., 1995; Witthoft et al., 1998). Previously we and others demonstrated that IKK
via NF-κB and the SAPK signaling pathways via Jun N-terminal kinase (JNK) and p38
kinase were key regulators of the up-regulation of the proinflammatory gene program
(Chen et al., 1996; Elewaut et al., 1999; Hardt et al., 1998; Hobbie et al., 1997), with NFκB appearing to be the most critical (Elewaut et al., 1999). Typically Salmonella infects
thirty-forty percent of IECs in culture models of infection (Valdivia et al., 1996),
however, we and others have found that Salmonella infection activates NF-κB DNA
binding activity to levels equivalent to that of TNFα which activates NF-κB in all of the
cells (Elewaut et al., 1999). Previous studies examining NF-κB activation by Salmonella
in HT29 colonic intestinal epithelial cells, which serve as model colonic epithelial cells in
culture, indicated that delivery of Salmonella proteins into the host cell via its type III
secretion system (TTSS), such as SopE and SopE2, the bacterially encoded exchange
factors for the Rho-family members Rac1 and CdC42, result in exchange factor
activation, cytoskeletal rearrangements and activation of the MAPK, SAPK and NF-κB
signaling pathways (Bakshi et al., 2000; Galan, 2001; Galan and Collmer, 1999; Hardt et
al., 1998; Hobbie et al., 1997; Kubori and Galan, 2002; Wood et al., 1996). Recent
observations that utilized Salmonella strains that were defective in invasion and delivery
of invasion proteins by the TTSS but not attachment indicated that additional factors
other than those delivered by the TTSS could lead to NF-κB activation (Eaves-Pyles et
al., 1999). Presently it is not clear what protein(s) dictate the activation of key signaling
pathways that lead to the temporal expression of the proinflammatory gene program,
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although the SopE proteins have been given extreme attention recently (Hardt et al.,
1998; Hobbie et al., 1997; Wood et al., 1996).
In searching for additional Salmonella proteins that could activate the
proinflammatory gene expression program, bacterial flagellin was recently found to be
such a protein (Eaves-Pyles et al., 1999; Gewirtz et al., 2001b; McDermott et al., 2000)
and had been shown previously to activate IL-8 expression in monocytes (CiacciWoolwine et al., 1998; McDermott et al., 2000; Moors et al., 2001). Flagellin was found
to activate NF-κB in polarized epithelial cells only when flagellin was present on their
basolateral surface (Gewirtz et al., 2001a) consistent with the idea that a cell surface
receptor was present there and could recognize it. The toll-like receptors (TLRs) have
been found to recognize pathogen associated molecular patterns (PAMPs) reviewed in
(Akira, 2001; Akira and Hemmi, 2003; Medzhitov and Janeway, 2000; O'Neill, 2001).
TLR2 interacts with TLR1 and TLR6 to recognize bacterial lipopeptides and zymosan
respectively (Hajjar et al., 2001; Ozinsky et al., 2000). TLR4 recognizes LPS only when
associated with its co-receptor MD2 and CD14 (Backhed et al., 2002; da Silva Correia et
al., 2001; Kawasaki et al., 2001; Nagai et al., 2002). Recently, flagellin was demonstrated
to be recognized by TLR5 and activate an innate host response (Gewirtz et al., 2001a;
Hayashi et al., 2001). However, little was known or demonstrated about the endogenous
levels of TLR5 in cells used in those studies and why those cells failed to respond to
flagellin. Here we have identified flagellin as the primary initiator and temporal regulator
of not only the major signaling pathways activated during Salmonella infection but also
of key target genes of the proinflammatory gene program too. We have also found
flagellin expression to be required for Salmonella bacterial invasion. Independently we
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found TLR5 recognizes flagellin but its signaling activity toward this PAMP is consistent
with either the aid of another flagellin-recognizing co-receptor (as TLR4 utilizes for LPS)
or the use of another adapter protein, perhaps similar to MyD88, that is absent or present
at low levels in flagellin non-or low-responding cells.

5.3 MATERIALS AND METHODS
5.3.1 Materials
Human tumor necrosis factor alpha (TNFα) and human IL-1 were purchased from
R&D Systems (Minneapolis, MN). Tris [hydroxymethyl]aminomethane (Tris) was
purchased from Fisher Scientific (Fairlawn, NJ). Fetal calf serum was purchased from US
Biotechnologies Inc. (Parkerford, PA). Para-nitro-phenylphosphate (PNPP) was
purchased from Aldrich Chemical (Milwaukee, WI). The Polyacrylamide gel
electrophoresis (PAGE) supplies: acrylamide, bis-acrylamide, sodium dodecyl sulfate
(SDS), TEMED, and ammonium persulfate were purchased from Bio-Rad Laboratories
(Hercules, CA). Dulbecco's modified essential medium (DMEM), DMEM:F12,
phosphate buffered saline (PBS), glutamine, penicillin G, streptomycin, amphotericin B,
and Grace's Insect medium were purchased from Invitrogen (Carlsbad, CA). Luria Broth
(LB) was purchased from Becton Dickson and Co (Sparks, MD). The protease inhibitors:
aprotinin, bestatin, leupeptin, pepstatin A, and phenylmethylsulfonyl fluoride (PMSF)
were purchased from Cal Biochem (La Jolla, CA). Protease inhibitor cocktail contained
10 μg/ml aprotinin, 2.5 μg/ml leupeptin, 8.3 μg/ml bestatin, and 1.7 μg/ml pepstatin A.
Phorbol 12-myristate 13 acetate (PMA), N-[2-hydroxyethyl]piperazine-N'-[2ethanesulfonic acid] (Hepes), anisomycin, and 2-[N-morpholino]ethanesulfonic acid
(MES) were purchased from Sigma Chemical (St. Louis, MO).
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5.3.2 Cell culture
HT29 human intestinal (colorectal adenocarcinoma) epithelial cells (ATCC HTB-38),
HeLa cervical epithelial adenocarcinoma cells (ATCC CCL-2), 293T kidney cells (CRL11268), A549 lung carcinoma cells (ATCC-185), and T98G glioblastoma cells (ATCC
CRL-1690) were cultured in DMEM with 2 mM glutamine, 10% Fetal Calf Serum, 100
Units/ml Penicillin G, and 100 μg/ml Streptomycin at 37°C in a humidified 5% CO2
atmosphere. T84 colorectal carcinoma cells (ATCC CCL-248) were cultured in
DMEM:F12 with 2 mM glutamine, 5% Fetal Calf Serum, 100 Units/ml Penicillin G, and
100 μg/ml Streptomycin at 37°C in a humidified 5% CO2 atmosphere. H5 insect cells
(Invitrogen) were cultured in Grace's medium with 2 mM glutamine, 10% Fetal Calf
Serum, 100 Units/ml Penicillin G, 100 μg/ml Streptomycin, and 0.25 μg/ml amphotericin
B at 28°C. MyD88-/- & TLR2-/-/TLR4-/- double knockout cells were obtained from Shizuo
Akira and Osamu Takeuchi (Univ. of Osaka, Japan) and grown in DMEM with 2 mM
glutamine, 10% Fetal Calf Serum, 100 Units/ml Penicillin G, and 100 μg/ml
Streptomycin at 37°C in a humidified 5% CO2 atmosphere.
5.3.3 Bacterial strains
Salmonella typhimurium strain SJW1103 (FliC, phase 1 flagellin, stabilized)
(Yamaguchi et al., 1984) is a wild-type Salmonella typhimurium and can only express the
Phase I fliC flagellin, SJW86 (SJW1103 FliC::TN10), and SJW134 (SJW1103 FliC and
FljB deletions) were obtained from Robert Macnab (Yale Univ., Conn) and have been
described (Williams et al., 1996). Salmonella serovar dublin strain 2229, strain SE1
(2229 SopE mutant), strain SB2 (2229 SopB mutant), and SE1SB2 (2229 SopE and SopB
mutant) were obtained from Edward Galyov (Compton Laboratory, Berkshire, UK) and
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have been described (Bakshi et al., 2000; Wood et al., 1996). Salmonella strains for
stimulation were grown in LB at 37°C without agitation for 16 hours, centrifuged at
6,000 × g for 1 minute, gently washed with PBS, and gently suspended in DMEM to
maintain cells with attached flagella.
Plasmid pFM10.1 (ampicillin resistance), encodes a green fluorescent protein (GFP)
expressed after the Salmonella host is internalized by mammalian cells, obtained from
Stanley Falkow (Stanford Univ., Stanford, CA) (Valdivia and Falkow, 1997; Valdivia et
al., 1996) and was transformed into strains SJW1103 and SJW134 by electroporation.
Strains containing pFM10.1 were designated SJW1103G and SJW134G.
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5.3.4 Preparation and analysis of Salmonella cell free culture supernatant
Native flagellin was harvested from S. dublin 2229 or S. typhimurium SJW1103.
Starter cultures were grown in Luria broth (LB) for 18 hours at 37°C with aeration,
diluted 1:5000 in fresh LB, and grown for 12 hours under the same conditions. All
subsequent procedures were performed at 4°C. Cells were removed from the medium by
centrifugation at 10,000 × g for 5 min and discarded. The supernatant containing flagellin
was filtered through a 0.8 micron filter (Millipore, Bedford, MA) to remove residual
cells. Supernatant was concentrated 100 fold using an Amicon 100 kiloDalton (kDa)
cutoff membrane (Millipore). Initial studies used concentrated culture supernatant from S.
dublin strain 2229 that was treated with DNase, RNase, Protease K, boiled for 20 min or
100 mM DTT at 37°C for 2 hours and used for stimulation of cultured cells.
Concentrated S. typhimurium 1103 bacterial culture supernatant was washed 4 times
by 1:10 dilution with 50 mM MES, pH 6.0, 50 mM NaCl and re-concentrated. Material
not retained by the 100 kDa membrane was discarded. Washed culture supernatant was
fractionated by gel permeation or anion exchange chromatography for analysis. For longterm storage, washed culture supernatant was supplemented with protease cocktail and
stored at -20°C.
Fractionation by gel permeation chromatography was performed with a Superose
12HR column (Pharmacia) on a Bio-Logic system (Bio-Rad). One-half mililiter of 100×
washed supernatant (equivalent of 50 ml original culture supernatant) was separated on
the column at 0.4 ml/minute in 50 mM Hepes, pH 7.4, 200 mM NaCl. Fractions (0.5 ml)
were collected, and 50 μl was fractionated by SDS-PAGE and stained with Bio-Safe
Coomassie (Bio-Rad). Thirty microliters of each fraction was used for stimulation of
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HT29 cells (60 mm dishes) for 45 min and NF-κB DNA binding activity in the resulting
whole cell extracts were assayed by EMSA. The column was standardized with catalase
(232 kDa), aldolase (158 kDa), albumin (67 kDa), ovalbumin (43 kDa), and
Chymotripsinogen A (25 kDa), all obtained from Amersham-Pharmacia.
Fractionation by anion exchange chromatography was performed with Poros HQ
matrix (2 ml column, PerSeptive Biosystems, Farmingham, MA) on a Bio-Logic system.
Five mililiters of 100× washed supernatant (equivalent of 500 ml original culture
supernatant) was separated at 1 ml/minute in 50 mM Hepes, pH 7.4, and a NaCl gradient
from 50–500 mM. Fractions were collected and 5 μl of each fraction was examined by
10% SDS-PAGE. Proteins were fractionated on duplicate 10% SDS-PAGE precast gels
(BioRad). One gel was stained with Bio-Safe Coomassie (Bio-Rad) and the protein bands
were isolated for Mass Spectroscopy analysis (CCF Mass spectroscopy core facility)
from the other identical non-stained gel, by electro-elution with a whole gel eluter (BioRad) and SDS was removed with SDS-Out (Pierce, Rockland, IL) per the manufacturer’s
directions. Proteins isolated from bands B1 to B6 were acetone precipitated by addition
of 20 μg Aprotinin and 5 μg of BSA to each eluted fraction, ice-cold acetone (-20°C) was
added to 80%, mixed well and precipitated overnight at -20°C. Proteins were pelleted by
centrifugation at 14,000 × g in the cold for 30 min, acetone/liquid was removed and the
pellets washed 2× with 1 ml acetone (-20°C). After removal of the acetone, protein
pellets were air dried and then resuspended and denatured in 5 μl of 6 M guanidinium
hydrochloride (Gu-HCl) at room temperature for 30 min. Resuspended proteins were
two-fold serially diluted in DMEM to a final Gu-HCl concentration of 55 mM to renature
the proteins. Two hundred fifty microliters of individual renatured proteins/DMEM were
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added per ml to HT29 cells (60 mm dishes) and whole cell extracts were prepared 45 min
after stimulation and were assayed for NF-κB DNA binding activity by EMSA.

5.3.5 Purification of flagellin (purified flagellin)
The washed and concentrated culture supernatant from S. typhimurium 1103
containing flagellin was boiled for 20 minutes and precipitants removed by centrifugation
at 15,000 × g. The supernatant containing flagellin was diluted 1:2 with 50 mM MES, pH
6.0, 50 mM NaCl and mixed with 2 ml Poros SP cation exchange matrix (PerSeptive
Biosystems) per 1 liter of original culture. The Poros SP matrix was prepared as a 50%
slurry and equilibrated with 50 mM MES, pH 6.0. The flagellin preparation and matrix
were mixed on a roller at 12 to 14 RPM for 2 hours. The matrix along with bound
contaminants was removed by filtration through a 0.85 micron filter and discarded,
flagellin failed to bind to the cation exchange matrix at pH 6.0 and eluted in the
flowthrough and was collected.
The pH of the flowthrough was adjusted by five-fold dilution of the sample with 50
mM Hepes, pH 7.8, 50 mM NaCl, and loaded onto a Poros HQ anion exchange column
(2 ml column, PerSeptive Biosystems) equilibrated with 50 mM Hepes, pH 7.4, 50 mM
NaCl. The column was washed with 2 volumes 50 mM Hepes, pH, 7.4, 50 mM NaCl, and
eluted with a 10 column volume linear gradient of 50–500 mM NaCl in 50 mM Hepes,
pH 7.4. Flagellin eluted from the column between 200–275 mM NaCl. Fractions
containing flagellin were pooled and concentrated. The preparation was determined to be
pure by electrophoresis of 5 μg protein by SDS-PAGE and stained with Bio-Safe
Coomassie (Bio-Rad). Samples were stored at -80°C in 50 mM Hepes, pH 7.4, approx
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225 mM NaCl, 10% glycerol and protease cocktail. A 4 liter preparation of culture
supernatant yielded 2 mg purified flagellin.

5.3.6 In-gel tryptic digestion and protein identification by LC-MS
Gels were fixed and stained (Bio-Safe Blue, BioRad). All of the following procedures
were performed by the CCF Mass spectroscopy core facility. Excised gel bands were
reduced (100 mM DTT), and alkylated (100 mM iodoacetamide). Proteins in the gel
bands were digested with modified trypsin (Promega, 20 μg/mL) with an overnight
incubation at 37°C. Tryptic peptides were extracted from the gel with 50% acetonitrile,
0.1% acetic acid, concentrated in a SpeedVac (Thermo Savant) to remove acetonitrile,
and reconstituted to 20 uL with 0.1% acetic acid. Extracted peptides were subjected to
reversed phase (50 uM ID packed with Phenomenex Jupiter C18, 6 cm capillary column)
liquid chromatography (2%–70% solvent B; Solvent A, 50 mM acetic acid, aqueous,
Solvent B acetonitrile), coupled to a Finnigan LCQ DECA ion trap mass spectrometer for
peptide sequencing, as described (DiDonato et al., 1997a).
5.3.7 Preparation of GST-IκBa1-54 and GST-cJUN1-79 kinase substrates
IκBα amino acids 1 to 54 fused to GST or cJUN amino acids 1–79 fused to GST were
prepared as previously described (DiDonato, 2000; DiDonato et al., 1997a; Hibi et al.,
1993) and stored in kinase buffer (20 mM Hepes, pH 7.6, 10 MM MgCl2, 10 mM NaCl,
2 mM beta-glycerophosphate, 10 mM PNPP).
5.3.8 Preparation of cells for microscopy
HT29 cells for microscopic examination were grown in 6 well plates on sterile cover
slips to a density of 50–75%. Cells were stimulated as described above. After stimulation,
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cover slips with HT29 cells were washed 2 times with ice cold PBS and fixed with 4%
w/v formalin at room temperature for 20 minutes. Cells were washed 4 times with PBS
prior to mounting for visualization of Salmonella invasion. Cover slips were mounted
with Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA),
and cover slips sealed to slides.
Cells for antibody staining were treated with absolute methanol for 20 minutes
following formalin fixation, then washed 3 times with PBS supplemented with 0.1% BSA
(PBSB) and used directly or stored in the cold after azide was added to 0.02%. For
p65(RelA) localization, cells on coverslips were blocked for 1 h at 37°C with PBS
supplemented with 1% BSA. The PBSB was removed, washed once with PBSB and
coverslips were placed cell-side down onto 150 μl of p65 antibody (Zymed, South San
Francisco, CA) diluted 1:1500 in PBSB on a square of parafilm and placed in a
humidified chamber at 37°C for 1.5 h. Coverslips were removed and placed cell-side up
in 6-well dishes and washed 3 × 5 min with PBSB. Coverslips were then removed and
placed cell-side down onto 150 μl of FITC-labeled donkey anti-rabbit secondary antibody
(Jackson Immunoresearch Laboratories, West Grove, PA) (1:300 in PBSB) on a square of
parafilm and placed in a humidified chamber at 37°C for 1.5 h. Coverslips were removed
and placed cell-side up in 6-well dishes and washed 5 × 5 min with PBSB, removed and
placed cell-side down onto slides mounted with Vectashield (Vector Laboratories,
Burlingame, CA) with DAPI and then sealed. NF-κB localization was determined by
indirect immunofluorescence. Samples were observed on a Leica DMR upright
microscope (Leica Microsystems Inc., Heidelberg, Germany) at 400× with oil immersion
and equipped with FITC and UV filters. Images were collected with a MicroMax RS
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camera (Princeton Instruments Inc., Princeton, NJ), and Image Pro plus, version 4.5,
software (Media Cybermetics Inc., Carlsbad, CA). Color enhancements were performed
with Image Pro plus software. Visible light plus color overlays for (Fig. 5.1 and
Fig. 5.5b) were performed with MetaMorph Software (Universal Imaging Corp.,
Downington, PA).

5.3.9 Bacterial infection and cell stimulation
Mouse embryo fibroblasts (MEFs) or HT29 cells were grown in DMEM as above to a
density of 90% prior to stimulation. All cells were washed with warm PBS and
supplemented with DMEM without serum or antibiotics in preparation for stimulation.
Cells were stimulated with; 10 ng/ml TNFα, 1 μg/ml flagellin unless specified otherwise,
20 μg/ml Anisomycin, 12.5 ng/ml PMA, or 108 Salmonella/ml at 37°C for desired times
and extracts prepared as below. Cells harvested beyond one hour were washed with warm
PBS and supplemented with warm DMEM, 2 mM glutamine, and 200 ug/ml gentamycin
after 1 hour and returned to 37°C until extract preparation desired.
5.3.10 Whole cell extract preparation
Cells were washed with ice-cold PBS and all subsequent steps carried out at 4°C or on
ice. Cells were scraped from the dish in ice-cold PBS, and collected by centrifugation at
1000 × g for 1 minute. Cells were lysed by suspension in 50 mM Tris-HCl, pH 7.6, 400
mM NaCl, 25 mM beta-glycerol phosphate, 25 mM NaF, 10 mM PNPP, 10 % glycerol,
0.5 mM sodium orthovanadate, 0.5% nonidet-40 (NP-40), 5 mM benzamidine, 2.5 mM
metabisulfite, 1 mM PMSF, 1 mM DTT and protease inhibitor cocktail as described
(Elewaut et al., 1999).
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5.3.11 Electromobility shift assays (EMSA)
NF-κB DNA binding assays were carried out as previously described (DiDonato et al.,
1997a; DiDonato et al., 1995a; Elewaut et al., 1999). Anti-p65 antibody (Zymed, South
San Francisco), anti-p50 antibody (Santa Cruz Biotechnologies, Santa Cruz, CA), and
anti-STAT3 antibody (Santa Cruz) were used for EMSA supershifts.
5.3.12 Invasion assay
HT29 cells, 90–95% confluent in 35 mm round dishes, were prepared for stimulation
as above and treated with a 1 ml suspension of Salmonella SJW1103 or SJW134 or left
untreated in triplicate as above. After one hour, HT29 cells were washed 4× with warm
PBS, supplemented with warm DMEM, 2 mM glutamine, and 200 μg/ml gentamycin,
and incubated at 37°C for 4 hours. Cells were then harvested as above and lysed by
suspension in 1 ml sterile distilled water. Ten-fold serial dilutions were prepared in PBS
and 100 μl of each dilution was plated on LB agar plates and grown at 37°C for 20 hours.
Colonies were counted and averaged.
5.3.13 Kinase assays
Whole cell extracts (250 μg) were supplemented with 150 μl of Buffer A (20 mM
Hepes, pH 7.9, 20 mM beta-glycerophosphate, 10 mM NaF, 0.1 mM orthovanadate, 5
mM PNPP, 10 mM 2-mercaptoethanol, 0.5 mM PMSF, and protease inhibitor cocktail),
and immuno precipitation kinase assays carried out as described (Elewaut et al., 1999)
using either IKKα monoclonal antibody (PharMingen – Becton Dickson), anti-JNK1
(Santa Cruz Biotechnologies, Santa Cruz, CA), or anti-hemagglutinin (HA) epitope
antibody (Covence Antibodies, Princeton, NJ) as indicated. Protein G immunopellets
were collected by centrifugation at 500 × g for 30 sec, washed 3 times with Buffer B
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(Buffer A plus 250 mM NaCl), and one time with Buffer C (Buffer A plus 50 mM NaCl
and 10 mM MgCl2). Immunopellets were resuspended in 30 μl Kinase buffer with 0.1
mM orthovanadate, 50 μM "cold" ATP, 5 μCi γ-32P-ATP, 2 mM DTT, and 2 μg of
soluble GST-IκBα1–54 or GST-cJUN1-79, and incubated at 30°C for 30 minutes.
Reactions were stopped by the addition of 15 μl 4× SDS-PAGE loading buffer, heated at
95°C for 5 minutes, and resolved on 10% SDS-PAGE gels by standard procedures. Gels
were rinsed, stained with Bio-Safe Coomassie (Bio-Rad) to visualize protein bands,
rinsed, photographed then dried and exposed to Kodak X-OMAT AR film (Eastman
Kodak Co., Rochester, NY) to detect substrate phosphorylation.
5.3.14 Immunoblotting
Protein samples (40 μg) were resolved by SDS-PAGE on a 10% acrylamide gels by
standard procedures, and proteins transferred to PVDF membrane (Millipore) and probed
with antibodies as described (Elewaut et al., 1999). Membranes were washed 3× briefly
with TBST, incubated with a 1:1000 dilution (1:800 for anti-TLR5) of the primary
antibody in TBST, 1% non-fat milk for 1 hour, washed 3 × 5 min with TBST, and then
incubated with a 1:2000 dilution of the appropriate HRP-conjugated secondary antibody
in TBST, 0.5% non-fat milk for 1 hour. Primary antibodies used were: anti-IKKα/β (H470, Santa Cruz), anti-JNK1, anti-ERK2 (K-23, Santa Cruz), anti-phospho-ERK (E-4,
Santa Cruz), anti-p38MAPK (Cell Signaling Technologies, Beverly, MA), antiphosopho-p38MAPK (Cell Signaling), anti-TLR5 (H-127, Santa Cruz), anti-muc1 (H295, Santa Cruz) and anti-actin (C-11, Santa Cruz). Secondary antibodies used were:
anti-mouse IgG HRP conjugate (Amersham-Pharmacia), anti-rabbit IgG HRP conjugate
(Amersham-Pharmacia), anti-goat IgG-HRP conjugate (Santa Cruz). HRP activity was
149

detected by ECL (Amersham-Pharmacia) as per manufacturer’s instructions, on Kodak
X-OMAT AR film.
5.3.15 Construction of dominant-negative TLRs
All DN-TLRs were constructed using PCR. The universal 5' primer consisted of a
5'KPN I restriction site followed by sequences encoding the kozak sequence, translational
start site, and preprotrypsin leader sequence of pCMV-1 (Sigma) that all the wild-type
TLRs were initially cloned into. The 3' anti-sense (AS) primers were human TLRgenespecific primers (sequences available upon request) that created a stop codon
immediately after a conserved tryptophan in Box 9 of the TLR TIR homology domain
according to Bazan (Rock et al., 1998), thus creating carboxy terminus deletions. The 5'
end of the AS primer contained a number of convenient restriction sites to allow
directional cloning. PCR was performed with turbo-Pfu polymerase (Stratagene, La Jolla,
CA) using standard procedures on individual wild-type TLR pCMV-1 plasmid DNAs (5
ng each, kind gifts of R. Medzhitov, Yale Univ. and R. Ulevitch, TSRI) (Alexopoulou et
al., 2001; Chuang and Ulevitch, 2000) with the 150 ng each of the universal 5' sense
primer and individual gene-specific TLR 3' primers. PCR products were cleaned-up with
PCR cleanup kit (Qiagen, Germany) digested with appropriate restriction enzymes, gel
purified and then ligated into the mammalian expression vector pCDNA3.1 (Invitrogen).
Positive clones were sequenced to verify the mutations and tested for expression in
transient expression assays and detected on immunoblots by probing with anti-FLAG M2
monoclonal antibody (Sigma). All wild-type and DN-TLR alleles are amino terminus
FLAG epitope-tagged.
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5.3.16 Transfections
HT29 cells were transfected with Lipofectamine Plus (Invitrogen) as previously
described (Elewaut et al., 1999). In transfections monitoring reporter gene expression,
transfections were performed at least three times in 6 well dishes in triplicate with the
total DNA mass kept constant at 4 μg (2 μg effector plasmid DNA, 100 ng 2× NF-κB Luc
reporter gene, 50 ng pRL-TK, a thymidine kinase promoter driven Renilla luciferase
normalization reporter and 1.85 μg pCDNA3.1 plasmid DNA as bulk filler DNA) and
fire-fly luciferase expression was normalized to Renilla luciferase expression using the
dual-luciferase assay (Promega, Madison, WI). Fold inductions were calculated and
values between experiments did not vary more than 15%, a representative experiment is
presented. Transfection of 293T cells was performed with lipofectamine 2000
(Invitrogen) in 6-well dishes in triplicate as per the manufacture's protocol. TLR
expression plasmids were added at 2 μg/well, and NF-κB and normalization control
plasmids were as above with HT29 cells and pCDNA3.1 plasmid DNA as bulk filler
DNA to a final DNA mass of 4 μg/well. Fold inductions were calculated and values
between experiments (N of 3) did not vary more than 10%, a representative experiment is
presented.
5.3.17 Real Reverse Transcription and Real Time PCR (RT2PCR)
Cells (N = 3) were stimulated 3 hours at 37°C with TNFα or FliC or left untreated and
harvested for total RNA isolation. Total cellular RNA was extracted from cells with
Trizol reagent (Invitrogen) (Elewaut et al., 1999) and reverse transcribed with
ReactionReady first strand cDNA synthesis kit (SuperArray Bioscience Corp., Fredrick,
MD). RNA (2.5 ug per 20 ul reaction) was reverse transcribed using random primers and
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Moloney murine leukemia virus reverse transcriptase per manufacturer specified
conditions. Controls without reverse transcriptase (minus RT) was also generated for
each RNA sample. RT2PCR was performed with an iCycler (Bio-Rad) to quantify TLR1
through TLR10 mRNA, 18S rRNA, and GAPDH mRNA. RT2PCR (25 ul reaction
volume) was performed with the appropriate primers (SuperArray) per manufacturers
instructions in triplicate with HotStart Taq DNA polymerase (SuperArray) at 95°C for 15
min to activate Taq and amplified for 40 cycles (95°C, 30 sec, 55°C, 30 sec, 72°C, 30
sec). RT2PCR was performed on the minus RT controls with TLR5 primers to detect
DNA contamination. Real-time PCR analysis was performed using SYBR-green (PerkinElmer) according to manufacture's instructions with the specific primer pairs indicated
above and primer pairs for 18S ribosomal RNA as reference RNA (Classic 18S primer
pairs – Ambion Inc). Cycle time (Ct) was measured using the iCycler™ and its associated
software (Bio-Rad). Relative transcript quantities were calculated by the ΔΔCt method
using 18S ribosomal RNA as a reference amplified from samples using the Classic 18S
primer pairs from Ambion, Inc (Austin, TX). Normalized samples were then expressed
relative to the average ΔCt value for untreated controls to obtain relative fold-change in
expression levels. Fold change in mRNA expression was expressed as 2ΔΔCt. ΔCt is the
difference in threshold cycles for the TLR mRNAs and 18S rRNA. ΔΔCt is the difference
between ΔCt non-simulated control and ΔCt stimulated sample. Values for fold-induction
varied less than 5% among replicates.
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5.4 RESULTS
5.4.1 Salmonella infection leads to a minority of cells invaded but activates NF-κB
in nearly all cells
Previously, we have noted that pathogenic Salmonella sp. infection leads to potent
IKK and NF-κB activation and activation of the proinflammatory gene program (Elewaut
et al., 1999). Previous studies suggest that about thirty-forty percent of the intestinal
epithelial cells are infected during a typical Salmonella infection in cultured intestinal
epithelial cells (Valdivia et al., 1996). We wished to address the question of how bacterial
infection of about thirty percent of the host cells could give rise to NF-κB DNA binding
activity equivalent to activation of NF-κB in nearly all of the host cells as TNFα
treatment of the cells does. To examine this phenomenon in detail HT29 cells either
mock-infected or infected at a MOI of fifty for one-hour with wild-type S. typhimurium
that had been transformed with the plasmid pFM10.1, that encodes green fluorescent
protein (GFP) under the control of the Salmonella ssaH promoter and only functions once
the bacteria has invaded the host cell (Valdivia and Falkow, 1997). As can be seen in
(Fig. 5.1a), GFP expression occurs in about thirty to forty percent of the cells. We next
examined the localization of the NF-κB subunit p65 (RelA) in non-treated (mockinfected), Salmonella infected or TNFα (10 ng/ml) stimulated cells and found that p65
(RelA) was localized to the cytoplasm in non-treated cells whereas, in Salmonella
infected cells or in TNFα treated cells p65 (RelA) had localized to the nucleus (Fig.
5.1b). These results demonstrate that Salmonella infection activates NF-κB in virtually
all of the cells even though only a minority of them become infected and is consistent
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with and aids in explanation of our previous results examining Salmonella infection and
NF-κB activation (Elewaut et al., 1999).
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FIGURE 5.1
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Figure 5.1: Salmonella infection leads to NF-κB nuclear localization even in
non-infected cells.
HT29 cells were grown on glass coverslips and either mock-infected, left
untreated, infected with Salmonella typhimurium, or treated with TNFα (10
ng/ml). Cells fixed after 30 min (TNF) and 1 h (Salmonella) as described in
Experimental Procedures and Salmonella that had invaded HT29 cells were
detected by direct fluorescence microscopy of GFP expression, p65(RelA)
localization was monitored by indirect immunoflourescence of rabbit anti-p65
antibody detected with FITC-conjugated donkey anti-rabbit antibody. DAPI was
used to stain nuclei. a, HT29 cells were mock-infected or infected at an MOI of 50
with Salmonella typhimurium strain SJW1103G which expresses GFP from the
ssaH promoter that is only active inside infected host cells (Valdivia and Falkow,
1997; Valdivia et al., 1996). Cells were photographed using bright field
microscopy (BF), and immunoflourescence to detect GFP or DAPI staining as
indicated. Images were merged (overlay)to reveal cells that were infected. b,
HT29 cells were left untreated, infected with Salmonella typhimurium strain 1103
or treated with TNFα. NF-κB p65(RelA) localization under various conditions as
indicated was monitored by indirect immunofluorescence. Cells were visualized
by bright field microscopy (BF), cell nuclei were stained with DAPI and
p65(RelA) was visualized with FITC. DAPI staining was falsely colored red to
make visualization of the merge (overlay) easier to distinguish.
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5.4.2 Soluble bacterial product identified as flagellin can activate NF-κB in
intestinal epithelial cells
Since Salmonella sp. infection of intestinal epithelial cells in culture led to only
roughly thirty percent infection but activation of NF-κB in nearly all of the cells, we
anticipated that NF-κB activation was in response to host cell recognition of bacteria
structural components or products produced by the bacteria and not by the invasion
process. Invasion itself has been demonstrated not to be required for activation of the
proinflammatory gene program as had previously been thought (Eaves-Pyles et al., 1999).
To investigate this possibility sterile-filtered S. dublin culture broth left either untreated
or boiled for twenty minutes was used to challenge HT29 intestinal epithelial cells and
NF-κB DNA binding activity was monitored by electromobility shift assays (EMSAs) of
whole cell extracts (WCE) prepared forty-five minutes after exposure (DiDonato et al.,
1995a; Elewaut et al., 1999). Potent activation of NF-κB in response to the broth under
both conditions was observed indicating the activating factor was heat-stable (AD, TT
and JD, personal observations) and is not LPS since HT29 cells are not responsive to LPS
(DiDonato et al., 1995a; Elewaut et al., 1999).
The native sterile-filtered concentrated broth was subsequently treated with DNase,
RNase, proteinase K or crudely size fractionated on 100 kDa centricon filters. The
variously treated broths were then used to challenge HT29 intestinal epithelial cells and
WCEs were prepared after forty-five minutes and NF-κB DNA binding activity was
analyzed by EMSA (Fig 5.2a). Direct infection of HT29 cells by S. typhimurium 1103 or
exposure to the culture broths (supt), as indicated, induced NF-κB DNA binding activity,
while the activity-inducing factor was found to be sensitive to protease digestion and was
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retained by a 100 kDa filter (Fig. 5.2a). To further determine the identity of the NF-κB
inducing activity, sterile-filtered concentrated broth culture was fractionated by Superose
12 gel permeation chromatography (Fig. 5.2b) and by anion exchange chromatography
(Fig. 5.2c). Aliquots of chromatography fractions were assayed for their ability to
activate NF-κB in HT29 cells and analyzed by EMSA. As can be seen from the
Coomassie blue stained gel (Fig. 2b, top panel) increased NF-κB DNA binding activity
(Fig. 5.2b, lower panel lanes 4–6) corresponded to the increased abundance of an
approximately 55 kDa protein. Anion exchange chromatography on POROS HQ matrix
and elution of bound proteins with an increasing salt gradient as indicated (Fig. 5.2c)
demonstrated that NF-κB DNA binding-inducing activity corresponded to
chromatographic fractions containing an increased abundance of the 55 kDa protein (Fig.
5.2c top panel, and data not shown). Eluted fractions observed in Fig. 5.2c were
concentrated and fractionated on preparative 12% SDS-PAGE gels and bands
corresponding to B1-B6 were cut from the gels and the proteins eluted, precipitated and
renatured as described in Experimental Procedures and used to stimulate HT29 cells.
Whole cell extracts from these cells were assayed for NF-κB DNA binding-inducing
activity by EMSA and only band 2 (B2) corresponding to the 55 kDa protein (Fig. 5.2c
lower panel) was able to elicit NF-κB DNA binding activity while buffer from the
beginning or end of the salt gradient failed to activate NF-κB DNA binding activity.
Proteins corresponding to protein bands B1-B6 and blank areas of the gel were
further processed for peptide sequencing as described in Experimental Procedures.
Trypsin digestion of the protein corresponding to B2 and analysis by electrospray ion trap
LC/MS identified the amino acid sequence of twenty-one peptides. Flagellin (seventy-
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five percent coverage by the twenty-one peptides) was unambiguously identified as the
protein consistent with inducing NF-κB DNA binding activity (Fig 5.3).
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FIGURE 5.2
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Figure 5.2: Protein factor in Salmonella culture broth leads to NF-κB activation.
a, Salmonella dublin culture broth concentrated 100-fold was treated as indicated or
infectious bacteria, as indicated was used to challenge HT29 cells. NF-κB DNA
binding activity was assayed by EMSA from whole cell extracts prepared 45 min after
treatment. Authenticity of the NF-κB DNA:protein complex was determined using
p65(RelA)-specific and p50-specific antibody supershifts. b, Concentrated Salmonella
dublin culture broth (IN) was chromatographed by gel permeation on a Superose 12
column. Eluted protein fractions were analyzed by fractionation on 10% SDS-PAGE
and visualized by Coomassie blue (CB) staining. Molecular weight markers for
chromatography and on the gels are indicated. Aliquots of each fraction as indicated
was used to stimulate HT29 cells and resultant WCEs were analyzed by EMSA for
NF-κB DNA binding activity. c, Concentrated Salmonella dublin culture broth (IN)
was chromatographed by anion exchange chromatography on POROS HQ matrix.
Proteins were eluted with an increasing NaCl gradient as indicated and analyzed on
10% SDS-PAGE and visualized by Coomassie blue (CB) staining. Input and aliquots
of each fraction as indicated was used to stimulate HT29 cells and resultant WCEs
were analyzed by EMSA for NF-κB DNA binding activity. Eluted material
corresponding to protein bands B1-B6, a blank portion of the gel was isolated from a
duplicate 10% SDS-PAGE gel as described in Experimental Procedures along with
buffer samples from the beginning and end NaCl buffer gradient and used to stimulate
HT29 cells and resultant WCEs were analyzed by EMSA for NF-κB DNA binding
activity.
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FIGURE 5.3

Figure 5.3: Identification by mass spectrometry of flagellin as the NF-κB
activating factor in Salmonella culture broth.
Microcapillary HPLC tandem mass spectrometry of Band 2 digested by trypsin. Peaks
corresponding to Salmonella peptides are numbered and identified with the
corresponding numbered peptide sequence to the Right
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5.4.3 Flagellin is required to activate NF-κB in intestinal epithelial cells

To determine if flagellin was indeed the factor that was responsible for triggering
activation of NF-κB after exposure of intestinal epithelial cells to direct bacterial
infection or to filtered culture broths of pathogenic Salmonella sp. we prepared infectious
bacteria and boiled and filtered culture broths from the non-flagellated E. Coli DH5α,
pathogenic S. dublin strain 2229, an isogenic S. dublin 2229 SopE- mutant, isogenic S.
dublin 2229 SopB- mutant, isogenic S. dublin 2229 double SopE-/SopB- mutant (strain
SE1SB2), S. typhimurium strain 1103, and isogenic S. typhimurium fliC::Tn10 insertion
mutant (strain 86) and a S. typhimurium 1103 isogenic double mutant fliC-/fljB- and were
used to challenge HT29 cells. Bacteria and culture broths were used to challenge HT29
intestinal epithelial cells and WCE extracts were prepared after forty-five minutes and
analyzed for NF-κB DNA binding activity by EMSA. Salmonella strains could activate
NF-κB, while Salmonella strains failing to produce flagellin (fliC and fliC-/fljB- mutants
as indicated) also failed to activate NF-κB (Fig. 5.4a & 5.4b). E. Coli DH5α is nonflagellated and does not produce flagellin failed to activate NF-κB. We also noticed
through numerous experiments that S. dublin direct infections always activated NF-κB to
a greater extent than S. typhimurium as observed in Fig. 5.4a while culture broths from
both species activated NF-κB almost equally well (Fig. 5.4b). We believe this difference
is due perhaps to S. dublin releasing more flagellin into the cell culture media than S.
typhimurium during infection since purification of flagellin from both S. dublin and S.
typhimurium and addition of equivalent amounts of chromatographically purified
flagellin gave similar NF-κB activation profiles (TT & JD, unpublished observations).
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Of note is the total failure of the double flagellin gene mutants to activate NF-κB as
compared to the very minor activation observed in the single Phase I flagellin fliC::Tn10
insertion mutant (next to last lanes in Fig. 5.4a & 5.4b) which likely is due to the
extremely limited expression of the phase II flagellin (from fljB), although the strains of
Salmonella used here genetically are unable or rarely shift phases of flagellin production.
These results are consistent with previous reports identifying flagellin as a potent inducer
of the proinflammatory response and IL-8 production (Eaves-Pyles et al., 1999; Gewirtz
et al., 2000; Gewirtz et al., 2001b; McDermott et al., 2000). Since flagellin appears
required for activation of the NF-κB pathway upon direct infection of intestinal epithelial
cells it appeared possible that flagellin may also be the major determinant of other major
mitogenic and stress activated signaling pathways activated upon pathogenic Salmonella
infection of intestinal epithelial cells. Previously others and we have demonstrated that
direct Salmonella infection of intestinal epithelial cells results in JNK activation (Hobbie
et al., 1997) and also the activation of NF-κB via IKK (Elewaut et al., 1999). The
identification of flagellin as a potent NF-κB activator is significant since SopE had
previously been shown to be a pathogenic Salmonella bacteriophage encoded protein that
is injected into the host cell and acts as an exchange factor for the small Rho GTPases
Rac1 and CdC42 initiating cytoskeleton rearrangements and eventual activation of the
MAPK, SAPK and NF-κB pathways (Hardt et al., 1998; Wood et al., 1996), while SopB
is a Salmonella protein that functions as an inositol phosphate phosphatase and
participates in cytoskeletal rearrangements and stimulates host cell chloride secretion
(Norris et al., 1998).
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FIGURE 5.4

Figure 5.4: Flagellin mutants fail to activate NF-κB.
EMSAs assaying for NF-κB DNA binding activity in WCEs prepared
45 min from non-infected cells (UN) and after direct infection of HT29
cells with wild-type E. coli DH5α, wild-type Salmonella dublin or SopE
mutant, SopB- mutant, the SopE-/SopB- double mutant, wild-type
Salmonella typhimurium strain 1103, the fliC- mutant (fliC::Tn10), the
fliC-/fljB- double mutant as indicated at an MOI of 50. B, EMSAs
assaying for NF-κB DNA binding activity in WCEs prepared 45 min
after challenge of HT29 cells from non-infected cells (UN) or with
sterile-filtered concentrated culture broths from wild-type and mutant
bacteria as indicated.
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5.4.4 Flagellin triggers activation of the mitogen activated protein kinase, stress
activated protein kinase and IKK signaling pathways
Intestinal epithelial cells act as sentinels for invasion of luminal surfaces and
orchestrate the attraction of effector immune cells to the area by production of chemokine
genes like IL-8 and macrophage chemoattractant protein 1 (MCP1) proinflammatory
cytokine genes such as TNFα, IL-1 and IL-6 (Eckmann et al., 1997; Jung et al., 1995;
Kagnoff and Eckmann, 1997; Witthoft et al., 1998). Expression of these genes primarily
depends upon the action of transcription factors that are activated in response to the
transmission of signals via the MAPK, SAPK and IKK signaling pathways. Since NF-κB
is considered a central regulator/activator of the proinflammatory gene program we
decided to examine the effect that non-flagellin producing mutant strains of Salmonella
had on activation of the MAPK, SAPK and IKK signaling pathways compared to
infection of intestinal epithelial cells with wild-type Salmonella or by exposure of the
intestinal epithelial cells to purified flagellin. Infection of HT29 cells with wild-type S.
typhimurium resulted in activation of MAPKs ERK1&2, the SAPKs p38, JNK and IKK
(Fig. 5.5) as determined by use of activation-indicating phospho-specific antibodies in
immunoblot (IB) analysis or antibody-specific immuno-kinase assays (KA) for JNK and
IKK using their respective substrates GST-cJun 1–79 and GST-IκBα1–54 (DiDonato et
al., 1997a; DiDonato and John, 2000; Hibi et al., 1993). Interestingly, MAPK stimulation
is transient in nature as activation declines beginning at forty-five minutes while p38,
JNK and IKK activity increases with time through one hour. As seen in Fig. 5.4, the fliC/fljB- double mutant Salmonella also failed to induce IKK and NF-κB activity (Fig. 5.5 as
indicated). Surprisingly, the fliC-/fljB- double mutant Salmonella failed to induce the
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SAPKs p38 and JNK and only briefly (fifteen minutes) activated MAPK. This result is
puzzling since other Salmonella proteins such as SopE and SopE2 can activate the small
GTPases Rac and CdC42, and these Rho family GTPases have been linked to JNK and
p38 activation (Bakshi et al., 2000; Hardt et al., 1998; Hobbie et al., 1997; Wood et al.,
1996) yet appear not to function in the flagellin minus strain.
The fliC-/fljB- double mutant Salmonella failed to invade HT29 cells compared to the
wild-type Salmonella strain as determined by gentamycin protection/invasion assay (see
Experimental Procedures). The flagellin fliC-/fljB- double mutant displayed a four orders
of magnitude difference in its ability to invade HT29 cells (TT & JD, unpublished
observations). To demonstrate this point further, we infected HT29 cells with either wildtype Salmonella or the fliC-/fljB- double mutant Salmonella (strain 134), both strains were
transformed with the plasmid pFM10.1 that encodes GFP under the control of the
Salmonella ssaH promoter and only functions once the bacteria has invaded the host cell
(Valdivia and Falkow, 1997; Valdivia et al., 1996). The wild-type Salmonella clearly was
able to infect HT29 cells (GFP, Fig. 5.5b) while the flagellin mutant bacteria failed to
invade HT29 cells as evidenced by the lack of GFP expression (Fig. 5.5b). To determine
if flagellin is sufficient or that other bacterially produced proteins are required for
invasion, we added either purified flagellin or sterile-filtered culture broths or a
combination of both to HT29 cells that were challenged with the Salmonella fliC-/fljBdouble mutant and assayed for invasion. Intestinal epithelial cells failed to be invaded
using all tested combinations of purified flagellin and/or culture broths with the fliC-/fljBdouble mutant strain (TT & JD, unpublished observations). To our knowledge there is no
known direct connection between expression of flagellin genes and the effectiveness of
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the type III secretion system to deliver bacterially produced proteins such as SopE,
SopE2 and SipA or other Sip or Sop proteins (Bakshi et al., 2000; Galkin et al., 2002;
Hardt et al., 1998; Wallis et al., 1999; Wood et al., 1996) that play important roles in
initiating bacterial internalization. Furthermore, to evaluate the effectiveness of flagellin
to stimulate p65 (RelA) nuclear localization in intestinal epithelial cells we challenged
HT29 cells with purified flagellin and examined p65 (RelA) localization using indirect
immunofluorescence and found p65 (RelA) nuclear localization in nearly every cell (Fig.
5.5b as indicated).
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FIGURE 5.5
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Figure 5.5: Flagellin is required for activating multiple signaling pathways
during Salmonella infection and leads to nuclear localization of NF-κB.
HT29 cells were left untreated, stimulated with TNFα (10 ng/ml) or a cocktail of
anisomycin [An] (20 μg/ml)/PMA (12.5 ng/ml) for 15 min, or infected with either
wild-type (WT) Salmonella typhimurium strain 1103 or the Salmonella typhimurium
double fliC-/fljB- mutant strain 134 as indicated. WCE were prepared at the indicated
times or at 10 min for TNF-treated cells or 15 min for anisomycin/PMA treated cells
and used in EMSAs to analyze NF-κB DNA binding activity, or in immuno-kinase
assays (KA) using anti-IKK or anti-JNK antibodies to measure IKK and JNK kinase
activity on their respective substrates GST-IκBα 1–54 and GST-cJun 1–79 (as
indicated). Immunoblot (IB) analysis of equivalent amounts (40 μg) of protein from
each extract was fractionated on SDS-PAGE gels and transferred to PVDF
membranes and probed with the indicated antibodies to detect bulk IKK, JNK, ERK
and p38 as indicated. Immunoblot analysis using phospho-specific antibodies for ERK
and p38 to detect activated ERK and p38 are indicated. b, Immunofluorescence
demonstrating that flagellin mutant Salmonella fail to infect HT29 cells and that
purified flagellin stimulation of HT29 cells leads to NF-κB nuclear p65 (RelA)
localization as determined by indirect immunofluorescence. Imaging of the treatment
indicated HT29 cells
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Purified flagellin (0.5 μg/ml) was added to the culture media of HT29 cells and WCE
were prepared at various times as indicated after exposure and assayed for NF-κB DNA
binding activity in EMSAs (Fig. 5.6a). Flagellin potently activated NF-κB in a time
dependent manner similar to that observed for TNF (10 ng/ml) treatment of HT29 cells
(Fig. 5.6a). Analysis of the MAPK, SAPK and IKK signaling pathways (Fig. 5.6b) at
various times after flagellin treatment of HT29 cells using activation-specific phosphoantibodies to monitor MAPK and p38 kinase activation or antibody-specific
immunoprecipitation kinase assays for JNK and IKK activities demonstrated that JNK
and IKK activity increased through time to one-hour while p38 and MAPK (ERK1&2)
activity peaked at thirty minutes and began to decline to noticeably lower levels by onehour (Fig 5.6b as indicated). The activation profile of the MAPK, SAPK and IKK
signaling molecules ERK1&2, p38, JNK and IKK in intestinal epithelial cells in response
to purified flagellin exposure remarkably resembled that of intestinal epithelial cells
infected with wild-type Salmonella (Fig. 5.5a). From these observations we conclude that
the temporal activation of the signaling pathways examined here (MAPK, SAPK and
IKK), which reflect early events in Salmonella infection, are determined almost
exclusively by recognition and response of intestinal epithelial cells to flagellin.
We wished to further examine the effect of purified flagellin and flagellin present on
Salmonella on the temporal pattern of proinflammatory cytokine gene expression in
intestinal epithelial cells in order to differentiate the effects of flagellin alone vs.
flagellated Salmonella or non-flagellated Salmonella infection. HT29 cells were left
untreated, stimulated with TNFα (10 ng/ml), or stimulated with flagellin (0.5 ug/ml), or
infected with wild-type Salmonella typhimurium or the Salmonella fliC/fljB double
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mutant (at MOI of 50). Aliquots of the cDNA were used in semi-quantitative RT-PCR
reactions using IL1α, IL-1β, IL-8, TNFα, MCP1 and β-actin gene specific primers
(sequences available upon request) and the products were fractionated on ethidium
bromide containing 1.2% agarose gels. Expression of the known NF-κB target genes IL1β, IL-8, TNFα and MCP1 was increased in response to TNFα or purified flagellin
exposure (Fig. 5.6c). Wild-type Salmonella infection also led to activation of these same
genes although the expression of TNFα and MCP1 was transient in comparison and
occurred immediately after infection. The Salmonella fliC-/fljB- double mutant failed to
induce IL-1β, IL-8 and TNFα expression, however MCP1 expression was induced,
although at lower levels than that induced by wild-type Salmonella, and also, the
expression of MCP1 was not transient in nature and continued throughout the time course
(9 h) (Fig. 5.6c). The expression level of β-actin served as an internal standard for
comparison. Interestingly, IL-1α, which is not an NF-κB target gene was stimulated in
response to HT29 cell challenge by all of the treatments. Obviously, the Salmonella fliC/fljB- double mutant can activate other signaling pathways leading to IL-1α expression.
We presently do not know the identity of these signaling pathways.
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FIGURE 5.6
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Figure 5.6: Purified flagellin activates signaling pathways and
proinflammatory gene expression in intestinal epithelial cells mimicking that
of wildtype a wild-type Salmonella infection.
HT29 cells were left untreated or treated with TNFα (10 ng/ml) or a cocktail of
anisomycin [An] (20 μg/ml)/PMA (12.5 ng/ml) for 10 min, or with flagellin (1
μg/ml) for the indicated times. WCE were prepared and analyzed by EMSA for
NF-κB DNA binding activity, immuno-kinase assays (KA) or immunoblot
analysis using phospho-specific antibodies for ERK or p38 to detect activation
and with kinase-specific antibodies as described in Fig. 5a to detect bulk kinase
abundance as indicated. A, EMSA to detect NF-κB DNA binding activity.
Authenticity of the NF-κB bandshift was tested with supershift of the complex
with p65(RelA)-specific antibody (α p65), normal rabbit serum (NRS) served as
an irrelevant antibody control. b, immunoblot and kinase assays to detect IKK,
JNK, ERK and p38 kinase activities and protein abundance as in Fig. 5a. c, semiquantitative RT-PCR of proinflammatory gene expression of non-treated, wildtype and flagellin double mutant Salmonella typhimurium infected, TNFα (10
ng/ml) or flagellin (1 μg/ml) stimulated cells. HT29 cells were harvested at the
indicated times after the indicated treatments and isolated RNA was used to make
first strand cDNA that subsequently used in RT-PCR reactions (as described in
Experimental Procedures) using gene-specific primers for IL1α, IL-1, IL-8,
TNF- MCP1, and ,Actin was used as a standard for normalizing expression
patterns. Resulting PCR products were fractionated on 2% agarose gels and
visualized by ethidium bromide staining
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5.4.5 Flagellin activates NF-κB DNA binding in a MyD88-dependent manner
Flagellin was capable of activating the requisite signaling pathways consistent with
proinflammatory gene activation similar to that of a cytokine like TNFα that activates all
cells on which a functional cell surface receptor for it is present (see p65 [RelA] nuclear
localization in Fig. 5.1 and Fig. 5.5c) we decided to examine the potential of the Tolllike receptors, to activate the NF-κB pathway in response to flagellin exposure. To
quickly test this hypothesis we examined the effect that a dominant-negative MyD88 (aa
152–296) (Muzio et al., 1997) expressing adenovirus had on flagellin-mediated NF-κB
activation in HT29 cells. MyD88 is an adapter protein utilized by the IL-1 receptor and
all of the known TLRs, which share homology to IL-1 through their cytoplasmic
signaling domain and is required for immediate activation of the NF-κB pathway
(Medzhitov et al., 1998; Takeuchi and Akira, 2002). We found that expression of DNMyD88 in HT29 cells blocked the activation of NF-κB DNA binding activity assayed by
EMSA analysis in response to IL-1 or flagellin exposure, consistent with the action of a
TLR-mediated activation of NF-κB (TT & JD, unpublished observations). To examine
this possibility further we initially used wild-type, MyD88-/- and TLR2-/-/TLR4-/- MEFs (a
gift of S. Akira, Univ. of Osaka, JA) to verify the role of MyD88 and to examine the
potential role of two of the TLRs to respond to flagellin or to direct wild-type Salmonella
infection and lead to NF-κB activation (Fig. 5.7). Wild-type Salmonella infection
activates NF-κB potently in both the wild-type and TLR deficient MEFs (lanes 2 & 15)
but this activation is somewhat defective in the MyD88 deficient MEFs (lane 10).
Challenge of all three types of cells with concentrated sterile-filtered wild-type S. dublin
or the double SopE-/SopB- isogenic mutant S. dublin strain SE1SB2 culture broths
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activated NF-κB in wild-type MEFs and TLR2/4 double deficient cells but failed to
activate NF-κB in MyD88 deficient cells (compare lanes 11 and 12 with lanes 3, 4, 6, 7,
16 and 17). NF-κB was potently activated in wild-type MEFs by exposure to purified
flagellin (0.5 μg/ml) and therefore eliminated the possibility that LPS played a role in
NF-κB activation in these experiments. The exclusion of LPS as a major contributor to
NF-κB activation is also provided by the potent activation of the TLR2/4 double deficient
MEFs (lanes 16 & 17). TLRs 2 and 4 respond to bacterial lipopeptides, peptidoglycans,
certain LPSs and gram negative LPS respectively (Lien et al., 2000; Lien et al., 1999;
Yoshimura et al., 1999). IL-1 stimulation verified the functional requirement of MyD88
in transmission of IL-1 and flagellin-mediated signals.
To further define a possible role for the TLRs in flagellin recognition we assayed for
the ability of overexpressed TLRs to activate NF-κB in cells that normally respond
poorly to flagellin exposure. Choosing cells that responded slightly to purified flagellin
ensured that the signaling components and adapters that flagellin uses were present and
functional and that the limiting factor was likely only to be the receptor that responds to
flagellin. We found that HeLa cells and HEK293T cells activated NF-κB DNA binding
activity in response to IL-1 stimulation but poorly to flagellin exposure (Fig. 5.9b) and
we chose HEK293T cells to use further because of their greater transfection efficiency.
Amino-terminus FLAG epitope-tagged TLRs 1–9 (kind gifts of R. Medzhitov, Yale
Univ. and R. Ulevitch, TSRI) (Alexopoulou et al., 2001; Chuang and Ulevitch, 2000)
were overexpressed in HEK 293T cells in transient transfections along with the 2×-NFκB-dependent promoter driven luciferase reporter gene (Devary et al., 1993) and the
expression of luciferase in response to no treatment, flagellin (0.5 μg/ml) or TNFα (10
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ng/ml) was determined. TLR5 was the only TLR whose expression resulted in a
noticeable response to flagellin challenge of the cells (Table 5.1).
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FIGURE 5.7

Figure 5.7: Flagellin-mediated activation of NF-κB is MyD88 dependent.
Infectious wild-type Salmonella Dublin (MOI of 100), IL-1 (20 ng/ml), purified
flagellin (1 μg/ml) (as indicated), sterile-filtered and concentrated 100 kDa filter
retentate supernatant (spt) from wild-type Salmonella dublin and SopE-/SopB- double
mutant Salmonella dublin strain SE1SB2 (S2, as indicated) was used to challenge
wild-type, MyD88-/- knockout or TLR2-/-/TLR4-/- double knockout MEFs as
indicated. WCEs were prepared 45 min after treatments and examined by EMSA to
analyze NF-κB DNA binding activity. IL-1 (20 ng/ml) was used as a positive control
to monitor MyD88 function.
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TABLE 5.1
No Stim

TNF-α

FliC

Vector

1

13.5

4.9

TLR1

1.7

ND

5.1

TLR2

1.6

ND

5.3

TLR3

1.5

ND

5.0

TLR4

1.8

ND

5.4

TLR5

1.6

ND

9.2*

TLR7

1.5
ND
5.2
Table5.1: TLR5 responds to flagellin and activates NF-κB

293T
individual listed
TLR8cells were transfected
1.4 with empty vector
ND(pCDNA3.1) or the 5.0
wild-type TLR alleles in triplicate in 6-well dishes. Cells were left untreated (No
Stim), TNF-α (10ng/ml) or flagellin (10ug/ml). NF-κB reporter activity was adjusted
TLRN
1.5 to control RenillaND
by
normalizing expression
luciferase activity and5.1
fold induction was
calculated as reporter gene activity in treated cells/reporter gene activity in nonstimulated cells. ND is not determined
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To further determine the likelihood of TLR5 being the TLR through which flagellin
activated NF-κB, we constructed dominant-negative signaling mutations by deletion of
the carboxyl portion of each TLR to a conserved tryptophan in the TIR domain (see
Materials and Methods). A similar mutation in the IL-1 receptor abrogates its ability to
lead to NF-κB activation (Croston et al., 1995; Heguy et al., 1992). Each DN-TLR along
with a reverse cloned TLR5 (AS-TLR5) were cloned into the mammalian expression
vector pCDNA3.1 (Invitrogen, Carlsbad, CA). All mutant proteins were expressed well
(TT & JD unpublished observations). Each DN-TLR mammalian expression vector and
empty expression vector along with 2× NF-κB Luc was transfected as previously
described (Elewaut et al., 1999) into HT29 cells which respond very well to flagellin. The
transfected cells were left untreated, stimulated with TNFα (10 ng/ml) or with purified
flagellin (0.5 μg/ml). Reporter gene expression was observed not to be affected by DNTLR expression in response to TNFα stimulation of transfected cells (Fig. 5.8a) however,
only expression of either the DN-TLR5 or an antisense TLR5 construct resulted in a
nearly fifty percent and twenty-five percent inhibition of flagellin-mediated reporter gene
activation respectively (Fig. 5.8b), while DN-TLR2 also was found to mildly inhibit
flagellin-mediated reporter expression. These results imply that TLR5 takes part in cell
surface recognition of flagellin and initiates the signaling pathway leading to NF-κB
activation. The effect of DN-TLR2 on NF-κB-dependent reporter gene activation may be
non-specific since its expression also inhibited TNFα-mediated reporter activation as
compared to the other DN-TLRs. DN-TLR2 may also compete for an unknown adapter
protein that both TLR2 and TLR5 might share. In any event, TLR2 and TLR4 were
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shown by the results presented in Fig. 5.7 not to be required for flagellin-mediated
activation of NF-κB.
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FIGURE 5.8

Figure 5.8: TLR5 inhibits flagellin-mediated NF-κB reporter gene activity.
HT29 cells were transfected in triplicate in 6-well dishes using the indicated
DN-TLR mammalian expression vectors or antisense TLR5 (AS TLR5) (2
μg/well), 2× NF-κB Luc reporter gene (100 ng/well), pRL-TK Renilla luciferase
for normalization (50 ng/well) adjusted to 4 μg total DNA/well with empty
vector pCDNA3.1 DNA. A, Fold-induction of 2× NF-κB Luc reporter gene in
non-stimulated cells (light shading) and in TNFα (10 ng/ml) treated cells (dark
shading). Lysates were prepared 12 h after stimulation. Results of a
representative experiment are shown. b, HT29 cells transfected as in A were
treated with flagellin (1 μg/ml) and cell lysates were prepared and analyzed as in
Fig. 8A. Results of a representative experiment are shown.
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5.4.6 Flagellin-mediated activation of NF-κB in intestinal epithelial cells leads to
increased and decreased expression of a subset of TLRs
Stimulation of intestinal epithelial cells with S. typhimurium or with purified flagellin
led to activation of the proinflammatory gene program (Fig. 5.6c). We wished to examine
whether or not expression of TLR genes would also be altered in flagellin stimulated
cells. HT29 cells were treated or not with purified flagellin (0.5 μg/ml) or with TNFα (10
μg/ml) and total RNA was isolated from non-treated and treated cells three hours after
stimulation and used to make first-strand cDNA. Real-time RT-PCR using gene-specific
primers for each of the TLRs (Superarray, Frederick, MD) and first-strand cDNA
prepared from non-stimulated or flagellin stimulated cells was used to generate SYBRgreen (Perkin-Elmer) labeled DNA products that were detected in an iCycler™ (BioRad). Interestingly, flagellin only mildly activated the expression of TLR2, while
expression levels of TLRs 5, 6, 9 and 10 were decreased by 2-fold (Table 5.2).
Contrastingly, TNF stimulation led to increased expression of TLRs 3 and 4 (1.6- and
3.5-fold respectively), while TLRs 2, 9 and 10 were decreased by approximately 2-, 5and 3-fold respectively. GAPDH expression served as comparative standard.

183

TABLE 5.2
Gene

Fold Change

Fold change

TNF-α stimulation

FliC stimulation

TLR1

ND

ND

TLR2

0.6

1.3

TLR3

1.6

0.6

TLR4

3.5

1.1

TLR5

0.9

0.5

TLR6

0.9

0.6

TLR7

M

M

TLR8

ND

ND

TLR9

0.2

0.5

TLR105.2: Change in TLR mRNA levels
0.3 following TNF-α or FliC
0.5stimulation.
Table
GAPDH
NDNon detected by RT2 PCR

1.0

1.0

M -None detected above level of minus RT control.
Reverse Transcription and Real Time PCR ( RT2PCR)-RNA was prepared from cells
left untreated, stimulated with TNF-α (10ng/ml) or flagellin (1ug/ml) for 3h. RT2PCR
was performed with an iCycler (Bio-Rad) to quantify SYBR-green labeled products
generated from PCR products of 1st strand cDNA prepared from TLR1 through
TLR10 mRNA, 18s rRNA, and GAPDH mRNA. RT2PCR (25ul reaction volume) was
performed with the appropriate primers (Super Array) in triplicate with HotStart Taq
DNA polymerase (SuperArray) at 950 C for 5 min. to activate Taq and amplified for
40 cycles (950 C, 30sec., 550 C, 30sec., 720 C, 30sec.). RT2PCR was performed on the
minus RT controls with TLR5 primers to detect DNA contamination. Fold Change in
mRNA expression was expressed as 2ΔΔCt . ΔCt is the difference in threshold cycles
for the TLR mRNAs and 18S rRNA, Δ ΔCt is the difference between ΔCt nonstimulated control and ΔCt stimulated sample.
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5.4.7 TLR5 is expressed in cells that don't respond well to flagellin
This study and others (Akira, 2001; Gewirtz et al., 2001a) have identified TLR5 as the
likely TLR through which flagellin activates NF-κB. Previous reports made no
determination on the presence or abundance of TLR5 in the cells that they used to
ascertain its function (Akira, 2001; Gewirtz et al., 2001a). We wished to determine if
TLR5 protein abundance was absent or greatly decreased in cells that failed to respond or
responded poorly to challenge by flagellin. TLR5 abundance in a number of cell lines
was examined by immunoblot analysis using a TLR5-specific antibody and compared
with the ability of purified flagellin to induce NF-κB DNA binding activity of WCEs
prepared from them. Intestinal epithelial cell lines T84 and HT29 were used as was the
lung adenocarcinoma cell line A549, the human cervical adenocarcinoma cell line HeLa,
the human embryonic kidney cell line expressing large T antigen HEK293T, and the
glioblastoma cell line T98G. TLR5 protein was detected in all cell lines examined by
immunoblot with TLR5-specific antibody (Fig. 5.9a). T84 cells exhibited the highest
abundance while expression levels of the other cell lines were similar and appeared not to
differ by more than two-fold (Fig. 5.9a). NF-κB DNA binding activity in non-stimulated,
TNFα and flagellin stimulated cells was analyzed by EMSA assays of WCEs prepared
from each cell type (Fig 5.9b). HT29 and A549 cells responded strongly to flagellin and
to TNFα stimulation while HeLa, 293T and T98G cells responded poorly (HeLa, 293T)
or not at all (T98G) to flagellin stimulation. The authenticity of the NF-κB DNA binding
complex was determined using p65-specific antibody to supershift the NF-κB
DNA:protein complex. It is of interest that some cells that express TLR5 either do not
respond at all or do so very poorly. This may be due to either lack of receptor presence at
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the plasma membrane and intracellular localization, inactivating or detrimental mutations
in the TLR5 gene in these cell lines or lack of or low abundance of a required co-receptor
or adapter protein (as is the case in some cells for TLR4 and its co-receptor/adapter MD2
(Akashi et al., 2001; Nagai et al., 2002; Schromm et al., 2001)). IL-1 can activate NF-κB
DNA binding activity in all of the examined cell lines so it appears that the signaling
apparatus downstream of MyD88 to NF-κB is intact.
Recently Muc1 a secreted and membrane bound mucin protein was shown to serve as
a receptor that bound Pseudomonas aeruginosa and its flagellin, leading to activation of
the MAPK pathway (Lillehoj et al., 2002; Lillehoj et al., 2004) although NF-κB activity
was not examined. We examined the muc1 abundance levels in HT29 (strong flagellin
responder), A549 (strong flagellin responder), HeLa, 293T (both weak flagellin
responders) and T98G (no flagellin response) to determine if its expression correlated
with the activation profile of NF-κB and MAPK in these cells in response to flagellin
(Lillehoj et al., 2004). Should this be the case then muc1 might serve as a viable coreceptor for TLR5 in propagating activation signals leading to NF-κB activation. We
observed that only HT29 cellular proteins gave a strong signal by immunoblot analysis
using an muc1-specific antibody while muc1 was barely detectable in the other cell lines
(Fig. 5.9c). These results suggest that muc1 does not serve the role of a TLR5 co-receptor
that leads to NF-κB activation and likely plays little to no role activating MAPK
pathways in A549 cells where we have observed similar temporal MAPK activation in
response to flagellin exposure as we do in HT29 cells (TT and JD, unpublished results).
Further examination of muc1's role in HT29 cells in regards to NF-κB and MAPK
signaling using siRNA is warranted.
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FIGURE 5.9

Figure 5.9: TLR5 is expressed in numerous cell types and has variable responses
to flagellin.
A, whole cell extracts were prepared from non-stimulated T84, HT29, A549, HeLa,
293T and T98G cells and fractionated on a 8% SDS-PAGE gel, proteins were
transferred to PVDF membrane and probed with anti-TLR5 antibody for immunoblot
analysis (IB). Protein loading was examined by probing with anti-actin antibody. b,
HT29, A549, HeLa, 293T and T98G cells were left untreated (--), treated with
flagellin (F) or TNFα (T) and WCEs were prepared after 45 min and used in EMSA to
monitor NF-κB DNA binding activity. Authenticity of the NF-κB bandshift was tested
with supershift of the complex with p65(RelA)-specific antibody (αp65), normal
rabbit serum (NRS) served as an irrelevant antibody control. c, HT29, A549, HeLa,
293T and T98G cells WCEs (50 μg) were fractionated on a 8% SDS-PAGE gel,
proteins transferred to Immobilon P and immunoprobed with anti-muc I (1:450, Santa
Cruz). Size markers are listed and muc 1 position is indicated with an arrow.
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5.5 DISCUSSION
Intestinal epithelial cells at mucosal surfaces serve as innate immune sentinels
controlling the innate host defense instruction to the immune effector cells inside the
body in response to the external environment (Eckmann et al., 1995; Kagnoff and
Eckmann, 1997). Previous studies examining pathogenic Salmonella invasion of
intestinal epithelial cells demonstrated activation of the proinflammatory gene program
and invasion of only a minor portion of the cells (Valdivia et al., 1996). We previously
demonstrated that NF-κB is as potently induced in pathogenic Salmonella .sp infected
cells similar to those treated with the proinflammatory cytokines that are potent NF-κB
activators such as TNFα and IL-1β and that this activity was IKK-mediated (Elewaut et
al., 1999). Here we examined how bacterial invasion of only a third of the cells could
give rise to NF-κB activity profiles consistent with activation of NF-κB in every cell such
as the profile TNFα stimulation provides. We found that bacterial infection activates
nuclear translocation of p65 (RelA) in nearly all of the intestinal epithelial cells
consistent with the hypothesis that a cell surface receptor was recognizing either a soluble
product that bacteria were producing, or a bacterial product on the bacteria, or both. We
examined bacterial culture broths and found a bacterial product that was protein in
composition and when used to challenge intestinal epithelial cells it potently activated
NF-κB DNA binding activity (Fig. 5.2a). We further purified this protein by gel
permeation and anion exchange chromatography and found the protein to be flagellin by
electrospray ion trap mass spectroscopy (Fig. 5.2b & 5.2c and Fig. 5.3). While our
studies were in progress, flagellin was identified as being a potent proinflammatory
mediator leading to IL-8 production and secretion (Eaves-Pyles et al., 1999; Gewirtz et
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al., 2000; Gewirtz et al., 2001b). We demonstrate in this study that flagellin appears to be
exclusively responsible for activating NF-κB in intestinal epithelial cells since flagellin
mutant strains do not activate NF-κB (Fig. 5.4) nor lead to their internalization (Fig.
5.5b). Furthermore, flagellin challenge of intestinal epithelial cells leads to p65 (RelA)
nuclear localization in nearly all of the treated cells (Fig. 5.5b). Transcription factors like
activator protein 1 (AP-1) and NF-κB, which are key regulators/activators of the
proinflammatory gene program (Jobin and Sartor, 2000; Karin et al., 2001) are activated
by engagement of the MAPK, SAPK and IKK signaling pathways. We demonstrate that
the MAPK, SAPK and IKK signaling pathways activation fails to occur in host cells by
infection/exposure to Salmonella strains devoid of flagellin or products in the culture
broths derived from those mutant Salmonella strains (Figs. 5.5a and 5.6b). We also
demonstrate here that combined mutants of both fliC and fljB exhibit a severe lack of
invasion (10-4 less than wild-type) and failure to activate stress response signaling, which
has not been revealed previously. It is likely that the lack of flagellin production
interferes with the functioning of the type III secretion system (TTSS) although flagellin
is not known to effect expression of TTSS-required gene products. This hypothesis seems
credible since supply of flagellin or bacterial culture components from wild-type
Salmonella cultures in trans to the double fliC-/fljB- mutant bacteria fails to compliment
their lack of infectivity in gentamycin invasion assays (TT & JD, unpublished
observations and see Fig. 5.5b). In fact, we found the abundance of a subset of Sip and
Sop proteins (SipA and SopD) released into the bacterial culture media to be drastically
reduced in the flagellin mutant strains used here (TT & JD, unpublished observations).
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These two proteins have not previously been identified as activators of NF-κB nor are
they considered as such here.
The TTSS translocates the Salmonella invasion proteins (Sips) and the SopE proteins
into the host cell initiating cytoskeletal rearrangements that ultimately lead to bacterial
internalization,(Galan, 2001; Galan and Collmer, 1999; Wallis et al., 1999). In any event,
it is clear that purified flagellin activates a similar cadre of proinflammatory genes as
does infection of intestinal epithelial cells with wild-type flagellated Salmonella. The
temporal expression pattern of these genes was found to be remarkably similar (Fig. 5.6c)
indicating that flagellin-mediated temporal activation of the MAPK, SAPK and IKK
signaling pathways can suffice for signaling pathways activated by Sips or SopE and
SopE2 and largely recapitulates the temporal activation of key proinflammatory genes as
does infection of intestinal epithelial cells with wild-type flagellated Salmonella.
The rapid, and potent activation of the MAPK, SAPK and IKK signaling pathways by
flagellin was consistent with and indicative of the activation of a cell surface receptor. In
this study and in other studies TLR5 has been demonstrated to play an integral role in the
recognition of flagellin leading to activation of NF-κB and expression of the IL-8 gene
(Fig. 5.6c) (Gewirtz et al., 2001a; Hayashi et al., 2001). Identification of TLR5 utilized
transfection of TLRs 1 – 9 into cell lines which responded poorly to flagellin (this study)
or not at all (Gewirtz et al., 2001a; Hayashi et al., 2001) and challenging the transfectants
with flagellin to identify which TLR responded to this PAMP. Previous studies that
identified TLR5 as the receptor for flagellin did not examine the abundance of TLR5 in
these cells or account for the lack of TLR5-mediated signaling in response to flagellin
(Gewirtz et al., 2001a; Hayashi et al., 2001). We demonstrate here that cells which
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respond poorly (HeLa and HEK293T) or not at all (T98G) contain TLR5 in at least
equivalent abundance as HT29 cells which are highly responsive to flagellin. We propose
at least three possibilities to account for this discrepancy, first, this may be due to either
lack of TLR5 receptor presence at the plasma membrane and intracellular localization;
second, inactivating or detrimental mutations in the TLR5 gene in these cell lines; and
lastly, lack of or low abundance of a required co-receptor or adapter protein required for
either efficient ligand recognition and/or signaling. These possibilities are currently being
investigated. We favor the last possibility since surface biotinylation experiments indicate
that TLR5 is present on the cell surface in both flagellin responding cells and in nonresponders mentioned above (data not shown). Invocation of the second hypothesis
would require inactivating mutations be present in three different cell lines, a highly
improbable outcome.
How do the findings presented here correlate with events during a "normal"
Salmonella infection? We have indicated in this study that defective type III secretion
system functioning leads to loss of host cell infectivity and underscores the importance of
this system in the normal course of infection. In the in vivo setting, polarized epithelial
cells express TLR5 on the basolateral surface (Alexopoulou et al., 2001) and flagellin can
only reach the receptor either after either breaching the tight junction barrier by physical
damage or by loosening of the junctions in response to Sips and Sops delivered into the
intestinal epithelial cells by the TTSS or by delivery of flagellin across the intestinal
epithelial cell by the bacteria itself (Gewirtz et al., 2001b; McCormick, 2003; Sakaguchi
et al., 2002; Wood et al., 2000). This scenario would imply the main function of the type
III secretion system would be to trigger stress response signaling facilitating invasion and
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lead to loosening the tight junctions and result in flagellin/ flagellated bacteria to passing
through the junctions and infected cells allowing access the basolateral surface and then
systemic dispersion. TLR5 on the basolateral surface of the intestinal epithelial cells, in
response to flagellin, could then lead to activation of NF-κB and the proinflammatory
gene program and host protection. This model is consistent with activation of the
proinflammatory gene program observed in response to flagellated Salmonella sp.
infection in many reports too numerous to cite here and would allow the innate host
defense system a fail-safe way to recognize pathogen exposure. In instances where
infection of intestinal epithelial cells by naturally occurring non-flagellated Salmonella
occurs, a strong proinflammatory response would not initially be presented but the
Salmonella would instead lead to systemic infection as is the case in chickens with S.
galinarum and S. pollorum and result in typhoid-like disease (Kaiser et al., 2000).
Infection of chicken epithelial cells does not lead to proinflammatory gene expression by
these non-flagellated pathogens but does when infected with S. typhimurium or S. Dublin
(Kaiser et al., 2000).
Argument for the existence of an additional TLR5 co-receptor/adapter being in limited
abundance or absent might be in evidence from the transfection results presented in Table
1 which demonstrated that overexpression of cell surface localized FLAG-tagged TLR5
only resulted in slightly over a two-fold increase in NF-κB reporter gene expression in
response to flagellin. If only TLR5 was required for activation of the signaling pathway
should not a much more robust response been observed? We have also used DN-TLR5
transfections and NF-κB-dependent reporter gene assays or overexpression of DN-TLR5
using recombinant adenoviruses and analysis of resulting NF-κB DNA binding activity in
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response to flagellin to examine its effectiveness to completely inhibit TLR5-mediated
flagellin activation of NF-κB. We have found it difficult to gain more than a fifty-percent
reduction in either reporter gene activation or NF-κB DNA binding activity in HT29
cells(TT, AD & JD, unpublished observations). These results suggest that the resting
TLR5 signaling complex may be quite stable as has recently been suggested (Mizel and
Snipes, 2002). Should the endogenous TLR5 signaling complex be extremely stable it
would therefore be expected that titration of a required pre-stimulus bound adapter or coreceptor away would be inefficient and this is what we have observed. Expression of a
DN-MAL (TIRAP), a MyD88-related TLR adapter (Fitzgerald et al., 2001; Hong et al.,
2000) had little to no effect on flagellin-mediated NF-κB activity in transient transfection
NF-κB reporter gene assays (TT & JD, unpublished observations). Recently, TLR5 has
been shown to bind flagellin (Mizel et al., 2003; Murthy et al., 2004; Smith et al., 2003)
and that this is likely a direct interaction due to failure of the human TLR5 to respond to a
purified flagellin derived from a mouse-specific Salmonella strain (Smith et al., 2003).
These observations still do not preclude the existence of a co-receptor or adapter that is
critical for signal transmission. Detailed biochemical characterization of the TLR5
signaling complex will resolve this issue. Muc1, a recently described flagellin interacting
membrane protein by virtue of its ability to trigger activation of the MAPK pathway in
response to flagellin exposure (Lillehoj et al., 2004) was considered a viable candidate
for such a co-receptor but our observations suggest that it can not serve as the putative
TLR5 co-receptor as it is expressed at similar levels in flagellin non-responding cell lines
examined here as it is in A549 cells which respond strongly to flagellin and both cell line
types express similar levels of TLR5 (Fig. 5.9).
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In conclusion, our data clearly

demonstrates that flagellin can act as the major determinant in activating key stress
response signaling pathways and proinflammatory gene program expression in a temporal
and qualitative fashion as observed during infection of intestinal epithelial cells by wildtype Salmonella sp. that express flagellin, a point that was not well established until this
study. In addition, expression of the fli C gene appears to play an important role in the
proper functioning of the TTSS since mutants that fail to express fli C are defective in
expressing a subset of Sip proteins and fail to invade host cells. Flagellin added in trans
cannot restore the ability of the fli C mutant bacteria to invade intestinal epithelial cells.
Flagellin is "sensed" by TLR5 and in response propagates signaling pathways
culminating in potent proinflammatory gene expression. Interestingly we found that
TLR5 is expressed in weakly responding and also in some flagellin non-responding cells,
293T, HeLa and T98G cells respectively at levels similar to cells such as HT29 and A549
cells that respond strongly to flagellin and can be found on the cell surface, raising a
strong possibility that productive TLR5 signaling may require an additional
factor/adaptor other than those already known to be key in the IL-1 signaling pathway,
which shares extensive similarities to the TLRs signaling pathways.
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CHAPTER VI
SUMMARY AND FUTURE DIRECTIONS
6.1 INTRODUCTION
NF-κB activation is a hallmark of the inflammatory response, and is an essential
component in both adaptive and innate immunity. It is induced by a number cytokines
that propagate not only the inflammatory response but in some instances the induction of
the apoptotic pathway, as can a number of chemotherapeutic anti-cancer drugs. NF-κB is
also activated by pathogen-manufactured ligands which are by-products of invasion and
infection. The function of NF-κB’s activation can be varied, however a significant
portion of its function is involved in the inhibition of apoptosis, and the promotion of cell
survival.
Cancer is a pathological condition that is pseudo-inflammatory in nature. The
unchecked growth of cancer cells is a failure in the induction of cell death programs
which results in the accumulation of tumor cells.

NF-B has been found to be

constitutively active in many cancer cell-types, giving the neoplastic growth a biological
survival advantage. Neoplastic cell growth may be attributed to cellular mutations that
result in a gain or loss of function in normally highly regulated cellular signal
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transduction pathways. A number of chemotherapeutic drugs target the apoptotic
pathway for activation. However, these drugs also simultaneously activate NF-B
resulting in increased cell survival and inhibiton of the death pathways.
We hypothesized that if an adjuvant drug that inhibits NF-B is administered in
concert with a chemotherapeutic drug, whose mode of action targets the cellular
apoptotic pathway, then the efficacy of the chemotherapeutic drug would be increased.
The adjuvant drug we have chosen to study is the Nitric Oxide donor nitrosylcobalamin.
6.2 NF-B, TRAIL/Apo2L, CHEMOTHERAPEUTIC DRUGS AND NO-Cbl
In chapter II, we began by revealing the synergistic effects that a combination
treatment involving NO-Cbl and Apo2L/TRAIL had on A375, WM9 and WM3211
cells. These three melanoma cell lines had previously been shown to be resistant to
Apo2L/TRAIL induced apoptosis. Sequential drug treatment resulted in synergistic antiproliferative activity in all three cell lines, demonstrating that a Nitric Oxide adjuvant
enhances the apoptotic effects of TRAIL. In addition, through the use of TUNNEL(IS
THIS 1N OR 2?) assays and western blot analysis we made evident that the apoptotic
activity in A375 cells treated with NO-Cbl and TRAIL was clearly increased over those
that had been treated with TRAIL or NO-Cbl alone.
In support of our hypothesis we demonstrated, by way of EMSA and IKK Kinase
Assays that both NF-B DNA binding activity and IKK kinase activity is repressed, in
combination-treated NO-Cbl and TRAIL cells compared to cells treated with either single
agent. This phenomenon was demonstrated by western blot assays that exhibited a
decrease in IB degradation, indicating diminished NF-B activity. Lastly, A375
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melanoma xenograft solid tumors in mice, treated with a combination of TRAIL and NOCbl exhibited a marked decrease in tumor growth as compared to single drug treated mice
or vehicle alone treated controls.
Chapter III explored the effects of combinatorial treatment of NO-Cbl and
chemotherapeutic drugs, utilizing 4 dissimilar cancer cell lines, A375 (melanoma), MCF7 (breast cancer), SW480 (colon cancer) and OVCAR-3 ( ovarian cancer). Utilizing 10
different cancer cell lines in combination with 18 chemotherapeutic drugs we confirmed
that combined, NO-Cbl and Chemotherapeutic drug treatment, induced a synergistic
anti-proliferative effect in approximately 78% of the combinations examined.
Next we showed the effects of NO-Cbl co-treatment on two anti-apoptotic proteins,
Akt and XIAP. Overall, the phosphorylated form of Akt was inhibited by NO-Cbl
combinatorial treatment and XIAP expression is decreased. NF-B DNA binding
activity and IKK kinase activity exhibited mixed results; however, in general NO-Cbl
inhibited IKK kinase and NF-κB transcription factor activity. Ovcar-3 cells treated with
a combination treatment of NO-Cbl and Doxorubicin demonstrated an increased
apoptotic activity, as indicated by the increase expression of the activated apoptotic
biomarkers Caspase 8, PARP and XIAP. Lastly, combination-treated mice in an Ovcar-3
tumor xenograft model exhibited a marked decrease in tumor size, as well as increased
animal survival compared to untreated or singularly treated mice. Murine leukemia
tumor models resulted in 60% increased survival compared to untreated or singular
treated mice.
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A major advantage of Nitrosylcobalamin appears to be its tumor-specific
accumulation. Cobalamin (Cbl) is avidly taken up by tumor cells relative to most normal
cells.(Collins and Hogenkamp, 1997) NO-Cbl is therefore relatively tumor-specifically
accumulated due to higher transcobalamin receptor (TCII-R) expression in tumor cells
compared with normal tissue. NO-Cbl has a sustained half-life, allowing for a slow NOrelease mechanism inside the cell. This results in decreased cellular toxicity as evidenced
in Figure 6.1 A. There is little Chk2 protein phosphorylation by ATM kinase (an
indicator of DNA damage), in cells treated with NO-Cbl alone compared to treatment
with DNA damaging agents.
In comparison, the Nitric oxide donor SNP can also inhibit NF-κB, but it lacks tumor
specific accumulation and due to its short half- life will release NO spontaneously and
indiscriminately. This will induce significant toxicity to normal cells (Volk et al., 1995;
Wink et al., 1996). As can be seen in Figure 6.1 B, HeLa cells treated with SNP show a
considerable amount of ATM activation, as noted by Chk2 phosphorylation, at a level
comparable to cells treated with DNA damaging agents.
In conclusion we have accumulated substantial data supporting the hypothesis that, the
novel nitric oxide donor NO-Cbl could potentially prove to be an effective adjuvant
therapy, to apoptotic-inducing chemotherapy.
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FIGURE 6.1
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Figure 6.1: Differential effects of NO-Cbl and SNP Treated HeLa cells on
Chk2 activation NF-κB inhibition
HeLa cells were cultured in DMEM supplemented with 10% Fetal bovine serum
and 1% antibiotic/antimycotic. Nuclear extracts were prepared as described in
(Dignam et al., 1983). EMSA’s and western blot analysis were preformed as
previously described in (Bauer et al., 2007), p-Chk antibody (Cell Signaling). a)
HeLa cells were pre-treated with 300μM of NO-Cbl for 16hrs then treated with
TNF-α (10ng/mL), IL-1β (10ng/mL) or DNA damaging agent, concentration and
time of treatment as noted in figure 6.1.
b) HeLa cells were pre-treated with SNP for 6hrs then treated with TNF-α
(10ng/ml) or Doxorubicin DNA damaging agent, time and concentration as
noted in figure 6.1.
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6.3 PROPOSED MECHANISM OF ACTION FOR NF-B INHIBITION
Previous studies by others suggested that a critical cysteine residue (C179) in the Tloop of IKK, a subunit of IKK and the main catalytic component of the IKK complex
resulting in IKB phosphorylation and resultant activation of NF-B, was nitrosylated
interfering with its ability to activate NF-B. A mutant form of IKK was constructed
converting the cysteine to alanine (C179A); this mutant was reported to be resistant to the
effects of Nitric Oxide. Our repeat of this experiment on two separate occasions
(Fig 6.2) and data not shown, found little difference between it and wt IKK. As can be
observed, the NO releasing compound DETA NONOate (Noc-18) can inhibit NF-B
DNA binding activity (Fig 6.3) and this inhibition was reflected by the decreased
abundance of p65 (as the lower panel in Fig. 6.3 indicates) to translocate to the nucleus
and is also an indication of decreased IB phosphorylation and degradation.

202

FIGURE 6.2

Figure 6.2: C179A Mutated IKK does not rescue Cells Treated with the Nitric
Oxide Donor NOC-18 from NF-B inhibition.
293T were cultured in DMEM supplemented with 10% fetal bovine serum and 1%
antibiotic/antimycotic. The Constructs (Gift of Michael Karin) were transfected into
293T cells by nucleofection utilizing the Calcium Chloride method as described in
(Graham and van der Eb, 1973). After 48 hours the 293T cells were. Transiently
expressing wt and mutated IKK, as verified by western blot analyses (data not
shown). The cells were then pretreated with the indicated concentrations of Noc-18
for 7h prior to stimulation with TNF-α (10ng/mL). Whole cell extracts were prepared
as previously described (Chawla-Sarkar et al., 2003), and NF-B DNA binding
activity was monitored utilizing 25μg of whole cell extract with EMSA.
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FIGURE 6.3

Figure 6.3 The Nitric Oxide Donor Noc-18 inhibits NF-B
HeLa cells were cultured in DMEM supplemented with 10% Fetal bovine serum
and 1% antibiotic/antimycotic. They were pretreated with the indicated
concentrations of Noc-18 for 7h prior, at concentrations as noted on figure. Then
stimulated with TNF-α (10ng/mL) 15minutes, Doxorubicin (20μM) 4 hrs,
Daunorubicin (20μM) 4hrs or Vp-16 (20μM) 4hrs as noted on figure. Nuclear
extracts ( 9μg for EMSA, 27μg for Western blot analysis) were prepared(Dignam et
al., 1983) and analyzed by EMSA for DNA binding and by immunoblot analysis
for the indicated proteins as previously described(Tallant et al., 2004).

204

Studies linking chemotherapeutic drugs utilizing the ZN finger of IKK to activate
NF-B, led us to postulate that this may be an important target for NO inhibition of IKK
activity. To further examine the possibility that IKK could be a target for NO-inhibition
we concentrated on likely residues in and around the ZN finger of IKK.
We focused on tyrosine (Y) 402 in the Zn finger and mutated this to a phenylalanine
(F). We produced stably expressing Wt-IKK and 402F-expressing IKK HeLa cells and
examined their sensitivity to NO release by SNP. As can be seen in Fig. 6.4, the 402F
IKK protein appeared to provide additional protection against IKK and NF-B
inhibition by NO compared to Wt-IKK.
We demonstrated conclusively that the NO-releasing compound NO-Cbl can inhibit
IKK and NF-B activity. It appeared most effective against weak inducers of NF-B or
inducers that are known to utilize the ZN finger region of IKK. NO-Cbl inhibition of
NF-B is accomplished with little cellular DNA damage, reducing the potential of DNA
damage that may done to normal cells. Our preliminary data indicated that the point of
inhibition may be upstream of IKK or p65, the current purported points of inhibition.
The questions still remaining to be answered are: Where is the location of the
modification on IKK effecting inhibition? For example, it is possible that nitric oxide
may nitrosylate one of the cysteines in the zinc finger causing instability and decreased
function of IKK. What, if any, may this modification have on IKK phosphorylation,
sumoylation, ubiquitination and nuclear import and export? Does the nitrosylation
modification effect the association of IKK with ancillary signaling proteins?
Secondly, can the expression of iNOS (also called NOS2) in cells increase the
205

effectiveness of chemotherapeutic drugs to kill cells, if so; can we stimulate high enough
endogenous levels of iNOS to increase NO levels high enough to result in sensitizing
cells to killing by doxorubicin or VP16? The ability to sensitize cells by triggering
increased NO production may provide a key chemotherapeutic benefit
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FIGURE 6.4
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Figure 6.4 Mutated version of IKK- protects cells from inhibition of NF-B
by SNP and inhibits apoptotic effects of TNF-
Protection of IKK and NF-B activity from NO by IKK- 402F. Stably
expressing WT or 402F Glu-Glu-epitope tagged IKK. HeLa cells were
pretreated or not with SNP at the indicated doses for 30 min prior to stimulation
with either TNF (10ng/mL) or IL-1 as indicated. Apoptotic effect of TNF- is
inhibited in mutant expressing cells as compared to wild type, as monitored by
PARP cleavage. Cell extracts were prepared as previously described (ChawlaSarkar et al., 2003). NF-B activity was monitored by EMSA (25ug of Whole
cell extract). EMSA and Western blot analyses performed as previously
described (Bauer et al., 2007). EMSA’s and western blot analysis are the results
from 2 independent experiments.
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SUPPLEMENTARY MATERIAL
SUPPLEMETAL FIGURE 1

Supplemental Figure 1: RT-PCR examining TLR expression in normal breast
tissue and in BC tumor tissue and BC cell line samples.
Total RNA was prepared from the indicated samples and RT-PCR was performed
with primer pairs specific to the indicated TLR is indicated on the right side of the
panel. Alpha tubulin expression served as the control RNA expression.
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Supplemental Data for Supplemental figures 1and 2
Cell Culture-- Human breast cancer cell lines MDA-MB-231, MDA-MB-468, T-47D,
MCF-7, SKBR3 Were cultured in Dulbecco’s Modified Eagles Medium (DMEM)
supplemented with heat inactivated 10% fetal bovine serum and 1% anti-biotic antimytotic and Cyprofloxin. The NIH OVCAR-3 cells were cultured in RPMI supplemented
with heat inactivated 10% fetal bovine serum and 1%. Antibiotic/Antimycotic and
Cyprofloxin. ACHN cells were cultured in Karatinocyte-SFM (GIBCO) media
supplemented with L-Glutamate, Epithelial Growth Factor (EGF) and Bovine Pituitary
Extract (BPE)
Reverse transcription PCR- Total cellular RNA was extracted from cells, grown in a
10cm plate, with TRIZOL reagent as described in {Chomczynski, 1988 #866}. Deidentified discarded frozen pathology sections from human primary tumor breast
biopsies, and human tonsil sections, were used as samples. Sections of frozen samples
were cut and placed directly in Trizol (50-100mg). The Tissue fragments were
homogenized using a microcentrifuge-tube pestle and total RNA extracted using TRIZOL
reagent as described in {Chomczynski, 1988 #866}. The first strand cDNA were made
using the following reagents.
Amount per 20µL Volume Reaction: 500ng Oligo (dT) 12-15; 1µg total cellular RNA; 1µL
10mM dNTP mix (10mM each dATP, dGTP, dCTP and dTTP); Sterile distilled water 59µL; Heat mixture to 650C for 5min. and quick chill on ice; 4µL 5x first strand buffer
(SuperScript II); 2µL 0.1 M DTT; 1µL RnaseOUT Recombinant Ribonuclease Inhibitor
Mix contents of the tube, incubate at 420C for 2minutes. Add 1µL (200 units)
SuperScriptII. Incubate 50minutes at 420C. Inactivate the reaction by heating at 700C for
15 minutes.
PCR product were made utilizing the following reagents: 5µL 10x PCR buffer (200mM
Tris, 500mM KCl); 50mM MgCl2; 10mM dNTP mix; 10µM Forward primer; 10µM
reverse primer; 10 Units Taq DNA polymerase; 200ng cDNA; 35-40µL distilled water.
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PCR amplification consists of 1minute initial denaturing at 950C, 35 cycles of 30 second
denaturing at 950C, 30 second annealing at 600C and 2 minute extension at 720C, then 1
final 10 minute extension at 720C. PCR products were fractionated on a 0.8% agarose
gel. Refer to Supplemental Table 1 for PCR primer sequence and product BP size.
Primers were made by Integrated DNA Technologies, Inc. Coralville, IA 52241.
SUPPLEMENTAL TABLE 1: Oligonucleotide Primers and PCR product sizes.

mRNA
Species
TLR 1
TLR 2
TLR 4
TLR 5
TLR 6
TLR 7
-Tub

5’ Primer
5CGTAAAACTGCAAGCTTTGCAAGA3
5CCAGGTAGGTCTTGGTGTTCA3
5CTGCAATGGATCAAGGACCA3
5CATTGTATGCACTGTGACTC3
5TAGGTCTCATGACGAAGGAT3
5-AGTGTCTAAAGAACCTGG3’
5CTGCCATTGCCACCATCAAAACCA3

3’ Primer
5CCTTGGGCCATTCCAAATAAGTCC3
5GGCCAGCAAATTACCTGTGTG3
5TCCCACTCCAGGTAAGTGTT3
5CCACCACCATGATGAGAGCA3
5GGCCACTGCAAATAACTCCG3
5CTTGGCCTTACAGAAATG33
5ATTCAGGGACCATGACATGCAGCAG3
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Size of
PCR
Product
(bp)
890
614
622
445
1107
544
661

SUPPLEMENTAL FIGURE 2

Supplemental Figure 2: Breast cancer cell lines produce factors that
activate NF-κB
HEK 293 cells stably expressing individual TLRs or combinations of TLRs
(Gift of Kate Fitzgerald, University of Massachusetts) as indicated to the left of
each panel were stimulated with TNFα (10ng/ml) or Macrophage activating
lipopepeptide [MALP2] (10pg/ml), partially repurified Lipopolysacharide
(LPS) [100ng/ml], or with the indicated conditioned medias after preincubation
with 20ug/ml neutralizing anti-TNFα antibody. Whole cell extracts (WCE)
were prepared 45 min after stimulation and assayed for NF-κB DNA binding
activity (indicated to the right of the panel) in EMSAs as previously described
(Tallant et al., 2004)
The T47D BC cell line produces a factor(s) that activates NF-κB in all cells
tested while MB-231 and MB-468 BC cell as does the ACHN kidney cancer
cell line produce factor(s) that activate TLRs 1, 2, 2+1, 2+6, and TLRs 8 and
10. The activation is specific and is not due to contamination of positive
cultures by endotoxin or by mycoplasmal contamination as all cells was grown
in antibiotics, anti-mycotics and ciprofloxin as stated above and have not tested
positive for mycoplasmal infection. It appears as though there may be multiple
factors produced by the MB-231 cells as TLRs 8 and 10 show increased NF-κB
activity in response to conditioned media from those cells.
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